Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Mar. 31, 2017	May 05, 2017	Sep. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,955,133
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 2,550.5

Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Revenues
Net sales									$ 881,113	$ 803,088	$ 710,070
Other revenues									947	3,159	4,553
Total revenues	$ 240,670	$ 216,763	$ 215,052	$ 209,575	$ 207,855	$ 200,195	$ 206,065	$ 192,132	882,060	806,247	714,623
Cost of Sales
Cost of sales	110,487	92,216	91,087	87,984	89,604	83,411	86,125	79,896	381,774	339,036	308,400
Gross profit	130,183	124,547	123,965	121,591	118,251	116,784	119,940	112,236	500,286	467,211	406,223
Operating Expenses
Advertising and promotion	41,450	30,682	28,592	27,635	26,552	29,935	27,893	26,422	128,359	110,802	99,651
General and administrative	28,760	22,131	18,795	19,457	20,232	18,135	16,462	17,589	89,143	72,418	81,273
Depreciation and amortization	6,651	5,852	6,016	6,832	6,198	6,071	5,687	5,720	25,351	23,676	17,740
Loss on divestitures	268	(3,405)	(496)	55,453					51,820	0	0
Total operating expenses	77,129	55,260	52,907	109,377	52,982	54,141	50,042	49,731	294,673	206,896	198,664
Operating income	53,054	69,287	71,058	12,214	65,269	62,643	69,898	62,505	205,613	260,315	207,559
Other (income) expense
Interest income									(203)	(162)	(92)
Interest expense									93,546	85,322	81,326
Gain on sale of asset									0	0	(1,133)
Loss on extinguishment of debt	1,420	0	0	0	17,519	0	0	451	1,420	17,970	0
Total other expense									94,763	103,130	80,101
Income before income taxes	18,802	50,733	50,228	(8,913)	24,603	43,181	49,231	40,170	110,850	157,185	127,458
Provision for income taxes	7,712	19,092	18,033	(3,382)	10,667	15,186	17,428	13,997	41,455	57,278	49,198
Net income	$ 11,090	$ 31,641	$ 32,195	$ (5,531)	$ 13,936	$ 27,995	$ 31,803	$ 26,173	$ 69,395	$ 99,907	$ 78,260
Earnings per share:
Basic (in USD per share)	$ 0.21	$ 0.60	$ 0.61	$ (0.10)	$ 0.26	$ 0.53	$ 0.60	$ 0.50	$ 1.31	$ 1.89	$ 1.50
Diluted (in USD per share)	$ 0.21	$ 0.59	$ 0.60	$ (0.10)	$ 0.26	$ 0.53	$ 0.60	$ 0.49	$ 1.30	$ 1.88	$ 1.49
Weighted average shares outstanding:
Basic (in shares)	53,009	52,999	52,993	52,881	52,833	52,824	52,803	52,548	52,976	52,754	52,170
Diluted (in shares)	53,419	53,359	53,345	52,881	53,252	53,203	53,151	52,958	53,362	53,143	52,670
Comprehensive income, net of tax:
Currency translation adjustments	$ 9,282	$ (8,736)	$ 2,703	$ (5,824)	$ 6,449	$ 4,922	$ (11,079)	$ (405)	$ (2,575)	$ (113)	$ (24,151)
Unrecognized net loss on pension plans	(252)								(252)	0	0
Total other comprehensive loss	9,030	(8,736)	2,703	(5,824)	6,449	4,922	(11,079)	(405)	(2,827)	(113)	(24,151)
Comprehensive income	$ 20,120	$ 22,905	$ 34,898	$ (11,355)	$ 20,385	$ 32,917	$ 20,724	$ 25,768	$ 66,568	$ 99,794	$ 54,109

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Current assets
Cash and cash equivalents	$ 41,855	$ 27,230
Accounts receivable, net	136,742	95,247
Inventories	115,609	91,263
Deferred income tax assets		10,108
Prepaid expenses and other current assets	40,228	25,165
Total current assets	334,434	249,013
Property, plant and equipment, net	50,595	15,540
Goodwill	615,252	360,191
Intangible assets, net	2,903,613	2,322,723
Other long-term assets	7,454	1,324
Total Assets	3,911,348	2,948,791
Current liabilities
Accounts payable	70,218	38,296
Accrued interest payable	8,130	8,664
Other accrued liabilities	83,661	59,724
Total current liabilities	162,009	106,684
Long-term debt
Principal amount	2,222,000	1,652,500
Less unamortized debt costs	(28,268)	(27,191)
Long-term debt, net	2,193,732	1,625,309
Deferred income tax liabilities	715,086
Deferred income tax liabilities		469,622
Other long-term liabilities	17,972	2,840
Total Liabilities	3,088,799	2,204,455
Commitments and Contingencies
Stockholders’ Equity
Preferred stock – $0.01 par value; Authorized – 5,000 shares; Issued and outstanding – None	0	0
Common stock-$0.01 par value; Authorized – 250,000 shares; Issued – XXXXX shares and 53,066 shares at March 31, 2017and 2016, respectively	533	530
Additional paid-in capital	458,255	445,182
Treasury stock, at cost – 332 shares at March 31, 2017 and 306 shares at March 31, 2016	(6,594)	(5,163)
Accumulated other comprehensive loss, net of tax	(26,352)	(23,525)
Retained earnings	396,707	327,312
Total Stockholders’ Equity	822,549	744,336
Total Liabilities and Stockholders’ Equity	$ 3,911,348	$ 2,948,791

Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2017	Mar. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	53,287,000	53,066,000
Treasury stock (in shares)	332,000	306,000

Consolidated Statements of Changes in Stockholders' Equity and Comprehensive Income - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive (Loss) Income	Retained Earnings (Accumulated Deficit)
Balances at Mar. 31, 2014	$ 563,360	$ 520	$ 414,387	$ (1,431)	$ 739	$ 149,145
Common stock (in shares) at Mar. 31, 2014		52,021,000
Treasury stock (in shares) at Mar. 31, 2014				206,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	6,918		6,918
Exercise of stock options	$ 3,954	$ 4	3,950
Exercise of stock options (in shares)	386,300	387,000
Preferred share rights	$ 0					0
Issuance of shares related to restricted stock		$ 1	(1)
Issuance of shares related to restricted stock (in shares)		154,000
Treasury share repurchases	(2,047)			$ (2,047)
Treasury share repurchases (in shares)				60,000
Excess tax benefits from share-based awards	1,330		1,330
Components of comprehensive income:
Net income	78,260					78,260
Unrecognized net loss on pension plans	0
Translation adjustments	(24,151)				(24,151)
Comprehensive income	54,109
Balances at Mar. 31, 2015	627,624	$ 525	426,584	$ (3,478)	(23,412)	227,405
Common stock (in shares) at Mar. 31, 2015		52,562,000
Treasury stock (in shares) at Mar. 31, 2015				266,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	9,954		9,954
Exercise of stock options	$ 6,688	$ 3	6,685
Exercise of stock options (in shares)	348,000	348,000
Issuance of shares related to restricted stock	$ 1	$ 2	(1)
Issuance of shares related to restricted stock (in shares)		156,000
Treasury share repurchases	(1,685)			$ (1,685)
Treasury share repurchases (in shares)				40,000
Excess tax benefits from share-based awards	1,960		1,960
Components of comprehensive income:
Net income	99,907					99,907
Unrecognized net loss on pension plans	0
Translation adjustments	(113)				(113)
Comprehensive income	99,794
Balances at Mar. 31, 2016	$ 744,336	$ 530	445,182	$ (5,163)	(23,525)	327,312
Common stock (in shares) at Mar. 31, 2016		53,066,000
Treasury stock (in shares) at Mar. 31, 2016	306,000			306,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 8,148		8,148
Exercise of stock options	$ 4,028	$ 2	4,026
Exercise of stock options (in shares)	126,800	127,000
Issuance of shares related to restricted stock	$ 0	$ 1	(1)
Issuance of shares related to restricted stock (in shares)		94,000
Treasury share repurchases	(1,431)			$ (1,431)
Treasury share repurchases (in shares)				26,000
Excess tax benefits from share-based awards	900		900
Components of comprehensive income:
Net income	69,395
Unrecognized net loss on pension plans	(252)
Translation adjustments	(2,575)
Comprehensive income	66,568
Balances at Mar. 31, 2017	$ 822,549	$ 533	$ 458,255	$ (6,594)	$ (26,352)	$ 396,707
Common stock (in shares) at Mar. 31, 2017		53,287,000
Treasury stock (in shares) at Mar. 31, 2017	332,000			332,000

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Operating Activities
Net income	$ 69,395	$ 99,907	$ 78,260
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	25,792	23,676	17,740
Loss on divestitures and sales of property and equipment	51,820	0	0
Gain on sale of asset	0	0	(1,133)
Deferred income taxes	(5,778)	46,152	28,922
Long term income taxes payable	581	(332)	2,294
Amortization of debt origination costs	8,633	8,994	8,821
Stock-based compensation costs	8,148	9,954	6,918
Stock-based compensation costs	8,148	9,954	6,918
Loss on extinguishment of debt	1,420	17,970	0
Premium payment on 2012 Senior Notes	0	(10,158)	0
Lease termination costs	524	0	785
Loss (gain) on sale or disposal of property and equipment	573	(35)	321
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(18,938)	1,824	1,608
Inventories	(10,262)	(3,005)	15,360
Prepaid expenses and other assets	(1,996)	(7,921)	4,664
Accounts payable	21,447	(11,348)	(17,637)
Accrued liabilities	2,497	(1,328)	9,332
Noncurrent assets and liabilities	(6,084)	0	0
Net cash provided by operating activities	147,772	174,350	156,255
Investing Activities
Purchases of property and equipment	(2,977)	(3,568)	(6,101)
Proceeds from divestitures	110,717	0	18,500
Proceeds from the sale of property and equipment	85	344	0
Proceeds from sale of asset	0	0	10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement	0	7,237	0
Proceeds from DenTek working capital arbitration settlement	1,419	0	0
Acquisition of DenTek, less cash acquired	0	(226,984)	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0	0	(749,666)
Acquisition of the Hydralyte brand	0	0	(77,991)
Acquisition of C.B. Fleet, less cash acquired	(803,839)	0	0
Net cash used in investing activities	(694,595)	(222,971)	(805,258)
Financing Activities
Proceeds from issuance of 2016 Senior Notes	0	350,000	0
Repayment of 2012 Senior Notes	0	(250,000)	0
Borrowings under Bridge term loans	0	80,000	0
Repayments under Bridge term loans	0	(80,000)	0
Proceeds from issuance of Term Loan	1,427,000	0	720,000
Term Loan repayments resulting from refinancing	(687,000)	0	0
Term Loan repayments	(175,500)	(60,000)	(130,000)
Borrowings under revolving credit agreement	110,000	115,000	124,600
Repayments under revolving credit agreement	(105,000)	(96,100)	(58,500)
Payments of debt origination costs	(11,140)	(11,828)	(16,072)
Proceeds from exercise of stock options	4,028	6,689	3,954
Proceeds from restricted stock exercises	0	544	57
Excess tax benefits from share-based awards	900	1,960	1,330
Fair value of shares surrendered as payment of tax withholding	(1,431)	(2,229)	(2,104)
Net cash provided by financing activities	561,857	54,036	643,265
Effects of exchange rate changes on cash and cash equivalents	(409)	497	(1,275)
Increase (decrease) in cash and cash equivalents	14,625	5,912	(7,013)
Cash and cash equivalents - beginning of year	27,230	21,318	28,331
Cash and cash equivalents - end of year	41,855	27,230	21,318
Interest paid	85,209	79,132	70,155
Income taxes paid	$ 47,999	$ 15,352	$ 11,939

Business and Basis of Presentation

12 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers and drug, food, dollar, convenience, and club stores in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to these Consolidated Financial Statements.

Basis of Presentation

Our Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All significant intercompany transactions and balances have been eliminated in consolidation. Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2017”) mean our fiscal year ended on March 31st of that year.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances and inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. At March 31, 2017, approximately 61% of our cash is held by a bank in Sydney, Australia. Substantially all of our remaining cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insures our domestic balances, up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at March 31, 2017 are uninsured.

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers’ financial condition, (iii) monitor the payment history and aging of customers’ receivables, and (iv) monitor open orders against an individual customer’s outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or market value, where cost is determined by using the first-in, first-out method. We reduce inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	17
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years.

Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Debt Origination Costs

We have incurred debt origination costs in connection with the issuance of long-term debt. Certain of these costs were recorded as deferred financing costs within long-term assets and others were recorded as a reduction to our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our bonds and our term loan facility and the straight-line method for our revolving credit facility. Effective April 1, 2015, in accordance with new accounting standards discussed below, we began reporting the costs related to our senior notes and the term loan facility as a reduction of debt. We continue to report the costs associated with our revolving credit facility as a long-term asset.

Revenue Recognition

Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) the selling price is fixed or determinable; (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when product is received by the customer and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of the promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Warehousing, shipping and handling and storage costs were $46.2 million for 2017, $39.2 million for 2016 and $37.7 million for 2015.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. Allowances for distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these slotting fee distribution arrangements, the retailers allow our products to be placed on the stores’ shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation expense by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Pension Expense

We have a defined contribution plan in which all U.S. full-time employees (excluding those employees of the recently acquired Fleet business discussed below) are eligible to participate. The participants may contribute from 1% to 60% of their compensation, as defined in the plan. We match 65% of the first 6% of each participant's base compensation with full vesting at 3 years of service. The Company's contribution is reduced by the amount of forfeitures that occur during the year. We may also make additional contributions to the plan as determined by the Board of Directors. The total expense for the defined contribution plan was less than $0.1 million for 2017.

In conjunction with the acquisition of Fleet (see Note 2), we assumed a number of additional employee retirement plans including a defined contribution plan and two defined benefit plans. All U.S. full-time employees of Fleet are eligible to participate in Fleet's defined contribution plan. The participants may contribute from 2% to 50% of their compensation, as defined in the plan. We match 100% of the first 6% of each participant's base compensation with full vesting upon entering the plan. The Company's contribution is reduced by the amount of forfeitures that occur during the year. We may also make additional contributions to the plan as determined by the Board of Directors. The total expense for the defined contribution plan was $0.2 million for 2017.

Certain employees of Fleet are covered by defined benefit pension plans. The Company's policy is to fund amounts allowable by applicable regulations. Benefits are based on years of service and levels of compensation. On December 16, 2014, the decision was made to freeze the benefits under the Company's U.S. qualified defined benefit pension plan with an effective date of March 1, 2015.

Our funding policy is to contribute annually not less than the amount recommended by our actuaries. The funded status of our pension plans is dependent upon many factors, including returns on invested assets and the level of certain market interest rates. We review pension assumptions regularly and we may from time to time make voluntary contributions to our pension plans, which exceed the amounts required by statute. During fiscal 2017, we made total pension contributions to our pension plans of $6.1 million. Changes in interest rates and the market value of the securities held by the plans could materially change, positively or negatively, the funded status of the plans and affect the level of pension expense and required contributions in fiscal 2017 and beyond.

Our discount rate assumption for our qualified defined benefit plan changed from 4.32% at January 26, 2017 to 4.21% at March 31, 2017. We do not expect to make any contributions to our qualified defined benefit pension plan during fiscal 2018.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested restricted stock units, are included in the diluted earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and restricted stock units has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share.

Recently Issued Accounting Standards

In March 2017, the FASB issued Accounting Standards Update ("ASU") 2017-07, Compensation - Retirement Benefits (Topic 715). This update changes the reporting line items for the components of net benefit costs. The amendments in this update are effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In February 2017, the FASB issued ASU 2017-06, Plan Accounting: Defined Benefit Pension Plans (Topic 960). Among other things, the amendments in this update require a plan's interest in master trusts and any change in that interest to be presented in separate line items in the statement of net assets available for benefits and in the statement of changes in net assets available for benefits, respectively. The amendments in this update are effective for fiscal periods beginning after December 15, 2018. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairments tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments. The amendments in this update provide clarification and guidance on eight cash flow classification issues. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU 2016-15 is not expected to have a material impact on our Consolidated Financial Statements.

In February 2016, the FASB issued ASU 2016-02, Leases. The amendments in this update include a new FASB ASC Topic 842, which supersedes Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We adopted this amendment prospectively in the fourth quarter of 2017.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The adoption of ASU 2015-11 is not expected to have a material impact on our Consolidated Financial Statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance will eliminate industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. This ASU primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. This ASU will also require additional disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. With the issuance of ASU 2016-08 in March 2016, the FASB clarified the implementation guidance on principals versus agent considerations in FASB ASC 606. In April 2016, the FASB issued ASU 2016-10, which clarified implementation guidance on identifying performance obligations and licensing in FASB ASC 606. Certain narrow aspects of the guidance in FASB ASC 606 were amended with the issuances of ASU 2016-12 in May 2016 and ASU 2016-20 in December 2016. We expect to adopt this guidance when effective and continue to evaluate the effect that the updated standard, as well as additional amendments, may have on our Consolidated Financial Statements and related notes. Our implementation approach includes performing a detailed study of the various types of agreements that we have with our customers and assessing conformance of our current accounting practices with the new standard. We have not yet selected a transition method.

Acquisitions

12 Months Ended

Mar. 31, 2017

Business Combinations [Abstract]

Acquisitions

Acquisition of Fleet

On January 26, 2017, the Company completed the acquisition of C.B. Fleet Company, Inc. ("Fleet") pursuant to the Agreement and Plan of Merger, dated as of December 22, 2016, for $823.7 million plus cash on hand at closing and subject to certain adjustments related to net working capital. The purchase price was funded by available cash on hand, additional borrowings under our asset-based revolving credit facility, and a new $740.0 million senior secured incremental term loan. As a result of the merger, we acquired multiple women's health, gastrointestinal and dermatological care OTC brands, including Summer’s Eve, Fleet, and Boudreaux's Butt Paste, as well as a “mix and fill” manufacturing facility in Lynchburg, Virginia. The financial results from the Fleet acquisition are included in the Company's North American and International OTC Healthcare segments.

The acquisition was accounted for in accordance with Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the January 26, 2017 acquisition date.



(In thousands)	January 26, 2017

Cash	$	19,884
Accounts receivable	25,293
Inventories	20,812
Prepaid expenses and other current assets	17,024
Property, plant and equipment, net	38,661
Goodwill	268,577
Intangible assets, net	747,600
Other long-term assets	1,137
Total assets acquired	1,138,988

Accounts payable	10,412
Accrued expenses	22,895
Deferred income taxes - long term	261,555
Other long term liabilities	20,403
Total liabilities assumed	315,265
Total purchase price	$	823,723

Based on this preliminary analysis, we allocated $648.7 million to non-amortizable intangible assets and $98.9 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 18.7 years. The weighted average remaining life for amortizable intangible assets at March 31, 2017 was 18.6 years.

We recorded goodwill of $268.6 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes.

The operating results of Fleet have been included in our Consolidated Financial Statements beginning January 26, 2017. Revenues of the acquired Fleet operations for the year ended March 31, 2017 since the date of acquisition were $38.7 million. Fleet had a net loss for the year ended March 31, 2017 of $2.5 million.

The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Fleet's operations been included in our operations commencing on April 1, 2015, based on available information related to Fleet's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Fleet acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.



	Year Ended March 31,
	2017		2016
(In thousands, except per share data)	(Unaudited)
Revenues	$	1,049,473	$	1,004,698
Net income	$	73,750	$	92,712

Earnings per share:
Basic EPS	$	1.39	$	1.76

Diluted EPS	$	1.38	$	1.74

Acquisition of DenTek

On February 5, 2016, the Company completed the acquisition of DenTek Holdings, Inc. ("DenTek"), a privately-held marketer and distributor of specialty oral care products. The closing was finalized pursuant to the terms of the merger agreement, announced November 23, 2015, under which the Company agreed to acquire DenTek from its stockholders for a purchase price of $226.9 million. The acquisition expanded the Company's portfolio of brands, strengthened its existing oral care platform and increased its geographic reach in parts of Europe. The Company financed the transaction with a combination of available cash on hand, available cash from its asset based loan revolver, and financing of an additional unsecured bridge loan. The DenTek brands are included in the Company's North American and International OTC Healthcare segments.

The DenTek acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.



(In thousands)	February 5, 2016

Cash acquired	$	1,359
Accounts receivable	9,187
Inventories	14,304
Deferred income taxes	3,303
Prepaids and other current assets	6,728
Property, plant and equipment, net	3,555
Goodwill	73,737
Intangible assets, net	206,700
Total assets acquired	318,873

Accounts payable	3,261
Accrued expenses	14,336
Deferred income tax liabilities - long term	74,352
Total liabilities assumed	91,949
Total purchase price	$	226,924

Based on this analysis, we allocated $179.8 million to non-amortizable intangible assets and $26.9 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 18.5 years.

In December 2016, as a result of an arbitration settlement and other post-closing adjustments, we recorded a reduction to goodwill of $2.8 million. As a result, we recorded goodwill of $73.7 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes.

The pro forma effect of this acquisition on revenues and earnings was not material.

Acquisition of Insight Pharmaceuticals

On September 3, 2014, the Company completed the acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $745.9 million in cash after receiving a return of approximately $7.2 million from escrow related to an arbitrator's ruling. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extended the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat, the leading North American brand in OTC yeast infection treatment. The acquisition also added brands to the Company's cough & cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, the Company sold one of the competing brands that it acquired from Insight on the same day as the Insight closing. Insight is primarily included in the Company's North American OTC Healthcare segment.

The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. During the quarter ended June 30, 2015, we adjusted the fair values of the assets acquired and liabilities assumed by increasing goodwill for certain immaterial items that came to our attention subsequent to the date of acquisition. Additionally, during the quarter ended December 31, 2015, we reduced goodwill, as we received $7.2 million as a result of a finalized arbitration ruling relating to the disputed working capital calculation, as determined under GAAP, as of the date of the Insight acquisition, which is clearly and directly related to the purchase price. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date, after giving effect of the adjustments noted above.



(In thousands)	September 3, 2014

Cash acquired	$	3,507
Accounts receivable	26,012
Inventories	23,456
Deferred income tax assets - current	1,032
Prepaids and other current assets	1,341
Property, plant and equipment, net	2,308
Goodwill	96,323
Intangible assets, net	724,374
Total assets acquired	878,353

Accounts payable	16,079
Accrued expenses	8,539
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	132,417
Total purchase price	$	745,936

Based on this analysis, we allocated $599.6 million to indefinite-lived intangible assets and $124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years.

We also recorded goodwill of $96.3 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired after of the adjustments described above. Goodwill is not deductible for income tax purposes.

The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. On September 3, 2014, we sold one of the brands we acquired from the Insight acquisition for $18.5 million, for which we had allocated $17.7 million, $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively.

The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.



	Year Ended March 31,
	2015
(In thousands, except per share data)	(Unaudited)
Revenues	$	783,217
Net income	$	86,844

Earnings per share:
Basic	$	1.66

Diluted	$	1.65

Acquisition of the Hydralyte brand

On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on hand and our existing senior secured credit facility.

Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment.

The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.



(In thousands)	April 30, 2014

Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041

Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets.

We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes.

The pro forma effect of this acquisition on revenues and earnings was not material.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Divestitures

12 Months Ended

Mar. 31, 2016

Discontinued Operations and Disposal Groups [Abstract]

Divestitures

Late in the first quarter of fiscal 2017, the Company was approached and discussed the potential to sell certain businesses. Prior to these discussions, the Company did not contemplate any divestitures, and the Company did not commit to any course of action to divest any of the businesses until entering into an agreement on June 29, 2016 to sell Pediacare, New Skin and Fiber Choice, which were reported under the North American OTC Healthcare segment in the Cough & Cold, Dermatologicals and Gastrointestinal product groups, respectively.

On July 7, 2016, we completed the sale of the Pediacare, New Skin and Fiber Choice brands for $40.0 million plus the cost of inventory. As a result, we received approximately $40.1 million including the cost of inventory of $2.6 million, less certain immaterial holdbacks, which will be paid upon meeting certain criteria as defined in the asset purchase agreement and within approximately 18 months following the closing date of the transaction. During the year ended March 31, 2017, we recorded a pre-tax loss on sale of $56.2 million. The proceeds were used to repay debt and related income taxes due on the dispositions.

The following table sets forth the components of the assets sold and the pre-tax loss recognized on the sale in July 2016.



(In thousands)	July 7, 2016
Components of assets sold:
Inventory	$	2,380
Intangible assets, net	91,208
Goodwill	2,920
Assets sold	96,508
Total purchase price received	42,380
	54,128
Costs to sell	2,018
Pre-tax loss on divestitures	$	56,146

Concurrent with the completion of the sale of these brands, we entered into a transitional services agreement with the buyer, whereby we agreed to provide the buyer with various services, including marketing, operations, finance and other services, from the date of the acquisition through January 7, 2017. We also entered into an option agreement with the buyer to purchase Dermoplast at a specified earnings multiple as defined in the option agreement. The buyer paid a $1.25 million deposit for this option in September 2016 and later notified us of its election to exercise the option.

In December 2016, we completed the sales of the Dermpolast and e.p.t brands for an aggregate amount of $59.6 million. As a result, we recorded a pre-tax net gain on these divestitures of $3.6 million, which is included within loss on divestitures on the Consolidated Statements of Income and Comprehensive Income.

The following table sets forth the components of the assets sold and the pre-tax net gain recognized on the sales of e.p.t and Dermoplast in December 2016.



(In thousands)	December 2016
Components of assets sold:
Inventory	$	3,266
Intangible assets, net	45,870
Goodwill	6,889
Assets sold	56,025
Total purchase price received	59,614
Pre-tax net (gain) on divestitures	(3,589		)

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

Accounts Receivable

12 Months Ended

Mar. 31, 2017

Receivables [Abstract]

Accounts Receivable

Accounts receivable consist of the following:



	March 31,
(In thousands)	2017			2016
Components of Accounts Receivable
Trade accounts receivable	$	148,339		$	105,592
Other receivables	1,413			1,261
	149,752			106,853
Less allowances for discounts, returns and uncollectible accounts	(13,010		)	(11,606		)
Accounts receivable, net	$	136,742		$	95,247

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

12 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:



	March 31,
(In thousands)	2017		2016
Components of Inventories
Packaging and raw materials	$	9,984	$	7,563
Work in process	369		—
Finished goods	105,256		83,700
Inventories	$	115,609	$	91,263

Inventories are carried and depicted above at the lower of cost or market, which includes a reduction in inventory values of $6.6 million and $4.8 million at March 31, 2017 and 2016, respectively, related to obsolete and slow-moving inventory.

Property, Plant and Equipment

12 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment, net consist of the following:



	March 31,
(In thousands)	2017			2016
Components of Property, Plant and Equipment
Land	550			—
Building	13,156			—
Machinery	31,456			7,734
Computer equipment	15,440			12,793
Furniture and fixtures	2,720			2,445
Leasehold improvements	7,497			7,389
	70,819			30,361
Accumulated depreciation	(20,224		)	(14,821		)
Property, plant and equipment, net	$	50,595		$	15,540

We recorded depreciation expense of $6.0 million, $5.2 million, and $3.8 million for 2017, 2016, and 2015, respectively.

Goodwill

12 Months Ended

Mar. 31, 2017

Goodwill [Abstract]

Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2015, 2016, and 2017:



(In thousands)	North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2014	160,157			23,365			7,389			190,911

2015 additions	103,254			1,224			—			104,478
2015 reductions	—			—			(589		)	(589		)
Effects of foreign currency exchange rates	—			(4,149		)	—			(4,149		)

Balance – March 31, 2015	263,411			20,440			6,800			290,651

2016 additions	74,441			2,393			—			76,834
2016 reductions	(7,237		)	—			—			(7,237		)
Effects of foreign currency exchange rates	—			(57		)	—			(57		)

Balance - March 31, 2016	330,615			22,776			6,800			360,191

2017 additions	258,438			10,139			—			268,577
2017 reductions	(12,600		)	—			(555		)	(13,155		)
Effects of foreign currency exchange rates	—			(361		)	—			(361		)

Balance - March 31, 2017	$	576,453		$	32,554		$	6,245		$	615,252

As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and recorded goodwill of $96.3 million, reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of net assets acquired, after giving affect to the following adjustments. During the quarter ended June 30, 2015, we increased goodwill by $0.3 million for certain immaterial items. During the quarter ending December 31, 2015, we decreased goodwill by $7.2 million, as we received that amount from escrow pursuant to an arbitrator's ruling in December 31, 2015 related to a disputed working capital calculation, as determined under GAAP, associated with the Insight acquisition, which is clearly and directly related to the purchase price. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and recorded goodwill of $1.2 million, reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of the net assets acquired.

As further discussed in Note 8, in December 2014, we completed a transaction to sell rights to use of the Comet brand in certain Eastern European countries to a third-party licensee. As a result, we recorded a gain on the sale of $1.3 million and reduced the carrying value of our intangible assets and goodwill. In August 2016, we sold the remaining rights to the use of the Comet brand in certain geographic areas and reduced goodwill by $0.6 million as a result.

As discussed in Note 2, on February 5, 2016, we completed the acquisition of DenTek. In connection with this acquisition, we recorded goodwill of $73.7 million based on the amount by which the purchase price exceeded the fair value of net assets acquired. In December 2016, we received $1.4 million as a result of an arbitration associated with the DenTek acquisition. As a result, we reduced goodwill by $2.8 million, including other post-closing adjustments of $1.4 million.

As discussed in Note 2, on January 26, 2017, we completed the acquisition of Fleet. In connection with this acquisition, we recorded goodwill of $268.6 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired.

On July 7, 2016, we completed the sale of Pediacare, New Skin and Fiber Choice (see Note 3 above for further details) for $40.0 million plus the cost of inventory and received $40.1 million including preliminary inventory, less certain immaterial holdbacks, and reduced goodwill by $2.9 million as a result. In addition, as discussed in Note 3, in connection with this sale, the buyer exercised its option to purchase the Dermoplast brand. The sale of Dermoplast was completed on December 30, 2016 and, as a result, we reduced goodwill by $5.5 million.

On December 28, 2016, we completed the sale of the e.p.t brand and, as a result, we reduced goodwill by $1.4 million.

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. At February 28, 2017 and February 29, 2016, in conjunction with the annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in 2017 or 2016.

We identify our reporting units in accordance with the FASB ASC Subtopic 280. The carrying value and fair value for intangible assets and goodwill for a reporting unit are calculated based on key assumptions and valuation methodologies previously discussed. The discounted cash flow methodology is a widely-accepted valuation technique utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at February 28, 2017 and February 29, 2016, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

The aggregate fair value of our reporting units, including the recently acquired Fleet business which was recently fair valued, exceeded the carrying value by 53.0% with no reporting unit's fair value exceeding the carrying value by less than 10%.

Intangible Assets

12 Months Ended

Mar. 31, 2017

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Intangible Assets

A reconciliation of the activity affecting intangible assets, net for each of 2015, 2016, and 2017 is as follows:



	Year Ended March 31, 2015
(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks and Customer Relationships			Totals
Gross Amount
Balance – March 31, 2014	$	1,273,878		$	204,740		$	1,478,618
Additions	673,180			124,774			797,954
Reclassifications	(46,506		)	46,506			—
Reductions	(9,548		)	(17,674		)	(27,222		)
Effects of foreign currency exchange rates	(17,600		)	(280		)	(17,880		)
Balance – March 31, 2015	$	1,873,404		$	358,066		$	2,231,470

Accumulated Amortization
Balance – March 31, 2014	$	—		$	83,801		$	83,801
Additions	—			12,995			12,995
Effects of foreign currency exchange rates	—			(26		)	(26		)
Balance – March 31, 2015	$	—		$	96,770		$	96,770

Intangibles, net – March 31, 2015	$	1,873,404		$	261,296		$	2,134,700

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,676,991		$	235,642		$	1,912,633
International OTC Healthcare	86,141			1,231			87,372
Household Cleaning	110,272			24,423			134,695
Intangible assets, net – March 31, 2015	$	1,873,404		$	261,296		$	2,134,700



	Year Ended March 31, 2016
(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks and Customer Relationships			Totals
Gross Amount
Balance – March 31, 2015	$	1,873,404		$	358,066		$	2,231,470
Additions	179,800			26,900			206,700
Reclassifications	(32,918		)	32,918			—
Effects of foreign currency exchange rates	(240		)	(4		)	(244		)
Balance – March 31, 2016	$	2,020,046		$	417,880		$	2,437,926

Accumulated Amortization
Balance – March 31, 2015	$	—		$	96,770		$	96,770
Additions	—			18,430			18,430
Effects of foreign currency exchange rates	—			3			3
Balance – March 31, 2016	$	—		$	115,203		$	115,203

Intangibles, net – March 31, 2016	$	2,020,046		$	302,677		$	2,322,723

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,823,873		$	277,762		$	2,101,635
International OTC Healthcare	85,901			2,237			88,138
Household Cleaning	110,272			22,678			132,950
Intangible assets, net – March 31, 2016	$	2,020,046		$	302,677		$	2,322,723



	Year Ended March 31, 2017
(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks and Customer Relationships			Totals
Gross Amount
Balance – March 31, 2016	$	2,020,046		$	417,880		$	2,437,926
Additions	648,700			98,900			747,600
Reclassifications	(2,064		)	2,064			—
Reductions	(77,248		)	(76,903		)	(154,151		)
Effects of foreign currency exchange rates	(279		)	(140		)	(419		)
Balance – March 31, 2017	$	2,589,155		$	441,801		$	3,030,956

Accumulated Amortization
Balance – March 31, 2016	$	—		$	115,203		$	115,203
Additions	—			19,753			19,753
Reductions	—			(7,610		)	(7,610		)
Effects of foreign currency exchange rates	—			(3		)	(3		)
Balance – March 31, 2017	$	—		$	127,343		$	127,343

Intangibles, net – March 31, 2017	$	2,589,155		$	314,458		$	2,903,613

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,404,336		$	287,056		$	2,691,392
International OTC Healthcare	83,558			6,468			90,026
Household Cleaning	101,261			20,934			122,195
Intangible assets, net – March 31, 2017	$	2,589,155		$	314,458		$	2,903,613

As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and allocated $724.4 million to intangible assets based on our analysis. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and allocated $73.6 million to intangible assets based on our analysis. Furthermore, on September 3, 2014, we sold one of the brands that we acquired from Insight, for which we had allocated $17.7 million to intangible assets.

As discussed in Note 2, on February 5, 2016, we completed the acquisition of DenTek. In connection with this acquisition, we allocated $206.7 million to intangible assets based on our analysis.

As discussed in Note 2, on January 26, 2017, we completed the acquisition of Fleet. In connection with this acquisition, we allocated $747.6 million to intangible assets based on our analysis.

On July 7, 2016, we completed the sale of the Pediacare, New Skin and Fiber Choice (see Note 3 above for further details) brands for $40.0 million plus the cost of inventory and received $40.1 million including the cost of preliminary inventory, less certain immaterial holdbacks, and reduced our indefinite and finite-lived trademarks by $37.2 million and $54.0 million, respectively. During the year ended March 31, 2017, we recorded a preliminary pre-tax loss of $56.2 million on the sale of these brands. In addition, as discussed in Note 3, in connection with this sale, the buyer exercised its option to purchase the Dermoplast brand. The sale of Dermoplast was completed on December 30, 2016, and we received $48.4 million. As a result, we reduced intangible assets by $31.0 million.

Historically, we received royalty income from the licensing of the names of certain of our brands in geographic areas or markets in which we do not directly compete. We have had royalty agreements for our Comet brand for several years, which included options on behalf of the licensee to purchase license rights in certain geographic areas and markets in perpetuity. In December 2014, we amended these agreements and we sold rights to use of the Comet brand in certain Eastern European countries to a third-party licensee in exchange for $10.0 million as a partial early buyout of the license. The amended agreement provided that we would continue to receive royalty payments of $1.0 million per quarter for the remaining geographic areas and also granted the licensee an option to acquire the license rights in the remaining geographic areas anytime after June 30, 2016. In July 2016, the licensee elected to exercise its option. In August 2016, we received $11.0 million for the purchase of the remaining license rights and, as a result, we recorded a pre-tax gain of $1.2 million and reduced our indefinite-lived trademarks by $9.0 million. Furthermore, the licensee is no longer required to make additional royalty payments to us, and as a result, our future royalty income will be reduced accordingly.

In December 2016, we also completed the sale of the e.p.t brand and, as a result, we reduced intangible assets by $14.8 million.

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

During the fourth quarter of each fiscal year, we perform our annual impairment analysis. We utilized the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test and the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of goodwill and intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record impairment charges in the future. In addition, we considered our market capitalization at February 28, 2017, which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. As a result of our analysis, we determined that the fair values exceeded the carrying values and as such, no impairment charge was recorded in 2017.

The aggregate fair value of the indefinite-lived intangible assets, including indefinite-lived intangible assets of the recently acquired Fleet business which was recently fair valued, exceeded the carrying value by 40.8%. Two of the individual indefinite-lived trade names exceeded their carrying values by less than 10%. The fair values of Beano and Comet exceed their carrying values of $78.4 million and $101.3 million, respectively, by 9.0% each.

After several periods of contraction and given the competitive landscape, including private label, Beano experienced growth in the latter part of the current fiscal year in response to strategic initiatives that we put in place. We expect these trends to continue and have factored this into our projections. The significant assumptions supporting the fair value of Beano include a discount rate of 9.5%, and returning to revenue growth as previously noted, coupled with investments in advertising and promotion that are in line with historical performance. If we are unable to meet our projections, the carrying value of Beano may exceed its fair value, which would result in an impairment charge. For example, a decrease in the annual cash flow of approximately 8.3% compared to the projected cash flow utilized in our analysis, or an increase in the discount rate of approximately 0.6% would result in an impairment charge.

Comet sales have performed in line with our expectations. The significant assumptions supporting the fair value of Comet include a discount rate of 9.5%, coupled with modest revenue growth, and advertising and promotion investments that are in line with historical performance. Revenue declines or changes in assumptions utilized in our quantitative indefinite-lived asset impairment analysis may result in the fair value no longer exceeding the carrying value. For example, a decrease in the annual cash flow of approximately 8.2% for Comet, compared to the projected cash flow utilized in our analysis, or an increase in the discount rate of approximately 0.7% could result in the carrying value of our trade name exceeding its fair value, which would result in an impairment charge. We will continue to review our results against forecasts and assess our assumptions to ensure they continue to be appropriate.

In Australia, all medications that contain Codeine will no longer be available to be sold over-the-counter and will only be sold behind the counter effective February 2018. One of our Australian brands, Painstop, contains Codeine and therefore will be subject to this market change. As a result of this market change, we have determined that an indefinite life is no longer appropriate for Painstop. Based upon our initial assessment of the changes and uncertainty in the market and the competitive landscape of established sellers of Codeine behind the counter, we have significantly reduced our revenue projections and determined that a 10 year life would be appropriate. As such, we have reclassified $2.1 million from an indefinite-lived to a finite-lived intangible asset. At the time of this change in useful life, the fair value exceeded its carrying value.

Additionally, certain of our North American OTC Healthcare and Household Cleaning brands have experienced recent declines in revenues and profitability. While the fair value of these indefinite-lived trade names exceed their respective carrying value by more than 10%, if we experience future declines in revenue or performance not in line with our expectations, the carrying value may no longer be recoverable, in which case a non-cash impairment charge may be recorded in future periods.

The weighted average remaining life for finite-lived intangible assets at March 31, 2017 was approximately 13.4 years, and the amortization expense for the year ended March 31, 2017 was $19.8 million. At March 31, 2017, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



Year Ending March 31,
2018	$	23,356
2019	23,356
2020	23,356
2021	22,933
2022	22,510
Thereafter	198,947
	$	314,458

Long-Term Debt

12 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Long-Term Debt

2012 Senior Notes:

On January 31, 2012, Prestige Brands, Inc. (the "Borrower") issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower could earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes were guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees were joint and several. There were no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and were being amortized over the term of the 2012 Senior Notes. The Company used the net proceeds from the 2016 Senior Notes issuance (discussed below) to repay all of the balances associated with the 2012 Senior Notes.

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower entered into a senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a 7-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a 5-year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25% (discussed below). The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, we entered into Amendment No. 1 ("Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under Term Loan Amendment No. 1 was based, at our option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin. In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver.

On September 3, 2014, we entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provided for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin, and (y) the Term B-2 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio).

Also on September 3, 2014, we entered into Amendment No. 3 ("ABL Amendment No. 3") to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., and (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty.

On May 8, 2015, we entered into Amendment No. 3 ("Term Loan Amendment No. 3") to the 2012 Term Loan. Term Loan Amendment No. 3 provided for (i) the creation of a new class of Term B-3 Loans under the 2012 Term Loan (the "Term B-3 Loans") in an aggregate principal amount of $852.5 million, which combined the outstanding balances of the Term B-1 Loans of $207.5 million and the Term B-2 Loans of $645.0 million, and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief. The maturity date of the Term B-3 Loans remained the same as the Term B-2 Loans' original maturity date of September 3, 2021.

On June 9, 2015, we entered into Amendment No. 4 (“ABL Amendment No. 4”) to the 2012 ABL Revolver. ABL Amendment No. 4 provides for (i) a $35.0 million increase in the accordion feature under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief and (iii) extended the maturity date of the 2012 ABL Revolver to June 9, 2020, which is five years from the effective date of ABL Amendment No. 4.

In connection with the DenTek acquisition on February 5, 2016, we entered into Amendment No. 5 (“ABL Amendment No. 5”) to the 2012 ABL Revolver. ABL Amendment No. 5 temporarily suspended certain financial and related reporting covenants in the 2012 ABL Revolver until the earliest of (i) the date that was 60 calendar days following February 4, 2016, (ii) the date upon which certain of DenTek’s assets were included in the Company’s borrowing base under the 2012 ABL Revolver and (iii) the date upon which the Company received net proceeds from an offering of debt securities.

In connection with the Fleet acquisition, on January 26, 2017, we entered into Amendment No. 4 ("Term Loan Amendment No. 4") to the 2012 Term Loan. Term Loan Amendment No. 4 provides for (i) the refinancing of all of our outstanding term loans and the creation of a new class of Term B-4 Loans under the 2012 Term Loan (the "Term B-4 Loans") in an aggregate principal amount of $1,427.0 million and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief. In addition, Citibank, N.A. was succeeded by Barclays Bank PLC as administrative agent under the 2012 Term Loan.

The 2012 Term Loan, as amended, bears interest at a rate that is based, at our option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 0.75%, or an alternative base rate plus a margin (with a margin step-down to 2.50% per annum based upon achievement of a specified first lien net leverage ratio). For the year ended March 31, 2017, the average interest rate on the 2012 Term Loan was 5.5%.

Also on January 26, 2017, we entered into Amendment No. 6 ("ABL Amendment No. 6") to the 2012 ABL Revolver. ABL Amendment No. 6 provides for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver, (ii) an extension of the maturity date of revolving commitments to January 26, 2022, and (iii) increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility consistent with Term Loan Amendment No. 4. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the year ended March 31, 2017, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.3%.

We used the proceeds from the Term B-4 Loans and borrowings under the 2012 ABL Revolver to finance the acquisition of Fleet, to refinance our outstanding term loans, and to pay fees and expenses incurred in connection with the Fleet acquisition.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.

2016 Bridge Term Loans:

On February 4, 2016, Prestige Brands Holdings, Inc. and the Borrower entered into a bridge credit agreement. The Bridge Credit Agreement provided for term loans in an aggregate principal amount of $80.0 million (the “Bridge Term Loans”), at an applicable interest rate margin equal to (i) for the period beginning on the closing date and ending on the 179th day following the closing date, 4.75% for Eurocurrency rate loans and 3.75% for base rate loans, (ii) for the period from and including the 180th day following the closing date and ending on the 269th day following the closing date, 5.00% for Eurocurrency rate loans and 4.00% for base rate loans, and (iii) for the period from and after the 270th day following the closing date, 5.25% for Eurocurrency rate loans and 4.25% for base rate loans. The Bridge Term Loans would have matured on February 2, 2017. The proceeds were used to partially fund the acquisition of DenTek. However, the Company used the net proceeds from the 2016 Senior Notes issuance (discussed below) to repay all of these Bridge Term Loans on February 19, 2016. In connection with the repayment of the Bridge Loan on February 19, 2016, we expensed $1.9 million of unamortized debt issuance costs which were classified as interest expense.

2016 Senior Notes:

On February 19, 2016, the Borrower completed the sale of $350.0 million aggregate principal amount of 6.375% senior notes due 2024 (the “2016 Senior Notes”), pursuant to a purchase agreement, dated February 16, 2016, among the Borrower, the guarantors party thereto (the “Guarantors”) and the initial purchasers party thereto. The 2016 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the Guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2016 Senior Notes offering, we incurred $5.5 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2016 Senior Notes. The proceeds were used to redeem the 2012 Senior Notes and repay the Bridge Term Loans that were utilized to partially fund the acquisition of DenTek.

The 2016 Senior Notes were issued pursuant to an indenture, dated February 19, 2016 (the “Indenture”). The Indenture provides, among other things, that interest will be payable on the 2016 Senior Notes on March 1 and September 1 of each year, beginning on September 1, 2016, until their maturity date of March 1, 2024. The 2016 Senior Notes are senior unsecured obligations of the Borrower.

Redemptions and Restrictions:

On February 19, 2016, the Company used the net proceeds from the 2016 Senior Notes issuance to redeem all of the 2012 Senior Notes at a redemption price equal to 104.063%, plus accrued and unpaid interest, and repay all of the Bridge Term Loans.

At any time prior to December 15, 2016, we had the option to redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we have had the option to redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we had the option to redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions were met. Subject to certain limitations, in the event of a change of control (as defined in the indenture governing the 2013 Senior Notes), the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

We have the option to redeem all or a portion of the 2016 Senior Notes at any time on or after March 1, 2019 at the redemption prices set forth in the Indenture, plus accrued and unpaid interest, if any. We may also redeem all or any portion of the 2016 Senior Notes at any time prior to March 1, 2019, at a price equal to 100% of the aggregate principal amount of notes redeemed, plus a "make-whole premium" calculated as set forth in the Indenture and accrued and unpaid interest, if any. In addition, before March 1, 2019, we may redeem up to 40% of the aggregate principal amount of the 2016 Senior Notes with the net proceeds of certain equity offerings, at the redemption price set forth in the Indenture, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control (as defined in the Indenture), we will be required to make an offer to purchase the 2016 Senior Notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

The indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes. At March 31, 2017, we were in compliance with the covenants under our long-term indebtedness.

Effective April 1, 2015, the Company elected to change its method of presentation relating to debt issuance costs in accordance with ASU 2015-03. Prior to 2016, the Company's policy was to present these costs in other long-term assets on the balance sheet, net of accumulated amortization. Beginning in 2016, the Company has presented these fees as a direct deduction to the related long-term debt. As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, and such costs are now presented as a direct deduction from the long-term debt liability.

At March 31, 2017, we had an aggregate of $1.3 million of unamortized debt costs related to the 2012 ABL Revolver included in other long-term assets, and $28.3 million of unamortized debt costs included in long-term debt costs, the total of which is comprised of $4.6 million related to the 2013 Senior Notes, $4.9 million related to the 2016 Senior Notes, and $18.8 million related to the 2012 Term Loan.

At March 31, 2016 we had an aggregate of $1.3 million of unamortized debt costs related to the 2012 ABL Revolver included in other long-term assets, and $27.2 million of unamortized debts costs included in long-term debt costs, the total of which is comprised of $5.4 million related to the 2013 Senior Notes, $5.4 million related to the 2016 Senior Notes, and $16.4 million related to the 2012 Term Loan.

At March 31, 2017, we had $90.0 million outstanding on the 2012 ABL Revolver and a borrowing capacity of $82.6 million.

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31, 2017			March 31, 2016
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024.	350,000			350,000
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	400,000			400,000
2012 Term B-4 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.75%, with a LIBOR floor of 0.75%, or a base rate plus a margin (with a margin step-down to 2.50%) due on January 26, 2024.	1,382,000			817,500
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022.	90,000			85,000
Total long-term debt (including current portion)	2,222,000			1,652,500
Current portion of long-term debt	—			—
Long-term debt	2,222,000			1,652,500
Less: unamortized debt costs	(28,268		)	(27,191		)
Long-term debt, net	$	2,193,732		$	1,625,309

As of March 31, 2017, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2016 Senior Notes and the 2013 Senior Notes are as follows:



(In thousands)
Year Ending March 31,	Amount
2018	$	—
2019	—
2020	—
2021	12,080
2022	504,270
Thereafter	1,705,650
	$	2,222,000

Fair Value Measurements

12 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant.

The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2013 Senior Notes, the Term B-4 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy (see summary below detailing the carrying amounts and estimated fair values of these borrowings at March 31, 2017 and 2016).



	March 31, 2017				March 31, 2016
(In thousands)	Carrying Value		Fair Value		Carrying Value		Fair Value
2016 Senior Notes	$	350,000	$	367,500	$	350,000	$	363,125
2013 Senior Notes	400,000		409,000		400,000		408,000
Term B-4 Loans	1,382,000		1,395,820		817,500		818,522
2012 ABL Revolver	90,000		90,000		85,000		85,000

At March 31, 2017 and 2016, we did not have any assets or liabilities measured in Level 1 or 3. During 2017, 2016 and 2015, there were no transfers of assets or liabilities between Levels 1, 2 and 3.

In accordance with ASU 2015-07, investments that are measured at fair value using net asset value ("NAV") per share as a practical expedient have not been classified in the fair value hierarchy.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through March 31, 2017. Pursuant to the provisions of various employee restricted stock awards, we repurchased 25,768 shares and 40,316 shares of restricted common stock from our employees during the years ended March 31, 2017 and 2016, respectively. The repurchases during the years ended March 31, 2017 and 2016 were at an average price of $55.51 and $41.80, respectively. All of the repurchased shares have been recorded as treasury stock.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Earnings Per Share

12 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:



	Year Ended March 31,
(In thousands, except per share data)	2017		2016		2015
Numerator
Net income	$	69,395	$	99,907	$	78,260

Denominator
Denominator for basic earnings per share - weighted average shares outstanding	52,976		52,754		52,170
Dilutive effect of unvested restricted stock units and options issued to employees and directors	386		389		500
Denominator for diluted earnings per share	53,362		53,143		52,670

Earnings per Common Share:
Basic net earnings per share	$	1.31	$	1.89	$	1.50

Diluted net earnings per share	$	1.30	$	1.88	$	1.49

For 2017, 2016, and 2015 there were 0.2 million, less than 0.1 million, and 0.3 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Share-Based Compensation

12 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Compensation

Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, the stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, increased the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any 12-month period from 1.0 million to 2.5 million shares, and extended the term of the Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During 2017, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $8.1 million and $2.6 million, respectively.

During 2016, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $10.0 million and $3.5 million, respectively.

During 2015, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $6.9 million and $1.9 million, respectively.

At March 31, 2017, there were $7.9 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management’s estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 0.8 years. The total fair value of options and restricted shares vested during 2017, 2016, and 2015 was $6.0 million, $7.0 million and $4.7 million, respectively. During the years ended March 31, 2017, 2016 and 2015, there were 94,718, 155,603 and 154,418 shares of restricted stock units that vested, respectively, and we issued shares of common stock. Additionally, we issued common stock as a result of 126,820, 348,055 and 386,254 stock options that were exercised during 2017, 2016 and 2015, respectively. Cash received from the exercise of stock options was $4.0 million during 2017, and we realized $0.9 million in tax benefits for the tax deductions resulting from option exercises in 2017. Cash received from the exercise of stock options was $6.7 million during 2016, and we realized $2.1 million in tax benefits for the tax deductions resulting from option exercises in 2016. Cash received from the exercise of stock options was $4.0 million during 2015, and we realized $2.2 million in tax benefits for the tax deductions from option exercises in 2015. At March 31, 2017, there were 2.4 million shares available for issuance under the Plan.

On May 9, 2016, the Compensation Committee of our Board of Directors granted 49,064 shares of restricted stock units and stock options to acquire 224,843 shares of our common stock to certain executive officers and employees under the Plan. All of the shares of restricted stock units vest in their entirety on the three-year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $57.18 per share, which is equal to the closing price for our common stock on the date of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested restricted stock units and the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.

On September 12, 2016, we announced that Christine Sacco had been appointed as Chief Financial Officer of the Company, effective that same day. In connection with Ms. Sacco's appointment as Chief Financial Officer on September 12, 2016, the Company executed an offer letter with Ms. Sacco, which sets forth the terms of her compensation as approved by the Compensation Committee of the Board of Directors. In accordance with the terms of her offer letter, the Company granted Ms. Sacco 5,012 shares of restricted stock units and stock options to acquire 25,746 shares of our common stock under the Plan. The restricted stock units vest in their entirety on the three-year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $47.39 per share, which is equal to the closing price of our common stock on the date of grant.

On November 14, 2016, we announced that William C. P'Pool had been appointed as Senior Vice President, General Counsel and Corporate Secretary, effective that same day. In connection with Mr. P'Pool's appointment as Senior Vice President, General Counsel and Corporate Secretary on November 14, 2016, the Company executed an offer letter with Mr. P'Pool, which sets forth the terms of his compensation as approved by the Compensation Committee of the Board of Directors. In accordance with the terms of his offer letter, the Company granted Mr. P'Pool 2,664 shares of restricted stock units and stock options to acquire 13,683 shares of our common stock under the Plan. The restricted stock units vest in their entirety on the three-year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $50.06 per share, which is equal to the closing price of our common stock on the date of grant.

Restricted Stock Units

Restricted stock units ("RSUs") granted to employees under the Plan generally vest over three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The RSUs provide for accelerated vesting if there is a change of control, as defined in the Plan. The RSUs granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the RSUs, unless otherwise accelerated by the Compensation Committee. The RSUs granted to directors vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, and will be settled by delivery to the director of one share of common stock of the Company for each vested RSU promptly following the earliest of the director's (i) death, (ii) disability or (iii) six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability.

At our annual meeting date on August 2, 2016, each of our six independent members of the Board of Directors received a grant of 1,896 restricted stock units under the Plan. Additionally, on May 26, 2016, the Compensation Committee granted 346 restricted stock units to a newly appointed Board member.

The fair value of the restricted stock units is determined using the closing price of our common stock on the date of the grant. The weighted-average grant-date fair value of restricted stock units granted during 2017, 2016, and 2015 was $55.44, $42.41 and $33.33, respectively.

A summary of the Company’s RSUs granted under the Plan is presented below:



RSUs	Shares (in thousands)		Weighted-Average Grant-Date Fair Value
Vested and Nonvested at March 31, 2014	437.5		$	16.76

Granted	106.9		33.33
Vested and issued	(154.4	)	13.37
Forfeited	(27.7	)	21.45
Vested and nonvested at March 31, 2015	362.3		22.74
Vested at March 31, 2015	76.6		11.62

Granted	266.1		42.41
Vested and issued	(155.6	)	18.31
Forfeited	(5.0	)	39.61
Vested and nonvested at March 31, 2016	467.8		35.22
Vested at March 31, 2016	69.8		14.76

Granted	68.4		55.44
Vested and issued	(94.7	)	28.51
Forfeited	(91.4	)	41.71
Vested and nonvested at March 31, 2017	350.1		39.29
Vested at March 31, 2017	63.4		20.12

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms of the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management’s estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options.

The weighted-average grant-date fair values of the options granted during 2017, 2016, and 2015 were $21.75, $17.24, and $15.95, respectively.



	Year Ended March 31,
	2017		2016		2015
Expected volatility	37.8	%	40.2	%	47.3	%
Expected dividends	—		—		—
Expected term in years	6.0		6.0		6.0
Risk-free rate	1.7	%	1.7	%	2.2	%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2014	994.9		$	15.24

Granted	317.9		33.54
Exercised	(386.3	)	10.24
Forfeited or expired	(55.3	)	26.77
Outstanding at March 31, 2015	871.2		23.40

Granted	208.2		42.13
Exercised	(348.0	)	19.22
Forfeited or expired	(3.7	)	35.72
Outstanding at March 31, 2016	727.7		30.70

Granted	264.3		55.86
Exercised	(126.8	)	31.75
Forfeited or expired	(92.9	)	42.66
Outstanding at March 31, 2017	772.3		37.70		7.3	$	14,118
Exercisable at March 31, 2017	367.4		25.40		6.0	$	11,083

The aggregate intrinsic value of options exercised during 2017, 2016 and 2015 was $3.2 million, $8.6 million and $9.3 million, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Income Taxes

12 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

Income before income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2017		2016		2015
United States	$	93,582	$	142,253	$	122,588
Foreign	17,268		14,932		4,870
	$	110,850	$	157,185	$	127,458

The provision for income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2017			2016			2015
Current
Federal	$	40,183		$	6,080		$	13,066
State	2,808			1,171			760
Foreign	4,242			3,905			3,228
Deferred
Federal	(5,421		)	44,787			31,012
State	(163		)	1,678			1,162
Foreign	(194		)	(343		)	(30		)
Total provision for income taxes	$	41,455		$	57,278		$	49,198

The principal components of our deferred tax balances are as follows:



	March 31,
(In thousands)	2017			2016
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	5,280		$	5,083
Inventory capitalization	1,881			1,838
Inventory reserves	1,880			1,367
Net operating loss carryforwards	609			12,350
State income taxes	17,727			10,293
Accrued liabilities	2,174			2,162
Accrued compensation	9,574			—
Stock compensation	5,790			4,411
Other	7,925			300
Total deferred tax assets	52,840			37,804

Deferred Tax Liabilities
Property, plant and equipment	(9,157		)	(833		)
Intangible assets	(754,322		)	(496,485		)
Total deferred tax liabilities	(763,479		)	(497,318		)

Net deferred tax liability before valuation allowance	$	(710,639	)	$	(459,514	)
Valuation allowance	(3,437		)	—
Net deferred tax liability	$	(714,076	)	$	(459,514	)

The net deferred tax liability shown above is net of $1.0 million of long-term deferred tax assets as of March 31, 2017 and $10.1 million of short-term deferred tax assets as of March 31, 2016.

At March 31, 2017 we have a valuation allowance of $3.4 million related to certain deferred tax assets acquired from Fleet that we have concluded are not more likely than not to be realized.

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
	2017					2016					2015
(In thousands)				%					%					%
Income tax provision at statutory rate	$	38,798		35.0		$	55,015		35.0		$	44,610		35.0
Foreign tax benefit	(2,322		)	(2.1	)	(2,894		)	(1.8	)	(2,019		)	(1.6	)
State income taxes, net of federal income tax benefit	1,820			1.7		3,284			2.0		2,865			2.3
Goodwill adjustment for sale of asset	3,208			2.9		—			—		206			0.2
Nondeductible transaction costs	686			0.6		1,071			0.7		2,936			2.3
Nondeductible compensation	342			0.3		758			0.5		566			0.4
Other	(1,076		)	(1.0	)	44			—		34			—
Total provision for income taxes	$	41,456		37.4		$	57,278		36.4		$	49,198		38.6

Uncertain tax liability activity is as follows:



	2017			2016		2015
(In thousands)
Balance – beginning of year	$	4,084		$	3,420	$	1,236
Additions based on tax positions related to the current year	583			664		2,229
Reductions based on lapse of statute of limitations	(1,016		)	—		(45		)
Balance – end of year	$	3,651		$	4,084	$	3,420

We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in 2015, 2016 or 2017. The amount of unrecognized tax benefits at March 31, 2017, 2016, and 2015 was $3.7 million, $4.1 million, and $3.4 million, respectively, which would reduce the effective tax rate by 3.3%, 2.6%, and 2.7%, respectively, if recognized. We do not anticipate any events or circumstances that would cause a significant change to these uncertainties during the ensuing year. We are subject to taxation in the United States and various state and foreign jurisdictions, and we are generally open to examination from the year ended March 31, 2014 forward.

The Company does not provide for U.S. income taxes on the undistributed earnings of our Australian subsidiary, which is intended to be indefinitely reinvested in operations outside of the United States. As of March 31, 2017, the cumulative amount of earnings upon which U.S. income taxes have not been provided is approximately $42.5 million. As of March 31, 2017, the amount of unrecognized deferred tax liability related to these earnings is estimated to be $4.8 million.

Employee Retirement Plans

12 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Emploee Retirement Plans

Employee Retirement Plans

Benefit Obligations and Plan Assets

The following table summarizes the changes in the U.S. pension plan obligations and plan assets from the date of acquisition to the end of our fiscal year, and includes a statement of the plans' funded status as of March 31, 2017:



	Period Ended
(In thousands)	March 31, 2017
Change in benefit obligation:
Projected benefit obligation at date of acquisition	$	61,187
Interest cost	456
Actuarial (gain) loss	791
Benefits paid	(720		)
Projected benefit obligations at end of year	$	61,714

Change in plan assets:
Fair value of plan assets at date of acquisition	$	41,560
Actual return on plan assets	854
Employer contribution	6,078
Benefits paid	(720		)
Fair value of plan assets at end of year	$	47,772

Funded status at end of year	$	(13,942	)

Amounts recognized in the balance sheet at the end of the period consist of the following:



	Period Ended
(In thousands)	March 31, 2017
Current liability	$	463
Long-term liability	13,479
Total	$	13,942

The primary components of Net Periodic Benefits consist of the following:



	Period Ended
(In thousands)	March 31, 2017
Interest cost	$	456
Expected return on assets	(462		)
Net periodic benefit cost (income)	$	(6	)

The accumulated benefit obligation was $61.7 million at March 31, 2017, and we had a net periodic benefit of less than $1.0 million for 2017.

The pension benefit amounts stated above include one pension plan that is an unfunded plan. The projected benefit obligation and accumulated benefit obligation for this unfunded plan were $6.0 million as of March 31, 2017.

The following table includes amounts that are expected to be contributed to the plans by the Company. It reflects benefit payments that are made from the plans' assets as well as those made directly from the Company's assets and includes the participants' share of the cost, which is funded by participant contributions. The amounts in the table are actuarially determined and reflect the Company's best estimate given its current knowledge; actual amounts could be materially different.



(In thousands)	Pension Benefits
Employer contributions:
2018 (expectation) to participant benefits	$	463

Expected benefit payments year ending March 31,
2018	$	3,152
2019	3,254
2020	3,329
2021	3,416
2022	3,578
2023-2027	18,888

During March 2017, we funded $6.1 million to the plan, which was invested as described in the plan assets below.

The Company's primary investment objective for its pension plan assets is to provide a source of retirement income for the plans' participants and beneficiaries. The asset allocation for the Company's funded retirement plan as of March 31, 2017, and the target allocation by asset category are as follows:



Asset Category	Target Allocation		Percentage of Plan Assets
Domestic large cap equities	36	%	41	%
Domestic small/mid cap equities	9		7
International equities	15		16
Balanced/asset allocation	4		2
Fixed income and cash	36		34
Total	100	%	100	%

The plan assets are invested in a diversified portfolio consisting primarily of domestic fixed income and publicly traded equity securities held within pooled separate mutual funds. International funds represent 16% of the portfolio. These assets are fair valued using NAV.

The following tables show the unrecognized actuarial loss included in accumulated other comprehensive income at March 31, 2017, as well as the prior service cost credit and actuarial loss expected to be reclassified from accumulated other comprehensive income (loss) to retirement expense during 2018:



(In thousands)
Balances in accumulated other comprehensive income (loss) as of March 31, 2017:
Unrecognized actuarial (loss)	$	399
Unrecognized prior service credit	—

Amounts expected to be reclassified from accumulated other comprehensive income (loss) during 2018:
Unrecognized actuarial (loss)	$	—
Unrecognized prior service credit	—

Assumptions used in determining the actuarial present value of the benefit obligation as of March 31, 2017 were as follows:



Weighted-average assumptions:
Discount rate	4.21	%
Expected return on plan assets	6.25	%
Rate of compensation increase	—

The determination of the expected long-term rate of return was derived from an optimized portfolio using an asset allocation software program. The risk and return assumptions, along with the correlations between the asset classes, were entered into the program. Based on these assumptions and historical experience, the portfolio is expected to achieve a long-term rate of return of 6.25%. The investment managers engaged to manage the portfolio are expected to outperform their expected benchmarks on a relative basis over a full market cycle.

Commitments and Contingencies

12 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

We are involved from time to time in routine legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess probability and amount of potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations.

Lease Commitments

We have operating leases for office facilities and equipment, including New York and other locations, which expire at various dates through fiscal 2023. These amounts have been included in the table below.

The following summarizes future minimum lease payments for our operating leases ^(a):



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2018	$	2,743	$	565	$	3,308
2019	2,787		248		3,035
2020	2,587		99		2,686
2021	1,451		7		1,458
2022	478		4		482
Thereafter	13		—		13
	$	10,059	$	923	$	10,982

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $0.7 million due in the future under non cancellable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



	Year ending March 31,
(In thousands)	2017			2016
Minimum lease payments	$	10,982		$	8,434
Less: Sublease rentals	(690		)	(1,165		)
	$	10,292		$	7,269

Rent expense was $2.0 million, $1.8 million, and $1.6 million for 2017, 2016, and 2015, respectively.

Purchase Commitments

Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.



(In thousands)
Year Ending March 31,
2018	$	1,013
2019	982
2020	559
2021	—
2022	—
Thereafter	—
	$	2,554

Concentrations of Risk	12 Months Ended
Concentrations of Risk	Mar. 31, 2017
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and convenience, dollar and club stores. During 2017, 2016, and 2015, approximately 40.0%, 41.9%, and 38.2%, respectively, of our gross revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. During 2017, 2016, and 2015, Walmart accounted for approximately 21.1%, 20.2%, and 18.1%, respectively, of our gross revenues. At March 31, 2017, approximately 33.1% of accounts receivable were owed by Walmart. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At March 31, 2017, we had relationships with 113 third-party manufacturers. Of those, we had long-term contracts with 47 manufacturers that produced items that accounted for approximately 78.4% of our gross sales for 2017, compared to 55 manufacturers with long-term contracts that accounted for approximately 79.9% of gross sales in 2016. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results from operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

12 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Business Segments

Segment information has been prepared in accordance with the Segment Reporting topic of FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.

The tables below summarize information about our operating and reportable segments.



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	724,991		$	73,287	$	87,035	$	885,313
Elimination of intersegment revenues	(4,200		)	—		—		(4,200		)
Third-party segment revenues	720,791			73,287		87,035		881,113
Other revenues	33			17		897		947
Total segment revenues	720,824			73,304		87,932		882,060
Cost of sales	282,750			30,789		68,235		381,774
Gross profit	438,074			42,515		19,697		500,286
Advertising and promotion	112,465			13,434		2,460		128,359
Contribution margin	$	325,609		$	29,081	$	17,237	371,927
Other operating expenses*								166,314
Operating income								205,613
Other expense								94,763
Income before income taxes								110,850
Provision for income taxes								41,455
Net income								$	69,395

*Other operating expenses for the year ended March 31, 2017 includes a pre-tax net loss of $51.8 million related to divestitures. These divestitures include Pediacare, New Skin, Fiber Choice, e.p.t, Dermoplast, and license rights in certain geographic areas pertaining to Comet. The assets and corresponding contribution margin associated with the pre-tax net loss on divestitures related to Pediacare, New Skin, Fiber Choice, e.p.t and Dermoplast are included within the North American OTC Healthcare segment, while the pre-tax gain on sale of license rights related to Comet are included in the Household Cleaning segment.



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues**	$	660,518		$	57,670	$	87,561	$	805,749
Elimination of intersegment revenues	(2,661		)	—		—		(2,661		)
Third-party segment revenues	657,857			57,670		87,561		803,088
Other revenues**	14			43		3,102		3,159
Total segment revenues	657,871			57,713		90,663		806,247
Cost of sales**	250,018			21,676		67,342		339,036
Gross profit	407,853			36,037		23,321		467,211
Advertising and promotion	97,393			11,114		2,295		110,802
Contribution margin	$	310,460		$	24,923	$	21,026	356,409
Other operating expenses								96,094
Operating income								260,315
Other expense								103,130
Income before income taxes								157,185
Provision for income taxes								57,278
Net income								$	99,907



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues**	$	569,643		$	57,729	$	86,085	$	713,457
Elimination of intersegment revenues	(3,387		)	—		—		(3,387		)
Third-party segment revenues	566,256			57,729		86,085		710,070
Other revenues	637			64		3,852		4,553
Total segment revenues	566,893			57,793		89,937		714,623
Cost of sales	216,781			22,820		68,799		308,400
Gross profit	350,112			34,973		21,138		406,223
Advertising and promotion	86,897			10,922		1,832		99,651
Contribution margin	$	263,215		$	24,051	$	19,306	306,572
Other operating expenses								99,013
Operating income								207,559
Other expense								80,101
Income before income taxes								127,458
Provision for income taxes								49,198
Net income								$	78,260

**Certain immaterial amounts relating to gross segment revenues, other revenues and cost of sales for each of the years ended March 31, 2016 and 2015 were reclassified between the International OTC Healthcare segment and the North American OTC Healthcare segment. There were no changes to the consolidated financial statements for any periods presented.

The tables below summarize information about our segment revenues from similar product groups.



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	120,253	$	1,922	$	—	$	122,175
Cough & Cold	90,795		17,990		—		108,785
Women's Health	147,071		3,811		—		150,882
Gastrointestinal	76,500		24,812		—		101,312
Eye & Ear Care	97,618		12,075		—		109,693
Dermatologicals	85,194		2,159		—		87,353
Oral Care	97,586		10,513		—		108,099
Other OTC	5,807		22		—		5,829
Household Cleaning	—		—		87,932		87,932
Total segment revenues	$	720,824	$	73,304	$	87,932	$	882,060



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	117,337	$	2,128	$	—	$	119,465
Cough & Cold	100,148		16,422		—		116,570
Women's Health	132,184		2,982		—		135,166
Gastrointestinal	74,568		20,019		—		94,587
Eye & Ear Care	95,515		11,983		—		107,498
Dermatologicals	82,941		2,133		—		85,074
Oral Care	49,099		2,026		—		51,125
Other OTC	6,079		20		—		6,099
Household Cleaning	—		—		90,663		90,663
Total segment revenues	$	657,871	$	57,713	$	90,663	$	806,247



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	111,954	$	2,597	$	—	$	114,551
Cough & Cold	103,686		18,080		—		121,766
Women's Health	71,506		2,261		—		73,767
Gastrointestinal	77,596		19,372		—		96,968
Eye & Ear Care	85,236		12,689		—		97,925
Dermatologicals	64,806		2,289		—		67,095
Oral Care	45,916		483		—		46,399
Other OTC	6,193		22		—		6,215
Household Cleaning	—		—		89,937		89,937
Total segment revenues	$	566,893	$	57,793	$	89,937	$	714,623

During fiscal 2017, 2016, and 2015, approximately 87.3%, 87.4%, and 85.2%, respectively, of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of total segment revenues in any of the periods presented. During fiscal 2017, 2016, and 2015, our Canada sales accounted for approximately 4.8%, 5.2%, and 5.9%, respectively, of our total segment revenues. During fiscal 2017, 2016, and 2015, our Australia sales accounted for approximately 5.2%, 5.6% and 6.9%, respectively, of our total segment revenues.

At March 31, 2017 and 2016, approximately 96.5% and 95.9%, respectively, of our consolidated goodwill and intangible assets were located in the United States and approximately 3.5% and 4.1%, respectively, were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



March 31, 2017 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	576,453	$	32,554	$	6,245	$	615,252

Intangible assets
Indefinite-lived	2,404,336		83,558		101,261		2,589,155
Finite-lived	287,056		6,468		20,934		314,458
Intangible assets, net	2,691,392		90,026		122,195		2,903,613
Total	$	3,267,845	$	122,580	$	128,440	$	3,518,865



March 31, 2016 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	330,615	$	22,776	$	6,800	$	360,191

Intangible assets
Indefinite-lived	1,823,873		85,901		110,272		2,020,046
Finite-lived	277,762		2,237		22,678		302,677
Intangible assets, net	2,101,635		88,138		132,950		2,322,723
Total	$	2,432,250	$	110,914	$	139,750	$	2,682,914

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Unaudited Quarterly Financial Information

12 Months Ended

Mar. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Unaudited Quarterly Financial Information

Unaudited quarterly financial information for 2017 and 2016 is as follows:

Year Ended March 31, 2017



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2016			September 30, 2016			December 31, 2016			March 31, 2017
Total revenues	$	209,575		$	215,052		$	216,763		$	240,670
Cost of sales	87,984			91,087			92,216			110,487
Gross profit	121,591			123,965			124,547			130,183

Operating expenses
Advertising and promotion	27,635			28,592			30,682			41,450
General and administrative	19,457			18,795			22,131			28,760
Depreciation and amortization	6,832			6,016			5,852			6,651
Loss (gain) on divestitures	55,453			(496		)	(3,405		)	268
Total operating expenses	109,377			52,907			55,260			77,129
Operating income	12,214			71,058			69,287			53,054
Net interest expense	21,127			20,830			18,554			32,832
Loss on extinguishment of debt	—			—			—			1,420
(Loss) income before income taxes	(8,913		)	50,228			50,733			18,802
(Benefit) provision for income taxes	(3,382		)	18,033			19,092			7,712
Net (loss) income	$	(5,531	)	$	32,195		$	31,641		$	11,090

(Loss) earnings per share:
Basic	$	(0.10	)	$	0.61		$	0.60		$	0.21
Diluted	$	(0.10	)	$	0.60		$	0.59		$	0.21

Weighted average shares outstanding:
Basic	52,881			52,993			52,999			53,009
Diluted	52,881			53,345			53,359			53,419

Comprehensive (loss) income, net of tax:
Currency translation adjustments	(5,824		)	2,703			(8,736		)	9,282
Unrecognized net loss on pension plans										(252		)
Total other comprehensive (loss) income	(5,824		)	2,703			(8,736		)	9,030
Comprehensive (loss) income	$	(11,355	)	$	34,898		$	22,905		$	20,120

Year Ended March 31, 2016



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2015			September 30, 2015			December 31, 2015		March 31, 2016
Total revenues	$	192,132		$	206,065		$	200,195	$	207,855
Cost of sales (exclusive of depreciation shown below)	79,896			86,125			83,411		89,604
Gross profit	112,236			119,940			116,784		118,251

Operating expenses
Advertising and promotion	26,422			27,893			29,935		26,552
General and administrative	17,589			16,462			18,135		20,232
Depreciation and amortization	5,720			5,687			6,071		6,198
	49,731			50,042			54,141		52,982
Operating income	62,505			69,898			62,643		65,269
Net interest expense	21,884			20,667			19,462		23,147
Loss on extinguishment of debt	451			—			—		17,519
Income before income taxes	40,170			49,231			43,181		24,603
Provision for income taxes	13,997			17,428			15,186		10,667
Net income	$	26,173		$	31,803		$	27,995	$	13,936

Earnings per share:
Basic	$	0.50		$	0.60		$	0.53	$	0.26
Diluted	$	0.49		$	0.60		$	0.53	$	0.26

Weighted average shares outstanding:
Basic	52,548			52,803			52,824		52,833
Diluted	52,958			53,151			53,203		53,252

Comprehensive income, net of tax:
Currency translation adjustments	(405		)	(11,079		)	4,922		6,449
Total other comprehensive income (loss)	(405		)	(11,079		)	4,922		6,449
Comprehensive income	$	25,768		$	20,724		$	32,917	$	20,385

Condensed Consolidating Financial Statements

12 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Financial Statements

As described in Note 10, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2016 Senior Notes and the 2013 Senior Notes, including the obligation to pay principal and interest with respect to the 2016 Senior Notes and the 2013 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2016 Senior Notes and the 2013 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., Medtech Personal Products Corporation, The Spic and Span Company, Blacksmith Brands, Inc., Insight Pharmaceuticals Corporation, Insight Pharmaceuticals, LLC, Practical Health Products, Inc., DenTek Holdings, Inc., C.B. Fleet Topco, LLC, C.B. Fleet Holdco, LLC, C.B.Fleet, LLC, C.B. Fleet Company, Incorporated, Peaks HBC Company, Inc., C.B. Fleet Investment Corporation, C.B.Fleet International, Inc., C.B. Fleet Holding Company, Incorporated, Medtech Online, Inc. and DenTek Oral Care, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2016 Senior Notes and the 2013 Senior Notes. Although holders of the 2016 Senior Notes and the 2013 Senior Notes will be direct creditors of the guarantors of the 2016 Senior Notes and the 2013 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands, Singapore and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2016 Senior Notes or the 2013 Senior Notes, and such subsidiaries will not be obligated with respect to the 2016 Senior Notes or the 2013 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2016 Senior Notes and the 2013 Senior Notes.

Presented below are supplemental Condensed Consolidating Balance Sheets as of March 31, 2017 and 2016 and Condensed Consolidating Income and Comprehensive Income Statements and Condensed Consolidating Statements of Cash Flows for each year in the three year period ended March 31, 2017. Such consolidating information includes separate columns for:

a) Prestige Brands Holdings, Inc., the parent,

b) Prestige Brands, Inc., the Issuer or the Borrower,

c) Combined Subsidiary Guarantors,

d) Combined Non-Guarantor Subsidiaries, and

e) Elimination entries necessary to consolidate the Company and all of its subsidiaries.

The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Annual Report on Form 10-K for the fiscal year ended March 31, 2017.

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2017



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	112,557		$	708,335		$	64,422		$	(4,201	)	$	881,113
Other revenues	—			295			1,033			1,655			(2,036		)	947
Total revenues	—			112,852			709,368			66,077			(6,237		)	882,060

Cost of Sales
Cost of sales	—			49,101			311,813			26,666			(5,806		)	381,774
Gross profit	—			63,751			397,555			39,411			(431		)	500,286

Operating Expenses
Advertising and promotion	—			13,581			101,573			13,205			—			128,359
General and administrative	6,612			9,033			65,528			7,970			—			89,143
Depreciation and amortization	3,170			634			21,013			534			—			25,351
Loss on divestitures	—			—			51,820			—			—			51,820
Total operating expenses	9,782			23,248			239,934			21,709			—			294,673
Operating income (loss)	(9,782		)	40,503			157,621			17,702			(431		)	205,613

Other (income) expense
Interest income	(47,881		)	(85,064		)	(5,644		)	(1,217		)	139,603			(203		)
Interest expense	33,734			93,538			100,233			5,644			(139,603		)	93,546
Loss on extinguishment of debt	—			1,420			—			—			—			1,420
Equity in (income) loss of subsidiaries	(67,467		)	(49,302		)	(9,481		)	—			126,250			—
Total other (income) expense	(81,614		)	(39,408		)	85,108			4,427			126,250			94,763
Income (loss) before income taxes	71,832			79,911			72,513			13,275			(126,681		)	110,850
Provision for income taxes	2,437			11,448			23,776			3,794			—			41,455
Net income (loss)	$	69,395		$	68,463		$	48,737		$	9,481		$	(126,681	)	$	69,395

Comprehensive income, net of tax:
Currency translation adjustments	(2,575		)	(2,575		)	(2,575		)	(2,575		)	7,725			(2,575		)
Unrecognized net loss on pension plans	(252		)	(252		)	(252		)	—			504			(252		)
Total other comprehensive income (loss)	(2,827		)	(2,827		)	(2,827		)	(2,575		)	8,229			(2,827		)
Comprehensive income (loss)	$	66,568		$	65,636		$	45,910		$	6,906		$	(118,452	)	$	66,568

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	111,747		$	643,330		$	50,672		$	(2,661	)	$	803,088
Other revenues	—			347			3,116			1,776			(2,080		)	3,159
Total revenues	—			112,094			646,446			52,448			(4,741		)	806,247

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			45,763			280,169			18,459			(5,355		)	339,036
Gross profit	—			66,331			366,277			33,989			614			467,211

Operating Expenses
Advertising and promotion	—			9,465			90,353			10,984			—			110,802
General and administrative	5,737			9,098			51,198			6,385			—			72,418
Depreciation and amortization	4,050			594			18,617			415			—			23,676
Total operating expenses	9,787			19,157			160,168			17,784			—			206,896
Operating income (loss)	(9,787		)	47,174			206,109			16,205			614			260,315

Other (income) expense
Interest income	(48,342		)	(85,882		)	(5,087		)	(531		)	139,680			(162		)
Interest expense	34,553			84,822			100,540			5,087			(139,680		)	85,322
Loss on extinguishment of debt	—			17,970			—			—			—			17,970
Equity in (income) loss of subsidiaries	(98,803		)	(70,953		)	(8,564		)	—			178,320			—
Total other (income) expense	(112,592		)	(54,043		)	86,889			4,556			178,320			103,130
Income (loss) before income taxes	102,805			101,217			119,220			11,649			(177,706		)	157,185
Provision for income taxes	2,898			11,016			40,279			3,085			—			57,278
Net income (loss)	$	99,907		$	90,201		$	78,941		$	8,564		$	(177,706	)	$	99,907

Comprehensive income, net of tax:
Currency translation adjustments	(113		)	(113		)	(113		)	(113		)	339			(113		)
Total other comprehensive (loss) income	(113		)	(113		)	(113		)	(113		)	339			(113		)
Comprehensive income (loss)	$	99,794		$	90,088		$	78,828		$	8,451		$	(177,367	)	$	99,794

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	106,439		$	555,388		$	51,630		$	(3,387	)	$	710,070
Other revenues	—			385			4,452			1,497			(1,781		)	4,553
Total revenues	—			106,824			559,840			53,127			(5,168		)	714,623

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			39,637			254,670			19,127			(5,034		)	308,400
Gross profit	—			67,187			305,170			34,000			(134		)	406,223

Operating Expenses
Advertising and promotion	—			8,828			79,944			10,879			—			99,651
General and administrative	4,571			9,090			55,209			12,403			—			81,273
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Total operating expenses	7,952			18,510			147,905			24,297			—			198,664
Operating income (loss)	(7,952		)	48,677			157,265			9,703			(134		)	207,559

Other (income) expense
Interest income	(48,543		)	(73,755		)	(5,373		)	(456		)	128,035			(92		)
Interest expense	34,198			81,326			88,464			5,373			(128,035		)	81,326
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Equity in (income) loss of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Total other expense (income)	(90,728		)	(44,002		)	79,945			4,917			129,969			80,101
Income (loss) before income taxes	82,776			92,679			77,320			4,786			(130,103		)	127,458
Provision for income taxes	4,516			14,798			27,111			2,773			—			49,198
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260

Comprehensive income, net of tax:
Currency translation adjustments	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Total other comprehensive income (loss)	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Comprehensive income (loss)	$	54,109		$	53,730		$	26,058		$	(22,138	)	$	(57,650	)	$	54,109

Condensed Consolidating Balance Sheet

March 31, 2017



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	6,168		$	—		$	4,984		$	30,703		$	—		$	41,855
Accounts receivable, net	—			15,787			105,403			15,552			—			136,742
Inventories	—			16,484			89,255			10,833			(963		)	115,609
Prepaid expenses and other current assets	15,072			245			23,444			1,467			—			40,228
Total current assets	21,240			32,516			223,086			58,555			(963		)	334,434

Property, plant and equipment, net	7,300			439			42,260			596			—			50,595
Goodwill	—			66,007			516,691			32,554			—			615,252
Intangible assets, net	—			191,253			2,622,226			90,134			—			2,903,613
Other long-term assets	2,500			2,774			1,170			1,010			—			7,454
Intercompany receivables	1,510,308			2,477,928			1,832,286			193,609			(6,014,131		)	—
Investment in subsidiary	1,708,095			2,397,916			276,933			—			(4,382,944		)	—
Total Assets	$	3,249,443		$	5,168,833		$	5,514,652		$	376,458		$	(10,398,038	)	$	3,911,348

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,150		$	14,576		$	49,025		$	4,467		$	—		$	70,218
Accrued interest payable	—			8,130			—			—			—			8,130
Other accrued liabilities	12,905			2,432			59,711			8,613			—			83,661
Total current liabilities	15,055			25,138			108,736			13,080			—			162,009

Long-term debt
Principal amount	—			2,222,000			—			—			—			2,222,000
Less unamortized debt costs	—			(28,268		)	—			—			—			(28,268		)
Long-term debt, net	—			2,193,732			—			—			—			2,193,732

Deferred income tax liabilities	—			55,945			659,132			9			—			715,086
Other long-term liabilities	—			—			17,920			52			—			17,972
Intercompany payables	2,411,839			1,260,499			2,253,319			88,474			(6,014,131		)	—
Total Liabilities	2,426,894			3,535,314			3,039,107			101,615			(6,014,131		)	3,088,799

Stockholders' Equity
Common stock	533			—			—			—			—			533
Additional paid-in capital	458,255			1,280,947			2,183,644			269,234			(3,733,825		)	458,255
Treasury stock, at cost	(6,594		)	—			—			—			—			(6,594		)
Accumulated other comprehensive income (loss), net of tax	(26,352		)	(26,352		)	(26,352		)	(26,100		)	78,804			(26,352		)
Retained earnings (accumulated deficit)	396,707			378,924			318,253			31,709			(728,886		)	396,707
Total Stockholders' Equity	822,549			1,633,519			2,475,545			274,843			(4,383,907		)	822,549
Total Liabilities and Stockholders' Equity	$	3,249,443		$	5,168,833		$	5,514,652		$	376,458		$	(10,398,038	)	$	3,911,348

Condensed Consolidating Balance Sheet

March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	4,440		$	—		$	2,899		$	19,891		$	—		$	27,230
Accounts receivable, net	—			12,025			74,446			8,776			—			95,247
Inventories	—			9,411			72,296			10,088			(532		)	91,263
Deferred income tax assets	316			681			8,293			818			—			10,108
Prepaid expenses and other current assets	15,311			257			8,379			1,218			—			25,165
Total current assets	20,067			22,374			166,313			40,791			(532		)	249,013

Property and equipment, net	9,166			210			5,528			636			—			15,540
Goodwill	—			66,007			271,409			22,775			—			360,191
Intangible assets, net	—			191,789			2,042,640			88,294			—			2,322,723
Other long-term assets	—			1,324			—			—			—			1,324
Intercompany receivables	1,457,011			2,703,192			1,083,488			10,738			(5,254,429		)	—
Investment in subsidiary	1,641,477			1,527,718			81,545			—			(3,250,740		)	—
Total Assets	$	3,127,721		$	4,512,614		$	3,650,923		$	163,234		$	(8,505,701	)	$	2,948,791

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,914		$	7,643		$	24,437		$	3,302		$	—		$	38,296
Accrued interest payable	—			8,664			—			—			—			8,664
Other accrued liabilities	12,285			1,714			38,734			6,991			—			59,724
Total current liabilities	15,199			18,021			63,171			10,293			—			106,684

Long-term debt
Principal amount	—			1,652,500			—			—			—			1,652,500
Less unamortized debt costs	—			(27,191		)	—			—			—			(27,191		)
Long-term debt, net	—			1,625,309			—			—			—			1,625,309

Deferred income tax liabilities	—			60,317			408,893			412			—			469,622
Other long-term liabilities	—			—			2,682			158			—			2,840
Intercompany payables	2,368,186			1,241,084			1,570,265			74,894			(5,254,429		)	—
Total Liabilities	2,383,385			2,944,731			2,045,011			85,757			(5,254,429		)	2,204,455

Stockholders' Equity
Common Stock	530			—			—			—			—			530
Additional paid-in capital	445,182			1,280,947			1,359,921			78,774			(2,719,642		)	445,182
Treasury stock, at cost	(5,163		)	—			—			—			—			(5,163		)
Accumulated other comprehensive income (loss), net of tax	(23,525		)	(23,525		)	(23,525		)	(23,525		)	70,575			(23,525		)
Retained earnings (accumulated deficit)	327,312			310,461			269,516			22,228			(602,205		)	327,312
Total Stockholders' Equity	744,336			1,567,883			1,605,912			77,477			(3,251,272		)	744,336
Total Liabilities and Stockholders’ Equity	$	3,127,721		$	4,512,614		$	3,650,923		$	163,234		$	(8,505,701	)	$	2,948,791

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2017



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	69,395		$	68,463		$	48,737		$	9,481		$	(126,681	)	$	69,395
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	3,170			634			21,454			534			—			25,792
Loss on divestitures and sales of property and equipment	—			—			51,820			—			—			51,820
Deferred income taxes	316			(3,691		)	(1,934		)	(469		)	—			(5,778		)
Long term income taxes payable	—			—			581			—			—			581
Amortization of debt origination costs	—			8,633			—			—			—			8,633
Stock-based compensation costs	8,148			—			—						—			8,148
Loss on extinguishment of debt	—			1,420			—			—			—			1,420
Lease termination costs	—			—			524			—			—			524
Loss on sale or disposal of property and equipment	—			—			573			—			—			573
Equity in income of subsidiaries	(67,467		)	(49,302		)	(9,481		)	—			126,250			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	—			(3,762		)	(5,725		)	(9,451		)	—			(18,938		)
Inventories	—			(7,073		)	(2,856		)	(764		)	431			(10,262		)
Prepaid expenses and other current assets	(2,261		)	(1,428		)	1,235			458			—			(1,996		)
Accounts payable	(790		)	6,933			14,155			1,149			—			21,447
Accrued liabilities	620			184			1,798			(105		)	—			2,497
Noncurrent assets and liabilities	—			—			(6,084		)	—			—			(6,084		)
Net cash provided by operating activities	11,131			21,011			114,797			833			—			147,772

Investing Activities
Purchases of property and equipment	(1,153		)	(327		)	(1,378		)	(119		)	—			(2,977		)
Proceeds from divestitures	—			—			110,717			—			—			110,717
Proceeds from the sale of property and equipment	—			—			85						—			85
Proceeds from DenTek working capital arbitration settlement	—			—			1,419			—			—			1,419
Acquisition of C.B. Fleet, less cash acquired	—			—			(803,839		)	—			—			(803,839		)
Intercompany activity, net	—			(823,723		)	823,723			—			—			—
Net cash (used in) provided by investing activities	(1,153		)	(824,050		)	130,727			(119		)	—			(694,595		)

Financing Activities
Proceeds from issuance of Term Loan	—			1,427,000			—			—			—			1,427,000
Term Loan repayments resulting from refinancing	—			(687,000		)	—			—			—			(687,000		)
Term Loan repayments	—			(175,500		)	—			—			—			(175,500		)
Borrowings under revolving credit agreement	—			110,000			—			—			—			110,000
Repayments under revolving credit agreement	—			(105,000		)	—			—			—			(105,000		)
Payments of debt origination costs	—			(11,140		)	—			—			—			(11,140		)
Proceeds from exercise of stock options	4,028			—			—			—			—			4,028
Excess tax benefits from share-based awards	900			—			—			—			—			900
Fair value of shares surrendered as payment of tax withholding	(1,431		)	—			—			—			—			(1,431		)
Intercompany activity, net	(11,747		)	244,679			(243,439		)	10,507			—			—
Net cash provided by (used in) financing activities	(8,250		)	803,039			(243,439		)	10,507			—			561,857

Effects of exchange rate changes on cash and cash equivalents	—			—			—			(409		)	—			(409		)
Increase in cash and cash equivalents	1,728			—			2,085			10,812			—			14,625
Cash and cash equivalents - beginning of year	4,440			—			2,899			19,891			—			27,230
Cash and cash equivalents - end of year	$	6,168		$	—		$	4,984		$	30,703		$	—		$	41,855

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	99,907		$	90,201		$	78,941		$	8,564		$	(177,706	)	$	99,907
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	4,050			594			18,617			415			—			23,676
Deferred income taxes	136			1,272			45,070			(326		)	—			46,152
Long-term income taxes payable	—			—			(332		)	—			—			(332		)
Amortization of debt origination costs	—			8,994			—			—			—			8,994
Stock-based compensation costs	9,794			—			—			160			—			9,954
Loss on extinguishment of debt	—			17,970			—			—			—			17,970
Premium payment on 2012 Senior Notes	—			(10,158		)	—			—			—			(10,158		)
(Gain) loss on sale or disposal of property and equipment	—			—			1			(36		)	—			(35		)
Equity in income of subsidiaries	(98,803		)	(70,953		)	(8,564		)	—			178,320			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	—			2,514			(388		)	(302		)	—			1,824
Inventories	—			(744		)	213			(1,860		)	(614		)	(3,005		)
Prepaid expenses and other current assets	(9,580		)	(116		)	1,977			(202		)	—			(7,921		)
Accounts payable	929			814			(11,284		)	(1,807		)	—			(11,348		)
Accrued liabilities	1,907			(2,749		)	(1,943		)	1,457			—			(1,328		)
Net cash provided by operating activities	8,340			37,639			122,308			6,063			—			174,350

Investing Activities
Purchases of property and equipment	(2,460		)	(93		)	(521		)	(494		)	—			(3,568		)
Proceeds from the sale of property and equipment	—			—			—			344			—			344
Proceeds from Insight Pharmaceuticals working capital arbitration settlement	—			—			7,237			—			—			7,237
Acquisition of DenTek, less cash acquired	—			—			(226,984		)	—			—			(226,984		)
Intercompany activity, net	—			(228,343		)	228,343			—			—			—
Net cash (used in) provided by investing activities	(2,460		)	(228,436		)	8,075			(150		)	—			(222,971		)

Financing Activities
Proceeds from issuance of 2016 Senior Notes	—			350,000			—			—			—			350,000
Repayment of 2012 Senior Notes	—			(250,000		)	—			—			—			(250,000		)
Borrowings under Bridge term loans	—			80,000			—			—			—			80,000
Repayments under Bridge term loans	—			(80,000		)	—			—			—			(80,000		)
Term loan repayments	—			(60,000		)	—			—			—			(60,000		)
Borrowings under revolving credit agreement	—			115,000			—			—			—			115,000
Repayments under revolving credit agreement	—			(96,100		)	—			—			—			(96,100		)
Payments of debt origination costs	—			(11,828		)	—			—			—			(11,828		)
Proceeds from exercise of stock options	6,689			—			—			—			—			6,689
Proceeds from restricted stock exercises	544			—			—			—			—			544
Excess tax benefits from share-based awards	1,960			—			—			—			—			1,960
Fair value of shares surrendered as payment of tax withholding	(2,229		)	—			—			—			—			(2,229		)
Intercompany activity, net	(19,791		)	143,725			(127,484		)	3,550			—			—
Net cash provided by (used in) financing activities	(12,827		)	190,797			(127,484		)	3,550			—			54,036

Effect of exchange rate changes on cash and cash equivalents	—			—			—			497			—			497
Increase (decrease) in cash and cash equivalents	(6,947		)	—			2,899			9,960			—			5,912
Cash and cash equivalents - beginning of year	11,387			—			—			9,931			—			21,318
Cash and cash equivalents - end of year	$	4,440		$	—		$	2,899		$	19,891		$	—		$	27,230

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Deferred income taxes	(192		)	2,462			26,795			(143		)	—			28,922
Long-term income taxes payable	—			—			2,294			—			—			2,294
Amortization of debt origination costs	—			8,821			—			—			—			8,821
Stock-based compensation costs	6,918			—			—			—			—			6,918
Lease termination costs	—			—			785			—			—			785
Loss on sale or disposal of equipment	—			—			—			321			—			321
Equity in income of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	473			(294		)	5,146			(3,717		)	—			1,608
Inventories	—			5,690			8,981			555			134			15,360
Prepaid expenses and other current assets	2,273			(28		)	2,631			(212		)	—			4,664
Accounts payable	(2,457		)	(829		)	(16,734		)	2,383			—			(17,637		)
Accrued liabilities	2,650			1,384			3,560			1,738			—			9,332
Net cash provided by operating activities	14,923			44,106			93,273			3,953			—			156,255

Investing Activities
Purchases of property and equipment	(5,029		)	(119		)	(739		)	(214		)	—			(6,101		)
Proceeds from divestitures	—			—			18,500			—			—			18,500
Proceeds from sale of asset	—			—			10,000			—			—			10,000
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)	—			—			(749,666		)
Acquisition of the Hydralyte brand	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net	—			(809,157		)	731,166			77,991			—			—
Net cash (used in) provided by investing activities	(5,029		)	(809,276		)	9,261			(214		)	—			(805,258		)

Financing Activities
Term loan borrowings	—			720,000			—			—			—			720,000
Term loan repayments	—			(130,000		)	—			—			—			(130,000		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Payments of debt origination costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	3,954			—			—			—			—			3,954
Proceeds from restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,330			—			—			—			—			1,330
Fair value of shares surrendered as payment of tax withholding	(2,104		)	—			—			—			—			(2,104		)
Intercompany activity, net	(26,388		)	125,142			(102,534		)	3,780			—			—
Net cash provided by (used in) financing activities	(23,151		)	765,170			(102,534		)	3,780			—			643,265

Effect of exchange rate changes on cash and cash equivalents	—			—			—			(1,275		)	—			(1,275		)
(Decrease) increase in cash and cash equivalents	(13,257		)	—			—			6,244			—			(7,013		)
Cash and cash equivalents - beginning of year	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of year	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318

Subsequent Events	12 Months Ended
Subsequent Events	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Share based compensation: On May 8, 2017, the Compensation Committee of our Board of Directors granted 35,593 performance share units, 54,269 RSUs and stock options to acquire 180,211 shares of our common stock to certain executive officers and employees under the Plan. Performance share units are earned based on achievement of the Performance Objectives set by the Compensation Committee and, if earned, vest in their entirety on the three-year anniversary of the date of grant. RSUs vest either 33.3% per year over three years or in their entirety on the three-year anniversary of the date of grant. Upon vesting, both performance share units and RSUs will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $56.11 per share, which is equal to the closing price for our common stock on the date of the grant. Except in cases of death, disability or retirement, termination of employment prior to vesting will result in forfeiture of the unvested performance share units, RSUs and the stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.

Schedule II Valuation and Qualifying Accounts

12 Months Ended

Mar. 31, 2017

Valuation and Qualifying Accounts [Abstract]

Schedule II Valuation and Qualifying Accounts

VALUATION AND QUALIFYING ACCOUNTS



(In thousands)	Balance at Beginning of Year		Amounts Charged to Expense			Deductions			Other			Balance at End of Year
Year Ended March 31, 2017
Reserves for sales returns and allowance	$	8,823	$	41,173		$	(41,417	)	$	850	^(a)	$	9,429
Reserves for trade promotions	12,641		69,475			(69,713		)	2,790		^(a)	15,193
Reserves for consumer coupon redemptions	4,323		7,616			(7,745		)	420		^(a)	4,614
Allowance for doubtful accounts	815		177			360			—			1,352
Deferred tax valuation allowance	—		—			—			3,437		^(a)	3,437

Year Ended March 31, 2016
Reserves for sales returns and allowance	6,716		41,217			(40,085		)	975		^(b)	8,823
Reserves for trade promotions	9,932		62,331			(62,409		)	2,787		^(b)	12,641
Reserves for consumer coupon redemptions	1,672		6,235			(5,637		)	2,053		^(b)	4,323
Allowance for doubtful accounts	1,277		(276		)	(186		)	—			815

Year Ended March 31, 2015
Reserves for sales returns and allowance	7,395		34,598			(35,277		)	—			6,716
Reserves for trade promotions	6,101		60,499			(56,668		)	—			9,932
Reserves for consumer coupon redemptions	1,742		5,089			(5,159		)	—			1,672
Allowance for doubtful accounts	1,035		340			(98		)	—			1,277

(a) Reflects the applicable amounts acquired from the purchase of Fleet on January 26, 2017.

(b) Reflects the applicable amounts acquired from the purchase of DenTek on February 5, 2016.

Business and Basis of Presentation (Policies)

12 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	17
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Goodwill

Intangible Assets

Deferred Financing Costs

Debt Origination Costs

Revenue Recognition

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.

Advertising and Promotion Costs

Stock-based Compensation

Pension Expense

Income Taxes

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Recently Issued Accounting Standards

Business and Basis of Presentation (Tables)

12 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	17
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Property, plant and equipment, net consist of the following:



	March 31,
(In thousands)	2017			2016
Components of Property, Plant and Equipment
Land	550			—
Building	13,156			—
Machinery	31,456			7,734
Computer equipment	15,440			12,793
Furniture and fixtures	2,720			2,445
Leasehold improvements	7,497			7,389
	70,819			30,361
Accumulated depreciation	(20,224		)	(14,821		)
Property, plant and equipment, net	$	50,595		$	15,540

Acquisitions (Tables)

12 Months Ended

Mar. 31, 2017

C.B. Fleet Company, Inc.

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the January 26, 2017 acquisition date.



(In thousands)	January 26, 2017

Cash	$	19,884
Accounts receivable	25,293
Inventories	20,812
Prepaid expenses and other current assets	17,024
Property, plant and equipment, net	38,661
Goodwill	268,577
Intangible assets, net	747,600
Other long-term assets	1,137
Total assets acquired	1,138,988

Accounts payable	10,412
Accrued expenses	22,895
Deferred income taxes - long term	261,555
Other long term liabilities	20,403
Total liabilities assumed	315,265
Total purchase price	$	823,723

Pro Forma Information

This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Fleet acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.



	Year Ended March 31,
	2017		2016
(In thousands, except per share data)	(Unaudited)
Revenues	$	1,049,473	$	1,004,698
Net income	$	73,750	$	92,712

Earnings per share:
Basic EPS	$	1.39	$	1.76

Diluted EPS	$	1.38	$	1.74

DenTek Oral Care, Inc.

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the February 5, 2016 acquisition date.



(In thousands)	February 5, 2016

Cash acquired	$	1,359
Accounts receivable	9,187
Inventories	14,304
Deferred income taxes	3,303
Prepaids and other current assets	6,728
Property, plant and equipment, net	3,555
Goodwill	73,737
Intangible assets, net	206,700
Total assets acquired	318,873

Accounts payable	3,261
Accrued expenses	14,336
Deferred income tax liabilities - long term	74,352
Total liabilities assumed	91,949
Total purchase price	$	226,924

Insight Pharmaceuticals Corporation

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date, after giving effect of the adjustments noted above.



(In thousands)	September 3, 2014

Cash acquired	$	3,507
Accounts receivable	26,012
Inventories	23,456
Deferred income tax assets - current	1,032
Prepaids and other current assets	1,341
Property, plant and equipment, net	2,308
Goodwill	96,323
Intangible assets, net	724,374
Total assets acquired	878,353

Accounts payable	16,079
Accrued expenses	8,539
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	132,417
Total purchase price	$	745,936

Pro Forma Information



	Year Ended March 31,
	2015
(In thousands, except per share data)	(Unaudited)
Revenues	$	783,217
Net income	$	86,844

Earnings per share:
Basic	$	1.66

Diluted	$	1.65

Hydralyte

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.



(In thousands)	April 30, 2014

Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041

Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Divestitures (Tables)

12 Months Ended

Mar. 31, 2016

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Divestitures

The following table sets forth the components of the assets sold and the pre-tax net gain recognized on the sales of e.p.t and Dermoplast in December 2016.



(In thousands)	December 2016
Components of assets sold:
Inventory	$	3,266
Intangible assets, net	45,870
Goodwill	6,889
Assets sold	56,025
Total purchase price received	59,614
Pre-tax net (gain) on divestitures	(3,589		)

The following table sets forth the components of the assets sold and the pre-tax loss recognized on the sale in July 2016.



(In thousands)	July 7, 2016
Components of assets sold:
Inventory	$	2,380
Intangible assets, net	91,208
Goodwill	2,920
Assets sold	96,508
Total purchase price received	42,380
	54,128
Costs to sell	2,018
Pre-tax loss on divestitures	$	56,146

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Inventories (Tables)

12 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:



	March 31,
(In thousands)	2017		2016
Components of Inventories
Packaging and raw materials	$	9,984	$	7,563
Work in process	369		—
Finished goods	105,256		83,700
Inventories	$	115,609	$	91,263

Property, Plant and Equipment (Tables)

12 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	17
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Property, plant and equipment, net consist of the following:



	March 31,
(In thousands)	2017			2016
Components of Property, Plant and Equipment
Land	550			—
Building	13,156			—
Machinery	31,456			7,734
Computer equipment	15,440			12,793
Furniture and fixtures	2,720			2,445
Leasehold improvements	7,497			7,389
	70,819			30,361
Accumulated depreciation	(20,224		)	(14,821		)
Property, plant and equipment, net	$	50,595		$	15,540

Goodwill (Tables)

12 Months Ended

Mar. 31, 2017

Goodwill [Abstract]

Summary of Changes in Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2015, 2016, and 2017:



(In thousands)	North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2014	160,157			23,365			7,389			190,911

2015 additions	103,254			1,224			—			104,478
2015 reductions	—			—			(589		)	(589		)
Effects of foreign currency exchange rates	—			(4,149		)	—			(4,149		)

Balance – March 31, 2015	263,411			20,440			6,800			290,651

2016 additions	74,441			2,393			—			76,834
2016 reductions	(7,237		)	—			—			(7,237		)
Effects of foreign currency exchange rates	—			(57		)	—			(57		)

Balance - March 31, 2016	330,615			22,776			6,800			360,191

2017 additions	258,438			10,139			—			268,577
2017 reductions	(12,600		)	—			(555		)	(13,155		)
Effects of foreign currency exchange rates	—			(361		)	—			(361		)

Balance - March 31, 2017	$	576,453		$	32,554		$	6,245		$	615,252

Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2017

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets, net for each of 2015, 2016, and 2017 is as follows:



	Year Ended March 31, 2015
(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks and Customer Relationships			Totals
Gross Amount
Balance – March 31, 2014	$	1,273,878		$	204,740		$	1,478,618
Additions	673,180			124,774			797,954
Reclassifications	(46,506		)	46,506			—
Reductions	(9,548		)	(17,674		)	(27,222		)
Effects of foreign currency exchange rates	(17,600		)	(280		)	(17,880		)
Balance – March 31, 2015	$	1,873,404		$	358,066		$	2,231,470

Accumulated Amortization
Balance – March 31, 2014	$	—		$	83,801		$	83,801
Additions	—			12,995			12,995
Effects of foreign currency exchange rates	—			(26		)	(26		)
Balance – March 31, 2015	$	—		$	96,770		$	96,770

Intangibles, net – March 31, 2015	$	1,873,404		$	261,296		$	2,134,700

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,676,991		$	235,642		$	1,912,633
International OTC Healthcare	86,141			1,231			87,372
Household Cleaning	110,272			24,423			134,695
Intangible assets, net – March 31, 2015	$	1,873,404		$	261,296		$	2,134,700



	Year Ended March 31, 2016
(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks and Customer Relationships			Totals
Gross Amount
Balance – March 31, 2015	$	1,873,404		$	358,066		$	2,231,470
Additions	179,800			26,900			206,700
Reclassifications	(32,918		)	32,918			—
Effects of foreign currency exchange rates	(240		)	(4		)	(244		)
Balance – March 31, 2016	$	2,020,046		$	417,880		$	2,437,926

Accumulated Amortization
Balance – March 31, 2015	$	—		$	96,770		$	96,770
Additions	—			18,430			18,430
Effects of foreign currency exchange rates	—			3			3
Balance – March 31, 2016	$	—		$	115,203		$	115,203

Intangibles, net – March 31, 2016	$	2,020,046		$	302,677		$	2,322,723

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,823,873		$	277,762		$	2,101,635
International OTC Healthcare	85,901			2,237			88,138
Household Cleaning	110,272			22,678			132,950
Intangible assets, net – March 31, 2016	$	2,020,046		$	302,677		$	2,322,723



	Year Ended March 31, 2017
(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks and Customer Relationships			Totals
Gross Amount
Balance – March 31, 2016	$	2,020,046		$	417,880		$	2,437,926
Additions	648,700			98,900			747,600
Reclassifications	(2,064		)	2,064			—
Reductions	(77,248		)	(76,903		)	(154,151		)
Effects of foreign currency exchange rates	(279		)	(140		)	(419		)
Balance – March 31, 2017	$	2,589,155		$	441,801		$	3,030,956

Accumulated Amortization
Balance – March 31, 2016	$	—		$	115,203		$	115,203
Additions	—			19,753			19,753
Reductions	—			(7,610		)	(7,610		)
Effects of foreign currency exchange rates	—			(3		)	(3		)
Balance – March 31, 2017	$	—		$	127,343		$	127,343

Intangibles, net – March 31, 2017	$	2,589,155		$	314,458		$	2,903,613

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,404,336		$	287,056		$	2,691,392
International OTC Healthcare	83,558			6,468			90,026
Household Cleaning	101,261			20,934			122,195
Intangible assets, net – March 31, 2017	$	2,589,155		$	314,458		$	2,903,613

Schedule of Expected Amortization Expense

At March 31, 2017, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



Year Ending March 31,
2018	$	23,356
2019	23,356
2020	23,356
2021	22,933
2022	22,510
Thereafter	198,947
	$	314,458

Long-Term Debt (Tables)

12 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31, 2017			March 31, 2016
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024.	350,000			350,000
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	400,000			400,000
2012 Term B-4 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.75%, with a LIBOR floor of 0.75%, or a base rate plus a margin (with a margin step-down to 2.50%) due on January 26, 2024.	1,382,000			817,500
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022.	90,000			85,000
Total long-term debt (including current portion)	2,222,000			1,652,500
Current portion of long-term debt	—			—
Long-term debt	2,222,000			1,652,500
Less: unamortized debt costs	(28,268		)	(27,191		)
Long-term debt, net	$	2,193,732		$	1,625,309

Schedule of Future Principal Payments



(In thousands)
Year Ending March 31,	Amount
2018	$	—
2019	—
2020	—
2021	12,080
2022	504,270
Thereafter	1,705,650
	$	2,222,000

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Earnings Per Share (Tables)

12 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:



	Year Ended March 31,
(In thousands, except per share data)	2017		2016		2015
Numerator
Net income	$	69,395	$	99,907	$	78,260

Denominator
Denominator for basic earnings per share - weighted average shares outstanding	52,976		52,754		52,170
Dilutive effect of unvested restricted stock units and options issued to employees and directors	386		389		500
Denominator for diluted earnings per share	53,362		53,143		52,670

Earnings per Common Share:
Basic net earnings per share	$	1.31	$	1.89	$	1.50

Diluted net earnings per share	$	1.30	$	1.88	$	1.49

Share-Based Compensation (Tables)

12 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Restricted Shares

A summary of the Company’s RSUs granted under the Plan is presented below:



RSUs	Shares (in thousands)		Weighted-Average Grant-Date Fair Value
Vested and Nonvested at March 31, 2014	437.5		$	16.76

Granted	106.9		33.33
Vested and issued	(154.4	)	13.37
Forfeited	(27.7	)	21.45
Vested and nonvested at March 31, 2015	362.3		22.74
Vested at March 31, 2015	76.6		11.62

Granted	266.1		42.41
Vested and issued	(155.6	)	18.31
Forfeited	(5.0	)	39.61
Vested and nonvested at March 31, 2016	467.8		35.22
Vested at March 31, 2016	69.8		14.76

Granted	68.4		55.44
Vested and issued	(94.7	)	28.51
Forfeited	(91.4	)	41.71
Vested and nonvested at March 31, 2017	350.1		39.29
Vested at March 31, 2017	63.4		20.12

Stock Options, Valuation Assumptions

The weighted-average grant-date fair values of the options granted during 2017, 2016, and 2015 were $21.75, $17.24, and $15.95, respectively.



	Year Ended March 31,
	2017		2016		2015
Expected volatility	37.8	%	40.2	%	47.3	%
Expected dividends	—		—		—
Expected term in years	6.0		6.0		6.0
Risk-free rate	1.7	%	1.7	%	2.2	%

Stock Option Activity

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2014	994.9		$	15.24

Granted	317.9		33.54
Exercised	(386.3	)	10.24
Forfeited or expired	(55.3	)	26.77
Outstanding at March 31, 2015	871.2		23.40

Granted	208.2		42.13
Exercised	(348.0	)	19.22
Forfeited or expired	(3.7	)	35.72
Outstanding at March 31, 2016	727.7		30.70

Granted	264.3		55.86
Exercised	(126.8	)	31.75
Forfeited or expired	(92.9	)	42.66
Outstanding at March 31, 2017	772.3		37.70		7.3	$	14,118
Exercisable at March 31, 2017	367.4		25.40		6.0	$	11,083

Income Taxes (Tables)

12 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

Income from Continuing Operations Before Income Taxes, Domestic and Foreign

Income before income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2017		2016		2015
United States	$	93,582	$	142,253	$	122,588
Foreign	17,268		14,932		4,870
	$	110,850	$	157,185	$	127,458

Components of Provision for Income Taxes

The provision for income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2017			2016			2015
Current
Federal	$	40,183		$	6,080		$	13,066
State	2,808			1,171			760
Foreign	4,242			3,905			3,228
Deferred
Federal	(5,421		)	44,787			31,012
State	(163		)	1,678			1,162
Foreign	(194		)	(343		)	(30		)
Total provision for income taxes	$	41,455		$	57,278		$	49,198

Components of Deferred Tax Balances

The principal components of our deferred tax balances are as follows:



	March 31,
(In thousands)	2017			2016
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	5,280		$	5,083
Inventory capitalization	1,881			1,838
Inventory reserves	1,880			1,367
Net operating loss carryforwards	609			12,350
State income taxes	17,727			10,293
Accrued liabilities	2,174			2,162
Accrued compensation	9,574			—
Stock compensation	5,790			4,411
Other	7,925			300
Total deferred tax assets	52,840			37,804

Deferred Tax Liabilities
Property, plant and equipment	(9,157		)	(833		)
Intangible assets	(754,322		)	(496,485		)
Total deferred tax liabilities	(763,479		)	(497,318		)

Net deferred tax liability before valuation allowance	$	(710,639	)	$	(459,514	)
Valuation allowance	(3,437		)	—
Net deferred tax liability	$	(714,076	)	$	(459,514	)

Reconciliation of Effective Tax Rate

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
	2017					2016					2015
(In thousands)				%					%					%
Income tax provision at statutory rate	$	38,798		35.0		$	55,015		35.0		$	44,610		35.0
Foreign tax benefit	(2,322		)	(2.1	)	(2,894		)	(1.8	)	(2,019		)	(1.6	)
State income taxes, net of federal income tax benefit	1,820			1.7		3,284			2.0		2,865			2.3
Goodwill adjustment for sale of asset	3,208			2.9		—			—		206			0.2
Nondeductible transaction costs	686			0.6		1,071			0.7		2,936			2.3
Nondeductible compensation	342			0.3		758			0.5		566			0.4
Other	(1,076		)	(1.0	)	44			—		34			—
Total provision for income taxes	$	41,456		37.4		$	57,278		36.4		$	49,198		38.6

Uncertain Tax Liability Activity

Uncertain tax liability activity is as follows:



	2017			2016		2015
(In thousands)
Balance – beginning of year	$	4,084		$	3,420	$	1,236
Additions based on tax positions related to the current year	583			664		2,229
Reductions based on lapse of statute of limitations	(1,016		)	—		(45		)
Balance – end of year	$	3,651		$	4,084	$	3,420

Employee Retirement Plans (Tables)

12 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Benefit Obligation and Plan Assets



	Period Ended
(In thousands)	March 31, 2017
Change in benefit obligation:
Projected benefit obligation at date of acquisition	$	61,187
Interest cost	456
Actuarial (gain) loss	791
Benefits paid	(720		)
Projected benefit obligations at end of year	$	61,714

Change in plan assets:
Fair value of plan assets at date of acquisition	$	41,560
Actual return on plan assets	854
Employer contribution	6,078
Benefits paid	(720		)
Fair value of plan assets at end of year	$	47,772

Funded status at end of year	$	(13,942	)

Schedule of Amounts Recognized in Balance Sheet

Amounts recognized in the balance sheet at the end of the period consist of the following:



	Period Ended
(In thousands)	March 31, 2017
Current liability	$	463
Long-term liability	13,479
Total	$	13,942

Schedule of Primary Components of Net Periodic Benefits

The primary components of Net Periodic Benefits consist of the following:



	Period Ended
(In thousands)	March 31, 2017
Interest cost	$	456
Expected return on assets	(462		)
Net periodic benefit cost (income)	$	(6	)

Schedule of Expected to be Contributed



(In thousands)	Pension Benefits
Employer contributions:
2018 (expectation) to participant benefits	$	463

Expected benefit payments year ending March 31,
2018	$	3,152
2019	3,254
2020	3,329
2021	3,416
2022	3,578
2023-2027	18,888

Schedule of Allocation of Plan Assets

The asset allocation for the Company's funded retirement plan as of March 31, 2017, and the target allocation by asset category are as follows:



Asset Category	Target Allocation		Percentage of Plan Assets
Domestic large cap equities	36	%	41	%
Domestic small/mid cap equities	9		7
International equities	15		16
Balanced/asset allocation	4		2
Fixed income and cash	36		34
Total	100	%	100	%

Schedule of Amounts in Accumulated Other Comprehensive Income (Loss)



(In thousands)
Balances in accumulated other comprehensive income (loss) as of March 31, 2017:
Unrecognized actuarial (loss)	$	399
Unrecognized prior service credit	—

Amounts expected to be reclassified from accumulated other comprehensive income (loss) during 2018:
Unrecognized actuarial (loss)	$	—
Unrecognized prior service credit	—

Schedule of Assumptions Used

Assumptions used in determining the actuarial present value of the benefit obligation as of March 31, 2017 were as follows:



Weighted-average assumptions:
Discount rate	4.21	%
Expected return on plan assets	6.25	%
Rate of compensation increase	—

Commitments and Contingencies (Tables)

12 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following summarizes future minimum lease payments for our operating leases ^(a):



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2018	$	2,743	$	565	$	3,308
2019	2,787		248		3,035
2020	2,587		99		2,686
2021	1,451		7		1,458
2022	478		4		482
Thereafter	13		—		13
	$	10,059	$	923	$	10,982

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $0.7 million due in the future under non cancellable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



	Year ending March 31,
(In thousands)	2017			2016
Minimum lease payments	$	10,982		$	8,434
Less: Sublease rentals	(690		)	(1,165		)
	$	10,292		$	7,269

Unrecorded Unconditional Purchase Obligations



(In thousands)
Year Ending March 31,
2018	$	1,013
2019	982
2020	559
2021	—
2022	—
Thereafter	—
	$	2,554

Business Segments (Tables)

12 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Information about our Operating and Reportable Segments

The tables below summarize information about our operating and reportable segments.



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	724,991		$	73,287	$	87,035	$	885,313
Elimination of intersegment revenues	(4,200		)	—		—		(4,200		)
Third-party segment revenues	720,791			73,287		87,035		881,113
Other revenues	33			17		897		947
Total segment revenues	720,824			73,304		87,932		882,060
Cost of sales	282,750			30,789		68,235		381,774
Gross profit	438,074			42,515		19,697		500,286
Advertising and promotion	112,465			13,434		2,460		128,359
Contribution margin	$	325,609		$	29,081	$	17,237	371,927
Other operating expenses*								166,314
Operating income								205,613
Other expense								94,763
Income before income taxes								110,850
Provision for income taxes								41,455
Net income								$	69,395



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues**	$	660,518		$	57,670	$	87,561	$	805,749
Elimination of intersegment revenues	(2,661		)	—		—		(2,661		)
Third-party segment revenues	657,857			57,670		87,561		803,088
Other revenues**	14			43		3,102		3,159
Total segment revenues	657,871			57,713		90,663		806,247
Cost of sales**	250,018			21,676		67,342		339,036
Gross profit	407,853			36,037		23,321		467,211
Advertising and promotion	97,393			11,114		2,295		110,802
Contribution margin	$	310,460		$	24,923	$	21,026	356,409
Other operating expenses								96,094
Operating income								260,315
Other expense								103,130
Income before income taxes								157,185
Provision for income taxes								57,278
Net income								$	99,907



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues**	$	569,643		$	57,729	$	86,085	$	713,457
Elimination of intersegment revenues	(3,387		)	—		—		(3,387		)
Third-party segment revenues	566,256			57,729		86,085		710,070
Other revenues	637			64		3,852		4,553
Total segment revenues	566,893			57,793		89,937		714,623
Cost of sales	216,781			22,820		68,799		308,400
Gross profit	350,112			34,973		21,138		406,223
Advertising and promotion	86,897			10,922		1,832		99,651
Contribution margin	$	263,215		$	24,051	$	19,306	306,572
Other operating expenses								99,013
Operating income								207,559
Other expense								80,101
Income before income taxes								127,458
Provision for income taxes								49,198
Net income								$	78,260

Information about our Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	120,253	$	1,922	$	—	$	122,175
Cough & Cold	90,795		17,990		—		108,785
Women's Health	147,071		3,811		—		150,882
Gastrointestinal	76,500		24,812		—		101,312
Eye & Ear Care	97,618		12,075		—		109,693
Dermatologicals	85,194		2,159		—		87,353
Oral Care	97,586		10,513		—		108,099
Other OTC	5,807		22		—		5,829
Household Cleaning	—		—		87,932		87,932
Total segment revenues	$	720,824	$	73,304	$	87,932	$	882,060



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	117,337	$	2,128	$	—	$	119,465
Cough & Cold	100,148		16,422		—		116,570
Women's Health	132,184		2,982		—		135,166
Gastrointestinal	74,568		20,019		—		94,587
Eye & Ear Care	95,515		11,983		—		107,498
Dermatologicals	82,941		2,133		—		85,074
Oral Care	49,099		2,026		—		51,125
Other OTC	6,079		20		—		6,099
Household Cleaning	—		—		90,663		90,663
Total segment revenues	$	657,871	$	57,713	$	90,663	$	806,247



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	111,954	$	2,597	$	—	$	114,551
Cough & Cold	103,686		18,080		—		121,766
Women's Health	71,506		2,261		—		73,767
Gastrointestinal	77,596		19,372		—		96,968
Eye & Ear Care	85,236		12,689		—		97,925
Dermatologicals	64,806		2,289		—		67,095
Oral Care	45,916		483		—		46,399
Other OTC	6,193		22		—		6,215
Household Cleaning	—		—		89,937		89,937
Total segment revenues	$	566,893	$	57,793	$	89,937	$	714,623

Allocation of Long-Term Assets to Segments

These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



March 31, 2017 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	576,453	$	32,554	$	6,245	$	615,252

Intangible assets
Indefinite-lived	2,404,336		83,558		101,261		2,589,155
Finite-lived	287,056		6,468		20,934		314,458
Intangible assets, net	2,691,392		90,026		122,195		2,903,613
Total	$	3,267,845	$	122,580	$	128,440	$	3,518,865



March 31, 2016 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	330,615	$	22,776	$	6,800	$	360,191

Intangible assets
Indefinite-lived	1,823,873		85,901		110,272		2,020,046
Finite-lived	277,762		2,237		22,678		302,677
Intangible assets, net	2,101,635		88,138		132,950		2,322,723
Total	$	2,432,250	$	110,914	$	139,750	$	2,682,914

Unaudited Quarterly Financial Information (Tables)

12 Months Ended

Mar. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

Unaudited quarterly financial information for 2017 and 2016 is as follows:

Year Ended March 31, 2017



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2016			September 30, 2016			December 31, 2016			March 31, 2017
Total revenues	$	209,575		$	215,052		$	216,763		$	240,670
Cost of sales	87,984			91,087			92,216			110,487
Gross profit	121,591			123,965			124,547			130,183

Operating expenses
Advertising and promotion	27,635			28,592			30,682			41,450
General and administrative	19,457			18,795			22,131			28,760
Depreciation and amortization	6,832			6,016			5,852			6,651
Loss (gain) on divestitures	55,453			(496		)	(3,405		)	268
Total operating expenses	109,377			52,907			55,260			77,129
Operating income	12,214			71,058			69,287			53,054
Net interest expense	21,127			20,830			18,554			32,832
Loss on extinguishment of debt	—			—			—			1,420
(Loss) income before income taxes	(8,913		)	50,228			50,733			18,802
(Benefit) provision for income taxes	(3,382		)	18,033			19,092			7,712
Net (loss) income	$	(5,531	)	$	32,195		$	31,641		$	11,090

(Loss) earnings per share:
Basic	$	(0.10	)	$	0.61		$	0.60		$	0.21
Diluted	$	(0.10	)	$	0.60		$	0.59		$	0.21

Weighted average shares outstanding:
Basic	52,881			52,993			52,999			53,009
Diluted	52,881			53,345			53,359			53,419

Comprehensive (loss) income, net of tax:
Currency translation adjustments	(5,824		)	2,703			(8,736		)	9,282
Unrecognized net loss on pension plans										(252		)
Total other comprehensive (loss) income	(5,824		)	2,703			(8,736		)	9,030
Comprehensive (loss) income	$	(11,355	)	$	34,898		$	22,905		$	20,120

Year Ended March 31, 2016



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2015			September 30, 2015			December 31, 2015		March 31, 2016
Total revenues	$	192,132		$	206,065		$	200,195	$	207,855
Cost of sales (exclusive of depreciation shown below)	79,896			86,125			83,411		89,604
Gross profit	112,236			119,940			116,784		118,251

Operating expenses
Advertising and promotion	26,422			27,893			29,935		26,552
General and administrative	17,589			16,462			18,135		20,232
Depreciation and amortization	5,720			5,687			6,071		6,198
	49,731			50,042			54,141		52,982
Operating income	62,505			69,898			62,643		65,269
Net interest expense	21,884			20,667			19,462		23,147
Loss on extinguishment of debt	451			—			—		17,519
Income before income taxes	40,170			49,231			43,181		24,603
Provision for income taxes	13,997			17,428			15,186		10,667
Net income	$	26,173		$	31,803		$	27,995	$	13,936

Earnings per share:
Basic	$	0.50		$	0.60		$	0.53	$	0.26
Diluted	$	0.49		$	0.60		$	0.53	$	0.26

Weighted average shares outstanding:
Basic	52,548			52,803			52,824		52,833
Diluted	52,958			53,151			53,203		53,252

Comprehensive income, net of tax:
Currency translation adjustments	(405		)	(11,079		)	4,922		6,449
Total other comprehensive income (loss)	(405		)	(11,079		)	4,922		6,449
Comprehensive income	$	25,768		$	20,724		$	32,917	$	20,385

Condensed Consolidating Financial Statements (Tables)

12 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Statements of Income and Comprehensive Income

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2017



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	112,557		$	708,335		$	64,422		$	(4,201	)	$	881,113
Other revenues	—			295			1,033			1,655			(2,036		)	947
Total revenues	—			112,852			709,368			66,077			(6,237		)	882,060

Cost of Sales
Cost of sales	—			49,101			311,813			26,666			(5,806		)	381,774
Gross profit	—			63,751			397,555			39,411			(431		)	500,286

Operating Expenses
Advertising and promotion	—			13,581			101,573			13,205			—			128,359
General and administrative	6,612			9,033			65,528			7,970			—			89,143
Depreciation and amortization	3,170			634			21,013			534			—			25,351
Loss on divestitures	—			—			51,820			—			—			51,820
Total operating expenses	9,782			23,248			239,934			21,709			—			294,673
Operating income (loss)	(9,782		)	40,503			157,621			17,702			(431		)	205,613

Other (income) expense
Interest income	(47,881		)	(85,064		)	(5,644		)	(1,217		)	139,603			(203		)
Interest expense	33,734			93,538			100,233			5,644			(139,603		)	93,546
Loss on extinguishment of debt	—			1,420			—			—			—			1,420
Equity in (income) loss of subsidiaries	(67,467		)	(49,302		)	(9,481		)	—			126,250			—
Total other (income) expense	(81,614		)	(39,408		)	85,108			4,427			126,250			94,763
Income (loss) before income taxes	71,832			79,911			72,513			13,275			(126,681		)	110,850
Provision for income taxes	2,437			11,448			23,776			3,794			—			41,455
Net income (loss)	$	69,395		$	68,463		$	48,737		$	9,481		$	(126,681	)	$	69,395

Comprehensive income, net of tax:
Currency translation adjustments	(2,575		)	(2,575		)	(2,575		)	(2,575		)	7,725			(2,575		)
Unrecognized net loss on pension plans	(252		)	(252		)	(252		)	—			504			(252		)
Total other comprehensive income (loss)	(2,827		)	(2,827		)	(2,827		)	(2,575		)	8,229			(2,827		)
Comprehensive income (loss)	$	66,568		$	65,636		$	45,910		$	6,906		$	(118,452	)	$	66,568

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	111,747		$	643,330		$	50,672		$	(2,661	)	$	803,088
Other revenues	—			347			3,116			1,776			(2,080		)	3,159
Total revenues	—			112,094			646,446			52,448			(4,741		)	806,247

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			45,763			280,169			18,459			(5,355		)	339,036
Gross profit	—			66,331			366,277			33,989			614			467,211

Operating Expenses
Advertising and promotion	—			9,465			90,353			10,984			—			110,802
General and administrative	5,737			9,098			51,198			6,385			—			72,418
Depreciation and amortization	4,050			594			18,617			415			—			23,676
Total operating expenses	9,787			19,157			160,168			17,784			—			206,896
Operating income (loss)	(9,787		)	47,174			206,109			16,205			614			260,315

Other (income) expense
Interest income	(48,342		)	(85,882		)	(5,087		)	(531		)	139,680			(162		)
Interest expense	34,553			84,822			100,540			5,087			(139,680		)	85,322
Loss on extinguishment of debt	—			17,970			—			—			—			17,970
Equity in (income) loss of subsidiaries	(98,803		)	(70,953		)	(8,564		)	—			178,320			—
Total other (income) expense	(112,592		)	(54,043		)	86,889			4,556			178,320			103,130
Income (loss) before income taxes	102,805			101,217			119,220			11,649			(177,706		)	157,185
Provision for income taxes	2,898			11,016			40,279			3,085			—			57,278
Net income (loss)	$	99,907		$	90,201		$	78,941		$	8,564		$	(177,706	)	$	99,907

Comprehensive income, net of tax:
Currency translation adjustments	(113		)	(113		)	(113		)	(113		)	339			(113		)
Total other comprehensive (loss) income	(113		)	(113		)	(113		)	(113		)	339			(113		)
Comprehensive income (loss)	$	99,794		$	90,088		$	78,828		$	8,451		$	(177,367	)	$	99,794

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	106,439		$	555,388		$	51,630		$	(3,387	)	$	710,070
Other revenues	—			385			4,452			1,497			(1,781		)	4,553
Total revenues	—			106,824			559,840			53,127			(5,168		)	714,623

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			39,637			254,670			19,127			(5,034		)	308,400
Gross profit	—			67,187			305,170			34,000			(134		)	406,223

Operating Expenses
Advertising and promotion	—			8,828			79,944			10,879			—			99,651
General and administrative	4,571			9,090			55,209			12,403			—			81,273
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Total operating expenses	7,952			18,510			147,905			24,297			—			198,664
Operating income (loss)	(7,952		)	48,677			157,265			9,703			(134		)	207,559

Other (income) expense
Interest income	(48,543		)	(73,755		)	(5,373		)	(456		)	128,035			(92		)
Interest expense	34,198			81,326			88,464			5,373			(128,035		)	81,326
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Equity in (income) loss of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Total other expense (income)	(90,728		)	(44,002		)	79,945			4,917			129,969			80,101
Income (loss) before income taxes	82,776			92,679			77,320			4,786			(130,103		)	127,458
Provision for income taxes	4,516			14,798			27,111			2,773			—			49,198
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260

Comprehensive income, net of tax:
Currency translation adjustments	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Total other comprehensive income (loss)	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Comprehensive income (loss)	$	54,109		$	53,730		$	26,058		$	(22,138	)	$	(57,650	)	$	54,109

Condensed Consolidating Balance Sheet

March 31, 2017



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	6,168		$	—		$	4,984		$	30,703		$	—		$	41,855
Accounts receivable, net	—			15,787			105,403			15,552			—			136,742
Inventories	—			16,484			89,255			10,833			(963		)	115,609
Prepaid expenses and other current assets	15,072			245			23,444			1,467			—			40,228
Total current assets	21,240			32,516			223,086			58,555			(963		)	334,434

Property, plant and equipment, net	7,300			439			42,260			596			—			50,595
Goodwill	—			66,007			516,691			32,554			—			615,252
Intangible assets, net	—			191,253			2,622,226			90,134			—			2,903,613
Other long-term assets	2,500			2,774			1,170			1,010			—			7,454
Intercompany receivables	1,510,308			2,477,928			1,832,286			193,609			(6,014,131		)	—
Investment in subsidiary	1,708,095			2,397,916			276,933			—			(4,382,944		)	—
Total Assets	$	3,249,443		$	5,168,833		$	5,514,652		$	376,458		$	(10,398,038	)	$	3,911,348

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,150		$	14,576		$	49,025		$	4,467		$	—		$	70,218
Accrued interest payable	—			8,130			—			—			—			8,130
Other accrued liabilities	12,905			2,432			59,711			8,613			—			83,661
Total current liabilities	15,055			25,138			108,736			13,080			—			162,009

Long-term debt
Principal amount	—			2,222,000			—			—			—			2,222,000
Less unamortized debt costs	—			(28,268		)	—			—			—			(28,268		)
Long-term debt, net	—			2,193,732			—			—			—			2,193,732

Deferred income tax liabilities	—			55,945			659,132			9			—			715,086
Other long-term liabilities	—			—			17,920			52			—			17,972
Intercompany payables	2,411,839			1,260,499			2,253,319			88,474			(6,014,131		)	—
Total Liabilities	2,426,894			3,535,314			3,039,107			101,615			(6,014,131		)	3,088,799

Stockholders' Equity
Common stock	533			—			—			—			—			533
Additional paid-in capital	458,255			1,280,947			2,183,644			269,234			(3,733,825		)	458,255
Treasury stock, at cost	(6,594		)	—			—			—			—			(6,594		)
Accumulated other comprehensive income (loss), net of tax	(26,352		)	(26,352		)	(26,352		)	(26,100		)	78,804			(26,352		)
Retained earnings (accumulated deficit)	396,707			378,924			318,253			31,709			(728,886		)	396,707
Total Stockholders' Equity	822,549			1,633,519			2,475,545			274,843			(4,383,907		)	822,549
Total Liabilities and Stockholders' Equity	$	3,249,443		$	5,168,833		$	5,514,652		$	376,458		$	(10,398,038	)	$	3,911,348

Condensed Consolidating Balance Sheet

March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	4,440		$	—		$	2,899		$	19,891		$	—		$	27,230
Accounts receivable, net	—			12,025			74,446			8,776			—			95,247
Inventories	—			9,411			72,296			10,088			(532		)	91,263
Deferred income tax assets	316			681			8,293			818			—			10,108
Prepaid expenses and other current assets	15,311			257			8,379			1,218			—			25,165
Total current assets	20,067			22,374			166,313			40,791			(532		)	249,013

Property and equipment, net	9,166			210			5,528			636			—			15,540
Goodwill	—			66,007			271,409			22,775			—			360,191
Intangible assets, net	—			191,789			2,042,640			88,294			—			2,322,723
Other long-term assets	—			1,324			—			—			—			1,324
Intercompany receivables	1,457,011			2,703,192			1,083,488			10,738			(5,254,429		)	—
Investment in subsidiary	1,641,477			1,527,718			81,545			—			(3,250,740		)	—
Total Assets	$	3,127,721		$	4,512,614		$	3,650,923		$	163,234		$	(8,505,701	)	$	2,948,791

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,914		$	7,643		$	24,437		$	3,302		$	—		$	38,296
Accrued interest payable	—			8,664			—			—			—			8,664
Other accrued liabilities	12,285			1,714			38,734			6,991			—			59,724
Total current liabilities	15,199			18,021			63,171			10,293			—			106,684

Long-term debt
Principal amount	—			1,652,500			—			—			—			1,652,500
Less unamortized debt costs	—			(27,191		)	—			—			—			(27,191		)
Long-term debt, net	—			1,625,309			—			—			—			1,625,309

Deferred income tax liabilities	—			60,317			408,893			412			—			469,622
Other long-term liabilities	—			—			2,682			158			—			2,840
Intercompany payables	2,368,186			1,241,084			1,570,265			74,894			(5,254,429		)	—
Total Liabilities	2,383,385			2,944,731			2,045,011			85,757			(5,254,429		)	2,204,455

Stockholders' Equity
Common Stock	530			—			—			—			—			530
Additional paid-in capital	445,182			1,280,947			1,359,921			78,774			(2,719,642		)	445,182
Treasury stock, at cost	(5,163		)	—			—			—			—			(5,163		)
Accumulated other comprehensive income (loss), net of tax	(23,525		)	(23,525		)	(23,525		)	(23,525		)	70,575			(23,525		)
Retained earnings (accumulated deficit)	327,312			310,461			269,516			22,228			(602,205		)	327,312
Total Stockholders' Equity	744,336			1,567,883			1,605,912			77,477			(3,251,272		)	744,336
Total Liabilities and Stockholders’ Equity	$	3,127,721		$	4,512,614		$	3,650,923		$	163,234		$	(8,505,701	)	$	2,948,791

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2017



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	69,395		$	68,463		$	48,737		$	9,481		$	(126,681	)	$	69,395
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	3,170			634			21,454			534			—			25,792
Loss on divestitures and sales of property and equipment	—			—			51,820			—			—			51,820
Deferred income taxes	316			(3,691		)	(1,934		)	(469		)	—			(5,778		)
Long term income taxes payable	—			—			581			—			—			581
Amortization of debt origination costs	—			8,633			—			—			—			8,633
Stock-based compensation costs	8,148			—			—						—			8,148
Loss on extinguishment of debt	—			1,420			—			—			—			1,420
Lease termination costs	—			—			524			—			—			524
Loss on sale or disposal of property and equipment	—			—			573			—			—			573
Equity in income of subsidiaries	(67,467		)	(49,302		)	(9,481		)	—			126,250			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	—			(3,762		)	(5,725		)	(9,451		)	—			(18,938		)
Inventories	—			(7,073		)	(2,856		)	(764		)	431			(10,262		)
Prepaid expenses and other current assets	(2,261		)	(1,428		)	1,235			458			—			(1,996		)
Accounts payable	(790		)	6,933			14,155			1,149			—			21,447
Accrued liabilities	620			184			1,798			(105		)	—			2,497
Noncurrent assets and liabilities	—			—			(6,084		)	—			—			(6,084		)
Net cash provided by operating activities	11,131			21,011			114,797			833			—			147,772

Investing Activities
Purchases of property and equipment	(1,153		)	(327		)	(1,378		)	(119		)	—			(2,977		)
Proceeds from divestitures	—			—			110,717			—			—			110,717
Proceeds from the sale of property and equipment	—			—			85						—			85
Proceeds from DenTek working capital arbitration settlement	—			—			1,419			—			—			1,419
Acquisition of C.B. Fleet, less cash acquired	—			—			(803,839		)	—			—			(803,839		)
Intercompany activity, net	—			(823,723		)	823,723			—			—			—
Net cash (used in) provided by investing activities	(1,153		)	(824,050		)	130,727			(119		)	—			(694,595		)

Financing Activities
Proceeds from issuance of Term Loan	—			1,427,000			—			—			—			1,427,000
Term Loan repayments resulting from refinancing	—			(687,000		)	—			—			—			(687,000		)
Term Loan repayments	—			(175,500		)	—			—			—			(175,500		)
Borrowings under revolving credit agreement	—			110,000			—			—			—			110,000
Repayments under revolving credit agreement	—			(105,000		)	—			—			—			(105,000		)
Payments of debt origination costs	—			(11,140		)	—			—			—			(11,140		)
Proceeds from exercise of stock options	4,028			—			—			—			—			4,028
Excess tax benefits from share-based awards	900			—			—			—			—			900
Fair value of shares surrendered as payment of tax withholding	(1,431		)	—			—			—			—			(1,431		)
Intercompany activity, net	(11,747		)	244,679			(243,439		)	10,507			—			—
Net cash provided by (used in) financing activities	(8,250		)	803,039			(243,439		)	10,507			—			561,857

Effects of exchange rate changes on cash and cash equivalents	—			—			—			(409		)	—			(409		)
Increase in cash and cash equivalents	1,728			—			2,085			10,812			—			14,625
Cash and cash equivalents - beginning of year	4,440			—			2,899			19,891			—			27,230
Cash and cash equivalents - end of year	$	6,168		$	—		$	4,984		$	30,703		$	—		$	41,855

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	99,907		$	90,201		$	78,941		$	8,564		$	(177,706	)	$	99,907
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	4,050			594			18,617			415			—			23,676
Deferred income taxes	136			1,272			45,070			(326		)	—			46,152
Long-term income taxes payable	—			—			(332		)	—			—			(332		)
Amortization of debt origination costs	—			8,994			—			—			—			8,994
Stock-based compensation costs	9,794			—			—			160			—			9,954
Loss on extinguishment of debt	—			17,970			—			—			—			17,970
Premium payment on 2012 Senior Notes	—			(10,158		)	—			—			—			(10,158		)
(Gain) loss on sale or disposal of property and equipment	—			—			1			(36		)	—			(35		)
Equity in income of subsidiaries	(98,803		)	(70,953		)	(8,564		)	—			178,320			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	—			2,514			(388		)	(302		)	—			1,824
Inventories	—			(744		)	213			(1,860		)	(614		)	(3,005		)
Prepaid expenses and other current assets	(9,580		)	(116		)	1,977			(202		)	—			(7,921		)
Accounts payable	929			814			(11,284		)	(1,807		)	—			(11,348		)
Accrued liabilities	1,907			(2,749		)	(1,943		)	1,457			—			(1,328		)
Net cash provided by operating activities	8,340			37,639			122,308			6,063			—			174,350

Investing Activities
Purchases of property and equipment	(2,460		)	(93		)	(521		)	(494		)	—			(3,568		)
Proceeds from the sale of property and equipment	—			—			—			344			—			344
Proceeds from Insight Pharmaceuticals working capital arbitration settlement	—			—			7,237			—			—			7,237
Acquisition of DenTek, less cash acquired	—			—			(226,984		)	—			—			(226,984		)
Intercompany activity, net	—			(228,343		)	228,343			—			—			—
Net cash (used in) provided by investing activities	(2,460		)	(228,436		)	8,075			(150		)	—			(222,971		)

Financing Activities
Proceeds from issuance of 2016 Senior Notes	—			350,000			—			—			—			350,000
Repayment of 2012 Senior Notes	—			(250,000		)	—			—			—			(250,000		)
Borrowings under Bridge term loans	—			80,000			—			—			—			80,000
Repayments under Bridge term loans	—			(80,000		)	—			—			—			(80,000		)
Term loan repayments	—			(60,000		)	—			—			—			(60,000		)
Borrowings under revolving credit agreement	—			115,000			—			—			—			115,000
Repayments under revolving credit agreement	—			(96,100		)	—			—			—			(96,100		)
Payments of debt origination costs	—			(11,828		)	—			—			—			(11,828		)
Proceeds from exercise of stock options	6,689			—			—			—			—			6,689
Proceeds from restricted stock exercises	544			—			—			—			—			544
Excess tax benefits from share-based awards	1,960			—			—			—			—			1,960
Fair value of shares surrendered as payment of tax withholding	(2,229		)	—			—			—			—			(2,229		)
Intercompany activity, net	(19,791		)	143,725			(127,484		)	3,550			—			—
Net cash provided by (used in) financing activities	(12,827		)	190,797			(127,484		)	3,550			—			54,036

Effect of exchange rate changes on cash and cash equivalents	—			—			—			497			—			497
Increase (decrease) in cash and cash equivalents	(6,947		)	—			2,899			9,960			—			5,912
Cash and cash equivalents - beginning of year	11,387			—			—			9,931			—			21,318
Cash and cash equivalents - end of year	$	4,440		$	—		$	2,899		$	19,891		$	—		$	27,230

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Deferred income taxes	(192		)	2,462			26,795			(143		)	—			28,922
Long-term income taxes payable	—			—			2,294			—			—			2,294
Amortization of debt origination costs	—			8,821			—			—			—			8,821
Stock-based compensation costs	6,918			—			—			—			—			6,918
Lease termination costs	—			—			785			—			—			785
Loss on sale or disposal of equipment	—			—			—			321			—			321
Equity in income of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	473			(294		)	5,146			(3,717		)	—			1,608
Inventories	—			5,690			8,981			555			134			15,360
Prepaid expenses and other current assets	2,273			(28		)	2,631			(212		)	—			4,664
Accounts payable	(2,457		)	(829		)	(16,734		)	2,383			—			(17,637		)
Accrued liabilities	2,650			1,384			3,560			1,738			—			9,332
Net cash provided by operating activities	14,923			44,106			93,273			3,953			—			156,255

Investing Activities
Purchases of property and equipment	(5,029		)	(119		)	(739		)	(214		)	—			(6,101		)
Proceeds from divestitures	—			—			18,500			—			—			18,500
Proceeds from sale of asset	—			—			10,000			—			—			10,000
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)	—			—			(749,666		)
Acquisition of the Hydralyte brand	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net	—			(809,157		)	731,166			77,991			—			—
Net cash (used in) provided by investing activities	(5,029		)	(809,276		)	9,261			(214		)	—			(805,258		)

Financing Activities
Term loan borrowings	—			720,000			—			—			—			720,000
Term loan repayments	—			(130,000		)	—			—			—			(130,000		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Payments of debt origination costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	3,954			—			—			—			—			3,954
Proceeds from restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,330			—			—			—			—			1,330
Fair value of shares surrendered as payment of tax withholding	(2,104		)	—			—			—			—			(2,104		)
Intercompany activity, net	(26,388		)	125,142			(102,534		)	3,780			—			—
Net cash provided by (used in) financing activities	(23,151		)	765,170			(102,534		)	3,780			—			643,265

Effect of exchange rate changes on cash and cash equivalents	—			—			—			(1,275		)	—			(1,275		)
(Decrease) increase in cash and cash equivalents	(13,257		)	—			—			6,244			—			(7,013		)
Cash and cash equivalents - beginning of year	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of year	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318

Business and Basis of Presentation (Property and Equipment) (Details)	12 Months Ended
	Mar. 31, 2017
Building
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	17 years
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer Equipment and Software
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years
Sydney, Australia
Property, Plant and Equipment [Line Items]
Percentage of deposits held in one location	61.00%

Business and Basis of Presentation (Cost of Sales) (Details) - USD ($) $ in Millions	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Warehousing, shipping and handling, and storage costs	$ 46.2	$ 39.2	$ 37.7

Business and Basis of Presentation (Pension Expense) (Details) - USD ($) $ in Thousands		12 Months Ended
	Jan. 26, 2017	Mar. 31, 2017
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, minimum annual contributions per participating employee, percent		1.00%
Defined contribution plan, maximum annual contributions per employee, percent		60.00%
Defined contribution plan, employer matching contribution, percent of match		65.00%
Defined contribution plan, employer matching contribution, percent of employees pay		6.00%
Defined contribution plan, employers matching contribution, vesting period		3 years
Defined contribution plan, cost recognized		$ 100
Pension plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contribution		$ 6,078
Discount rate	4.32%	4.21%
Fleet Employees Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, minimum annual contributions per participating employee, percent		2.00%
Defined contribution plan, maximum annual contributions per employee, percent		50.00%
Defined contribution plan, employer matching contribution, percent of match		100.00%
Defined contribution plan, employer matching contribution, percent of employees pay		6.00%
Defined contribution plan, cost recognized		$ 200

Acquisitions (Narrative) (Details)				1 Months Ended	2 Months Ended	3 Months Ended		12 Months Ended
Acquisitions (Narrative) (Details)	Jan. 26, 2017 USD ($)	Feb. 05, 2016 USD ($)	Sep. 03, 2014 USD ($) brand	Dec. 31, 2016 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Apr. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)
Business Acquisition [Line Items]
Additions to goodwill								$ 268,577,000	$ 76,834,000	$ 104,478,000
Goodwill					$ 615,252,000			$ 615,252,000	$ 360,191,000	$ 290,651,000		$ 190,911,000
C.B. Fleet Company, Inc.
Business Acquisition [Line Items]
Purchase price	$ 823,700,000
Indefinite-lived intangible assets	648,700,000
Finite-lived intangible assets	$ 98,900,000
Purchased amortizable intangible assets, weighted average useful life	18 years 8 months 12 days
Finite-lived intangible assets, weighted average remaining period	18 years 7 months 6 days
Goodwill, post-closing inventory and apportionment adjustment	$ 268,600,000
Pro forma revenue since acquisition					38,700,000
Pro Forma loss since acquisition					$ 2,500,000
Goodwill	268,577,000
Intangible assets, net	747,600,000
DenTek Oral Care, Inc.
Business Acquisition [Line Items]
Purchase price		$ 226,900,000
Indefinite-lived intangible assets		179,800,000
Finite-lived intangible assets		$ 26,900,000
Purchased amortizable intangible assets, weighted average useful life		18 years 6 months 12 days
Goodwill, post-closing inventory and apportionment adjustment				$ (2,800,000)
Additions to goodwill				$ 73,700,000
Goodwill		$ 73,737,000
Intangible assets, net		$ 206,700,000
Insight Pharmaceuticals Corporation
Business Acquisition [Line Items]
Indefinite-lived intangible assets			$ 599,600,000
Finite-lived intangible assets			$ 124,800,000
Purchased amortizable intangible assets, weighted average useful life			16 years 2 months 12 days
Goodwill, post-closing inventory and apportionment adjustment						$ (7,200,000)	$ 300,000
Purchase price, gross			$ 745,900,000
Number of brands acquired \| brand			27
Number of brands sold \| brand			1
Goodwill			$ 96,323,000
Assets sold on acquisition date, not included in consideration transferred			18,500,000
Intangible assets, net			724,374,000
Insight Pharmaceuticals Corporation \| Intangible assets
Business Acquisition [Line Items]
Assets sold on acquisition date, not included in consideration transferred			17,700,000
Insight Pharmaceuticals Corporation \| Inventory
Business Acquisition [Line Items]
Assets sold on acquisition date, not included in consideration transferred			600,000
Insight Pharmaceuticals Corporation \| Property, plant and equipment
Business Acquisition [Line Items]
Assets sold on acquisition date, not included in consideration transferred			$ 200,000
Hydralyte
Business Acquisition [Line Items]
Goodwill											$ 1,224,000
Intangible assets, net											$ 73,580,000
Term Loans \| C.B. Fleet Company, Inc.
Business Acquisition [Line Items]
Debt instrument, face amount	$ 740,000,000

Acquisitions (Allocations) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Jan. 26, 2017	Mar. 31, 2016	Feb. 05, 2016	Mar. 31, 2015	Sep. 03, 2014	Apr. 30, 2014	Mar. 31, 2014
Purchase Price
Goodwill	$ 615,252		$ 360,191		$ 290,651			$ 190,911
C.B. Fleet Company, Inc.
Purchase Price
Cash acquired		$ 19,884
Accounts receivable		25,293
Inventories		20,812
Prepaids and other current assets		17,024
Property, plant and equipment, net		38,661
Goodwill		268,577
Intangible assets, net		747,600
Other long-term assets		1,137
Total assets acquired		1,138,988
Accounts payable		10,412
Accrued expenses		22,895
Deferred income taxes - long term		261,555
Other long term liabilities		20,403
Total liabilities assumed		315,265
Net assets acquired		$ 823,723
DenTek Oral Care, Inc.
Purchase Price
Cash acquired				$ 1,359
Accounts receivable				9,187
Inventories				14,304
Deferred income taxes				3,303
Prepaids and other current assets				6,728
Property, plant and equipment, net				3,555
Goodwill				73,737
Intangible assets, net				206,700
Total assets acquired				318,873
Accounts payable				3,261
Accrued expenses				14,336
Deferred income tax liabilities - long term				74,352
Total liabilities assumed				91,949
Net assets acquired				$ 226,924
Insight Pharmaceuticals Corporation
Purchase Price
Cash acquired						$ 3,507
Accounts receivable						26,012
Inventories						23,456
Deferred income taxes						1,032
Prepaids and other current assets						1,341
Property, plant and equipment, net						2,308
Goodwill						96,323
Intangible assets, net						724,374
Total assets acquired						878,353
Accounts payable						16,079
Accrued expenses						8,539
Deferred income tax liabilities - long term						107,799
Total liabilities assumed						132,417
Net assets acquired						$ 745,936
Hydralyte
Purchase Price
Inventories							$ 1,970
Property, plant and equipment, net							1,267
Goodwill							1,224
Intangible assets, net							73,580
Total assets acquired							78,041
Accrued expenses							38
Other long term liabilities							12
Total liabilities assumed							50
Net assets acquired							$ 77,991

Acquisitions (Pro Forma) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
C.B. Fleet Company, Inc.
Pro Forma Information
Revenues	$ 1,049,473	$ 1,004,698
Net income	$ 73,750	$ 92,712
Earnings per share:
Basic (USD per share)	$ 1.39	$ 1.76
Diluted (USD per share)	$ 1.38	$ 1.74
Insight Pharmaceuticals Corporation
Pro Forma Information
Revenues		$ 783,217
Net income		$ 86,844
Earnings per share:
Basic (USD per share)		$ 1.66
Diluted (USD per share)		$ 1.65

Divestitures (Narrative) (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
Divestitures (Narrative) (Details) - USD ($) $ in Thousands	Jul. 07, 2016	Dec. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestitures			$ 110,717	$ 0	$ 18,500
North American OTC Healthcare \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| Pediacare, New Skin and Fiber Choice \| Disposal group, disposed of by sale, not discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration, excluding costs of inventory	$ 40,000
Proceeds from divestitures	40,100
Consideration, cost of inventory	$ 2,600
Consideration, holdback term	18 months
Total purchase price received	$ 42,380
Pre-tax net (gain) on divestitures	54,128
North American OTC Healthcare \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| Dermoplast \| Disposal group, disposed of by sale, not discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestitures		$ 48,400
Deposit for agreement to purchase	$ 1,250
North American OTC Healthcare \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| E.P.T. and Dermoplast \| Disposal group, disposed of by sale, not discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total purchase price received		59,614
Pre-tax net (gain) on divestitures		$ (3,589)

Divestitures (Schedule of Assets Held for Sale) (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended				12 Months Ended
	Jul. 07, 2016	Dec. 31, 2016	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax loss on divestitures			$ 268	$ (3,405)	$ (496)	$ 55,453	$ 51,820	$ 0	$ 0
North American OTC Healthcare \| Disposal group, disposed of by sale, not discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax loss on divestitures							51,800
Cough and Cold, Dermatologicals, and Gastrointestinal products group \| North American OTC Healthcare \| Pediacare, New Skin and Fiber Choice \| Disposal group, disposed of by sale, not discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventory	$ 2,380
Intangible assets, net	91,208
Goodwill	2,920
Assets sold	96,508
Total purchase price received	42,380
Pre-tax net (gain) on divestitures	54,128
Costs to sell	2,018
Pre-tax loss on divestitures	$ 56,146						$ 56,146
Cough and Cold, Dermatologicals, and Gastrointestinal products group \| North American OTC Healthcare \| E.P.T. and Dermoplast \| Disposal group, disposed of by sale, not discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventory		$ 3,266		3,266
Intangible assets, net		45,870		45,870
Goodwill		6,889		6,889
Assets sold		56,025		56,025
Total purchase price received		59,614		$ 59,614
Pre-tax net (gain) on divestitures		$ (3,589)

Accounts Receivable (Schedule of Accounts Receivable) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 149,752	$ 106,853
Less allowances for discounts, returns and uncollectible accounts	(13,010)	(11,606)
Accounts receivable, net	136,742	95,247
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	148,339	105,592
Other receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 1,413	$ 1,261

Inventories (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 9,984	$ 7,563
Work in process	369	0
Finished goods	105,256	83,700
Inventories	115,609	91,263
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 6,600	$ 4,800

Property, Plant and Equipment (Schedule of Property, Plant and Equipment, Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Components of Property, Plant and Equipment
Property, plant and equipment, gross	$ 70,819	$ 30,361
Accumulated depreciation	(20,224)	(14,821)
Property, plant and equipment, net	50,595	15,540
Depreciation expense	6,000	5,200	$ 3,800
Land
Components of Property, Plant and Equipment
Property, plant and equipment, gross	550	0
Building
Components of Property, Plant and Equipment
Property, plant and equipment, gross	13,156	0
Machinery
Components of Property, Plant and Equipment
Property, plant and equipment, gross	31,456	7,734
Computer equipment
Components of Property, Plant and Equipment
Property, plant and equipment, gross	15,440	12,793
Furniture and fixtures
Components of Property, Plant and Equipment
Property, plant and equipment, gross	2,720	2,445
Leasehold improvements
Components of Property, Plant and Equipment
Property, plant and equipment, gross	$ 7,497	$ 7,389

Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Goodwill [Roll Forward]
Goodwill, net, beginning	$ 360,191	$ 290,651	$ 190,911
Additions	268,577	76,834	104,478
Reductions	(13,155)	(7,237)	(589)
Effects of foreign currency exchange rates	(361)	(57)	(4,149)
Goodwill, net, ending	615,252	360,191	290,651
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill, net, beginning	330,615	263,411	160,157
Additions	258,438	74,441	103,254
Reductions	(12,600)	(7,237)	0
Effects of foreign currency exchange rates	0	0	0
Goodwill, net, ending	576,453	330,615	263,411
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill, net, beginning	22,776	20,440	23,365
Additions	10,139	2,393	1,224
Reductions	0	0	0
Effects of foreign currency exchange rates	(361)	(57)	(4,149)
Goodwill, net, ending	32,554	22,776	20,440
Household Cleaning
Goodwill [Roll Forward]
Goodwill, net, beginning	6,800	6,800	7,389
Additions	0	0	0
Reductions	(555)	0	(589)
Effects of foreign currency exchange rates	0	0	0
Goodwill, net, ending	$ 6,245	$ 6,800	$ 6,800

Goodwill (Narrative) (Details)					1 Months Ended			3 Months Ended		12 Months Ended
Goodwill (Narrative) (Details)	Jan. 26, 2017 USD ($)	Dec. 30, 2016 USD ($)	Dec. 28, 2016 USD ($)	Jul. 07, 2016 USD ($)	Dec. 31, 2016 USD ($)	Aug. 31, 2016 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2017 USD ($) unit	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($) acquisition	Feb. 05, 2016 USD ($)	Sep. 03, 2014 USD ($)	Apr. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)
Goodwill [Line Items]
Number of business acquisitions \| acquisition												2
Goodwill										$ 615,252,000	$ 360,191,000	$ 290,651,000				$ 190,911,000
Gain on sale of asset										0	0	1,133,000
Proceeds from DenTek working capital arbitration settlement										1,419,000	0	0
Proceeds from divestitures										110,717,000	0	18,500,000
Goodwill impairment charge										$ 0	0
Reporting unit, fair value in excess of carrying amount (percent)										53.00%
Number of reporting units with fair value exceeding carrying value by less than 10% \| unit										0
Comet Brand
Goodwill [Line Items]
Gain on sale of asset							$ 1,300,000
Goodwill, written off related to sale of business unit						$ 600,000
Insight Pharmaceuticals Corporation
Goodwill [Line Items]
Goodwill														$ 96,323,000
Goodwill, post-closing inventory and apportionment adjustment								$ (7,200,000)	$ 300,000
Hydralyte
Goodwill [Line Items]
Goodwill															$ 1,224,000
DenTek Oral Care, Inc.
Goodwill [Line Items]
Goodwill													$ 73,737,000
Goodwill, post-closing inventory and apportionment adjustment					$ (2,800,000)
Proceeds from DenTek working capital arbitration settlement					1,400,000
Goodwill, purchase accounting adjustments and other post closing adjustments					1,400,000
C.B. Fleet Company, Inc.
Goodwill [Line Items]
Goodwill	$ 268,577,000
Goodwill, post-closing inventory and apportionment adjustment	$ 268,600,000
North American OTC Healthcare
Goodwill [Line Items]
Goodwill										$ 576,453,000	$ 330,615,000	$ 263,411,000				$ 160,157,000
Pediacare, New Skin and Fiber Choice \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| Disposal group, disposed of by sale, not discontinued operations \| North American OTC Healthcare
Goodwill [Line Items]
Goodwill, written off related to sale of business unit				$ 2,900,000
Consideration, excluding costs of inventory				40,000,000
Proceeds from divestitures				$ 40,100,000
Dermoplast \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| Disposal group, disposed of by sale, not discontinued operations \| North American OTC Healthcare
Goodwill [Line Items]
Goodwill, written off related to sale of business unit		$ 5,500,000
Proceeds from divestitures					$ 48,400,000
E.P.T. \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| Disposal group, disposed of by sale, not discontinued operations \| North American OTC Healthcare
Goodwill [Line Items]
Goodwill, written off related to sale of business unit			$ 1,400,000

Intangible Assets (Reconciliation of Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	$ 2,020,046
Indefinite-lived intangibles, ending	2,589,155	$ 2,020,046
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning	115,203	96,770	$ 83,801
Finite-lived intangibles, accumulated amortization, additions	19,753	18,430	12,995
Finite-lived intangibles, accumulated amortization, reductions	(7,610)
Finite-lived intangibles, accumulated amortization, effects of foreign currency exchange rates	(3)	3	(26)
Finite-lived intangibles, accumulated amortization, ending	127,343	115,203	96,770
Intangible Assets, Gross [Abstract]
Intangible assets, gross, beginning	2,437,926	2,231,470	1,478,618
Intangible assets, additions	747,600	206,700	797,954
Intangible assets, reclassifications	0	0	0
Intangible assets, reductions	(154,151)		(27,222)
Intangible assets, effects of foreign currency exchange rates	419	244	17,880
Intangible assets, gross, ending	3,030,956	2,437,926	2,231,470
Finite-lived intangible assets	314,458	302,677
Intangible assets, net	2,903,613	2,322,723	2,134,700
North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	1,823,873
Indefinite-lived intangibles, ending	2,404,336	1,823,873
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	287,056	277,762
Intangible assets, net	2,691,392	2,101,635	1,912,633
International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	85,901
Indefinite-lived intangibles, ending	83,558	85,901
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	6,468	2,237
Intangible assets, net	90,026	88,138	87,372
Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	110,272
Indefinite-lived intangibles, ending	101,261	110,272
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	20,934	22,678
Intangible assets, net	122,195	132,950	134,695
Finite Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, gross, beginning	417,880	358,066	204,740
Finite-lived intangibles, additions	98,900	26,900	124,774
Finite-lived intangibles, reclassifications	2,064	32,918	46,506
Finite-lived intangibles, reductions, gross	(76,903)		(17,674)
Finite-lived intangibles, effects of foreign currency exchange rates	(140)	(4)	(280)
Finite-lived intangibles, gross, ending	441,801	417,880	358,066
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning	115,203	96,770	83,801
Finite-lived intangibles, accumulated amortization, additions	19,753	18,430	12,995
Finite-lived intangibles, accumulated amortization, reductions	(7,610)
Finite-lived intangibles, accumulated amortization, effects of foreign currency exchange rates	(3)	3	(26)
Finite-lived intangibles, accumulated amortization, ending	127,343	115,203	96,770
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	314,458	302,677	261,296
Finite Lived Trademarks and Customer Relationships \| North American OTC Healthcare
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	287,056	277,762	235,642
Finite Lived Trademarks and Customer Relationships \| International OTC Healthcare
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	6,468	2,237	1,231
Finite Lived Trademarks and Customer Relationships \| Household Cleaning
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	20,934	22,678	24,423
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	2,020,046	1,873,404	1,273,878
Indefinite-lived intangibles, additions	648,700	179,800	673,180
Indefinite-lived intangibles, reclassifications	(2,064)	(32,918)	(46,506)
Indefinite-lived intangibles, reductions	(77,248)		(9,548)
Indefinite-lived intangibles, effects of foreign currency exchange rates	(279)	(240)	(17,600)
Indefinite-lived intangibles, ending	2,589,155	2,020,046	1,873,404
Indefinite Lived Trademarks \| North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	1,823,873	1,676,991
Indefinite-lived intangibles, ending	2,404,336	1,823,873	1,676,991
Indefinite Lived Trademarks \| International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	85,901	86,141
Indefinite-lived intangibles, ending	83,558	85,901	86,141
Indefinite Lived Trademarks \| Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	110,272	110,272
Indefinite-lived intangibles, ending	$ 101,261	$ 110,272	$ 110,272

Intangible Assets (Narrative) (Details)				1 Months Ended			3 Months Ended				12 Months Ended
Intangible Assets (Narrative) (Details)	Jul. 07, 2016 USD ($)	Feb. 29, 2016 USD ($)	Sep. 03, 2014 USD ($) brand	Dec. 31, 2016 USD ($)	Aug. 31, 2016 USD ($)	Dec. 31, 2014 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2017 USD ($) brand	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($) acquisition	Jan. 26, 2017 USD ($)	Feb. 05, 2016 USD ($)	Apr. 30, 2014 USD ($)
Schedule of Intangible Assets [Line Items]
Number of business acquisitions \| acquisition													2
Proceeds from divestitures											$ 110,717,000	$ 0	$ 18,500,000
Loss on divestitures							$ 268,000	$ (3,405,000)	$ (496,000)	$ 55,453,000	51,820,000	0	0
Gain on sale of asset											0	0	1,133,000
Impairment of intangible assets											$ 0
Reporting unit, fair value in excess of carrying amount (percent)							53.00%				53.00%
Number of indefinite-lived trade names exceeding carrying value by less than 10% \| brand											2
Finite-lived intangible assets, weighted average remaining period											13 years 4 months 24 days
Amortization of intangible assets											$ 19,753,000	18,430,000	12,995,000
Minimum
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives											10 years
Maximum
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives											30 years
Painstop brand
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives		10 years
Indefinite-lived intangibles, reclassifications		$ 2,100,000
Insight Pharmaceuticals Corporation
Schedule of Intangible Assets [Line Items]
Intangible assets acquired			$ 724,374,000
Number of brands sold \| brand			1
Insight Pharmaceuticals Corporation \| One Brand Acquired from Insight subsequently sold
Schedule of Intangible Assets [Line Items]
Intangible assets acquired			$ 17,700,000
Hydralyte
Schedule of Intangible Assets [Line Items]
Intangible assets acquired																$ 73,580,000
DenTek Oral Care, Inc.
Schedule of Intangible Assets [Line Items]
Intangible assets acquired															$ 206,700,000
C.B. Fleet Company, Inc.
Schedule of Intangible Assets [Line Items]
Intangible assets acquired														$ 747,600,000
Trademarks
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, reductions					$ 9,000,000
Indefinite Lived Trademarks
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, reductions											$ 77,248,000		9,548,000
Reporting unit, fair value in excess of carrying amount (percent)							40.80%				40.80%
Indefinite-lived intangibles, reclassifications											$ 2,064,000	$ 32,918,000	$ 46,506,000
Beano Brand
Schedule of Intangible Assets [Line Items]
Reporting unit, fair value in excess of carrying amount (percent)							9.00%				9.00%
Indefinite-lived intangible assets							$ 78,400,000				$ 78,400,000
Fair value input, discount rate											9.50%
Decrease in annual cash flows, percent											(8.30%)
Increase in discount rate											0.60%
Comet Brand
Schedule of Intangible Assets [Line Items]
Proceeds from the sale of property and equipment					11,000,000	$ 10,000,000
Agreement election amount per quarter										$ 1,000,000
Gain on sale of asset					$ 1,200,000
Reporting unit, fair value in excess of carrying amount (percent)							9.00%				9.00%
Indefinite-lived intangible assets							$ 101,300,000				$ 101,300,000
Fair value input, discount rate											9.50%
Decrease in annual cash flows, percent											8.20%
Increase in discount rate											0.70%
Disposal group, disposed of by sale, not discontinued operations \| North American OTC Healthcare
Schedule of Intangible Assets [Line Items]
Loss on divestitures											$ 51,800,000
Disposal group, disposed of by sale, not discontinued operations \| Pediacare, New Skin and Fiber Choice \| North American OTC Healthcare \| Cough and Cold, Dermatologicals, and Gastrointestinal products group
Schedule of Intangible Assets [Line Items]
Consideration, excluding costs of inventory	$ 40,000,000
Proceeds from divestitures	40,100,000
Indefinite-lived intangibles, reductions	37,200,000
Finite-lived intangible assets, written off	54,000,000
Loss on divestitures	$ 56,146,000										$ 56,146,000
Disposal group, disposed of by sale, not discontinued operations \| Dermoplast \| North American OTC Healthcare \| Cough and Cold, Dermatologicals, and Gastrointestinal products group
Schedule of Intangible Assets [Line Items]
Proceeds from divestitures				$ 48,400,000
Indefinite-lived intangibles, reductions				31,000,000
Disposal group, disposed of by sale, not discontinued operations \| E.P.T. \| North American OTC Healthcare \| Cough and Cold, Dermatologicals, and Gastrointestinal products group
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, reductions				$ 14,800,000

Intangible Assets (Expected Amortization Expense) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Intangible Assets, Net (Excluding Goodwill) [Abstract]
2018	$ 23,356
2019	23,356
2020	23,356
2021	22,933
2022	22,510
Thereafter	198,947
Intangible assets, net	$ 314,458	$ 302,677

Other Accrued Liabilities (Schedule of Other Accrued Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Payables and Accruals [Abstract]
Accrued marketing costs	$ 29,384	$ 26,373
Accrued compensation costs	15,535	9,574
Accrued broker commissions	1,782	1,497
Income taxes payable	3,840	3,675
Accrued professional fees	2,412	1,787
Deferred rent	492	836
Accrued production costs	4,580	3,324
Accrued lease termination costs	843	448
Income tax related payable	19,000	6,354
Other accrued liabilities	5,793	5,856
Total other accrued liabilities	$ 83,661	$ 59,724

Long-Term Debt (Narrative 2012 Senior Notes) (Details) - 2012 Senior Notes	Jan. 31, 2012 USD ($)
Debt Instrument [Line Items]
Debt issuance costs capitalized	$ 12,600,000
Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount	$ 250,000,000.0
Debt instrument, stated interest rate	8.125%

Long-Term Debt (Narrative 2012 Term Loan and 2012 ABL Revolver) (Details) - USD ($)							3 Months Ended								12 Months Ended			38 Months Ended
	Jan. 26, 2017	Feb. 04, 2016	Jun. 09, 2015	Sep. 03, 2014	Feb. 21, 2013	Jan. 31, 2012	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2015	May 08, 2015
Debt Instrument [Line Items]
Loss on extinguishment of debt							$ 1,420,000	$ 0	$ 0	$ 0	$ 17,519,000	$ 0	$ 0	$ 451,000	$ 1,420,000	$ 17,970,000	$ 0
2012 Term Loan and ABL Revolver
Debt Instrument [Line Items]
Debt issuance costs capitalized						$ 20,600,000
2012 Senior Notes
Debt Instrument [Line Items]
Debt issuance costs capitalized						12,600,000
Term Loans \| 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount						$ 660,000,000.0
Debt instrument, term						7 years
Debt instrument, discount, percentage						1.50%
Proceeds from issuance of long-term debt						$ 650,100,000
Term Loans \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, reference rate floor				1.00%
Senior Notes \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount						$ 250,000,000.0
Debt instrument, stated interest rate						8.125%
2012 Term B-1 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount																			$ 207,500,000.0
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, face amount				$ 720,000,000.0
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount																			645,000,000.0
2012 Term B-3 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount																			$ 852,500,000.0
Term B-4 Loans \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,427,000,000.0
Debt instrument, conditional variable rate	2.50%						2.50%				2.50%				2.50%	2.50%
Debt instrument, average interest rate															5.50%
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, term						5 years
Line of credit facility, maximum borrowing capacity						$ 50,000,000.0	$ 135,000,000								$ 135,000,000
Revolving credit facility, increase in borrowing capacity	$ 40,000,000.0						$ 85,000,000								$ 85,000,000
Debt instrument, interest rate, decrease																		0.25%
Line of credit facility, commitment fee percentage						0.50%
Line of credit facility, conditional commitment fee percentage															0.375%
Revolver increase in accordion feature			$ 35,000,000.0
Debt instrument, average interest rate															2.30%
Revolving Credit Facility \| 2012 ABL Revolver, Amendment No. 3
Debt Instrument [Line Items]
Revolving credit facility, increase in borrowing capacity				$ 40,000,000.0
Revolving Credit Facility \| ABL Amendment No. 5
Debt Instrument [Line Items]
Debt Instrument, temporary suspension of financial reporting covenant, period		60 days
LIBOR \| Term Loans \| 2012 Term Loan, Amendment No. 1
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)					2.75%
Debt instrument, reference rate floor					1.00%
LIBOR \| Term Loans \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)				3.125%
LIBOR \| 2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)				3.50%
Debt instrument, reference rate floor				1.00%
LIBOR \| Term B-4 Loans \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)	2.75%														2.75%	2.75%
Debt instrument, variable rate, minimum	0.75%														0.75%	0.75%
LIBOR \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component				1.00%
LIBOR \| Minimum \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate				2.00%
LIBOR \| Maximum \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate				2.25%
Base Rate \| Term Loans \| 2012 Term Loan, Amendment No. 1
Debt Instrument [Line Items]
Debt instrument, reference rate floor					2.00%
Base Rate \| Term Loans \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, reference rate floor				2.00%
Base Rate \| 2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, reference rate floor				2.00%
Interest rate, contingent margin step-down per annum (percent)				3.25%
Base Rate \| Minimum \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate				1.00%
Base Rate \| Maximum \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate				1.25%
Federal Funds Rate \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component				0.50%

Long-Term Debt (Narrative 2013 Senior Notes) (Details) - Senior Notes - 2013 Senior Notes - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Dec. 17, 2013
Debt Instrument [Line Items]
Debt instrument, face amount			$ 400,000,000.0
Debt instrument, stated interest rate	5.375%	5.375%	5.375%
Debt issuance costs capitalized			$ 7,200,000

Long-Term Debt (Narrative 2016 Bridge Term Loans) (Details) - 2016 Bridge Term Loan - USD ($)	Feb. 19, 2016	Feb. 02, 2017	Aug. 05, 2016	Feb. 04, 2016
Eurodollar
Short-term Debt [Line Items]
Debt instrument, variable rate		5.25%	5.00%	4.75%
Bridge Loan
Short-term Debt [Line Items]
Debt instrument, face amount				$ 80,000,000.0
Debt issuance costs expensed	$ 1,900,000
Minimum \| Base Rate
Short-term Debt [Line Items]
Debt instrument, stated interest rate		4.25%	4.00%	3.75%

Long-Term Debt (Narrative 2016 Senior Notes) (Details) - Senior Notes - 2016 Senior Notes - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Feb. 19, 2016
Debt Instrument [Line Items]
Debt instrument, face amount			$ 350,000,000.0
Debt instrument, stated interest rate	6.375%	6.375%	6.375%
Debt issuance costs capitalized			$ 5,500,000

Long-Term Debt (Narrative Redemptions and Restrictions) (Details) - USD ($) $ in Thousands		12 Months Ended
	Feb. 19, 2016	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument [Line Items]
Less unamortized debt costs		$ 28,268	$ 27,191
Senior Notes \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount	104.063%
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount		101.00%
Less unamortized debt costs		$ 4,900	5,400
Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Less unamortized debt costs		4,600	5,400
Term Loans \| 2012 Term Loan
Debt Instrument [Line Items]
Less unamortized debt costs		18,800	16,400
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Less unamortized debt costs		1,300	1,300
Repayments of long-term debt		90,000
Revolving credit facility, remaining borrowing capacity		$ 82,600
Other long-term assets \| New Accounting Pronouncement, Early Adoption, Effect
Debt Instrument [Line Items]
Deferred finance costs, net			(27,400)
Long-term debt \| New Accounting Pronouncement, Early Adoption, Effect
Debt Instrument [Line Items]
Deferred finance costs, net			$ 27,400
Prior to December 15, 2016 \| Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount		100.00%
Debt instrument, redemption price, percentage of principal amount, using proceeds of equity offerings		105.375%
Prior to March 1, 2019 \| Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount	100.00%
Maximum \| Prior to December 15, 2016 \| Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, percentage of principal amount which can be redeemed		35.00%
Maximum \| Prior to March 1, 2019 \| Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, percentage of principal amount which can be redeemed	40.00%
Indirect guarantee of indebtedness \| Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount	101.00%

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands		12 Months Ended
	Jan. 26, 2017	Mar. 31, 2017	Mar. 31, 2016	Feb. 19, 2016	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Long-term debt, gross		$ 2,222,000	$ 1,652,500
Current portion of long-term debt		0	0
Long-term debt, gross, excluding current maturities		2,222,000	1,652,500
Less unamortized debt costs		(28,268)	(27,191)
Long-term debt, net		2,193,732	1,625,309
2012 ABL Revolver \| Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross		90,000	85,000
Less unamortized debt costs		$ (1,300)	$ (1,300)
Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate		6.375%	6.375%	6.375%
Long-term debt, gross		$ 350,000	$ 350,000
Less unamortized debt costs		$ (4,600)	$ (5,400)
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate		5.375%	5.375%		5.375%
Long-term debt, gross		$ 400,000	$ 400,000
Less unamortized debt costs		$ (4,900)	$ (5,400)
Senior Notes \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate						8.125%
Term B-4 Loans \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, conditional variable rate	2.50%	2.50%	2.50%
Long-term debt, gross		$ 1,382,000	$ 817,500
LIBOR \| Term B-4 Loans \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)	2.75%	2.75%	2.75%
Debt instrument, variable rate, minimum	0.75%	0.75%	0.75%

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Debt Disclosure [Abstract]
2018	$ 0
2019	0
2020	0
2021	12,080
2022	504,270
Thereafter	1,705,650
Aggregate future principal payments	$ 2,222,000	$ 1,652,500

Fair Value Measurements (Summary of Carrying Amounts and Estimated Fair Value) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Senior Notes \| 2016 Senior Notes \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	$ 350,000	$ 350,000
Senior Notes \| 2016 Senior Notes \| Fair value \| Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	367,500	363,125
Senior Notes \| 2013 Senior Notes \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	400,000	400,000
Senior Notes \| 2013 Senior Notes \| Fair value \| Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	409,000	408,000
Term Loans \| Term B-4 Loans \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	1,382,000	817,500
Term Loans \| Term B-4 Loans \| Fair value \| Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	1,395,820	818,522
Revolving Credit Facility \| 2012 ABL Revolver \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	90,000	85,000
Revolving Credit Facility \| 2012 ABL Revolver \| Fair value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	$ 90,000	$ 85,000

Stockholders' Equity (Narrative) (Details)	12 Months Ended
Stockholders' Equity (Narrative) (Details)	Mar. 31, 2017 USD ($) vote / shares $ / shares shares	Mar. 31, 2016 $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized \| shares	250,000,000	250,000,000
Common stock, par value (in USD per share) \| $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized \| shares	5,000,000	5,000,000
Preferred stock, par value (in USD per share) \| $ / shares	$ 0.01	$ 0.01
Voting rights, number of votes per common share owned \| vote / shares	1
Dividends declared on common stock \| $	$ 0
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period (in shares) \| shares	25,768	40,316
Restricted stock acquired, average cost per share (in USD per share) \| $ / shares	$ 55.51	$ 41.80

Earnings Per Share (Computation of Basic and Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Numerator
Net income	$ 11,090	$ 31,641	$ 32,195	$ (5,531)	$ 13,936	$ 27,995	$ 31,803	$ 26,173	$ 69,395	$ 99,907	$ 78,260
Denominator
Denominator for basic earnings per share - weighted average shares (in shares)	53,009	52,999	52,993	52,881	52,833	52,824	52,803	52,548	52,976	52,754	52,170
Dilutive effect of unvested restricted common stock and options issued to employees and directors (in shares)									386	389	500
Denominator for diluted earnings per share (in shares)	53,419	53,359	53,345	52,881	53,252	53,203	53,151	52,958	53,362	53,143	52,670
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.21	$ 0.60	$ 0.61	$ (0.10)	$ 0.26	$ 0.53	$ 0.60	$ 0.50	$ 1.31	$ 1.89	$ 1.50
Diluted net earnings per share (in USD per share)	$ 0.21	$ 0.59	$ 0.60	$ (0.10)	$ 0.26	$ 0.53	$ 0.60	$ 0.49	$ 1.30	$ 1.88	$ 1.49

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Millions	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	0.2	0.1	0.3

Share-Based Compensation (Narrative) (Details) $ / shares in Units, $ in Thousands							1 Months Ended	12 Months Ended
	Nov. 14, 2016 $ / shares shares	Sep. 12, 2016 $ / shares shares	Aug. 02, 2016 shares	May 26, 2016 shares	May 09, 2016 $ / shares shares	May 31, 2014 shares	Jun. 30, 2014 shares	Mar. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2016 USD ($) $ / shares shares	Mar. 31, 2015 USD ($) $ / shares shares	Aug. 04, 2014 director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase to plan term							10 years
Stock-based compensation costs \| $								$ 8,148	$ 9,954	$ 6,918
Tax benefit recognized from share-based compensation expense \| $								2,600	3,500	1,900
Share-based compensation expense, not yet recognized \| $								$ 7,900
Share-based compensation expense, not yet recognized, period for recognition								9 months 18 days
Total fair value of shares vested \| $								$ 6,000	$ 7,000	$ 4,700
Exercise of stock options (in shares)								126,800	348,000	386,300
Cash received from exercise of stock options \| $								$ 4,000	$ 6,700	$ 4,000
Income tax benefit realized from exercise of stock awards \| $								$ 900	$ 2,100	$ 2,200
Number of shares available for issuance under plan								2,400,000
Options granted, shares								264,300	208,200	317,900
Options granted, weighted-average exercise price (in USD per share) \| $ / shares								$ 55.86	$ 42.13	$ 33.54
Restricted Shares
Number of directors, board of directors \| director											6
Options
Options exercised, intrinsic value \| $								$ 3,200	$ 8,600	$ 9,300
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested in period (in shares)								94,718	155,603	154,418
Common stock units granted in period, shares			1,896		49,064			68,400	266,100	106,900
Award vesting period					3 years
Restricted Shares
Period following director's term In which stock awards may be settled								6 months
Granted, weighted-average grant-date fair value (in USD per share) \| $ / shares								$ 55.44	$ 42.41	$ 33.33
Restricted Stock Units (RSUs) \| Chief Financial Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock units granted in period, shares		5,012
Restricted Stock Units (RSUs) \| Executive Vice President
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock units granted in period, shares	2,664
Restricted Stock Units (RSUs) \| Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period								3 years
Restricted Stock Units (RSUs) \| Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock units granted in period, shares				346
Award vesting period								1 year
Restricted Stock Units (RSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period								3 years
Restricted Stock Units (RSUs) \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period								5 years
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of stock options (in shares)								126,820,000	348,055,000	386,254,000
Options granted, shares					224,843
Award vesting period					3 years
Award vesting rights, percentage					33.30%
Expiration period					10 years
Grant date exercise price (in USD per share) \| $ / shares					$ 57.18
Restricted Shares
Granted, weighted-average grant-date fair value (in USD per share) \| $ / shares								$ 21.75	$ 17.24	$ 15.95
Stock Options \| Chief Financial Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted, shares		25,746
Award vesting period		3 years
Expiration period		10 years
Grant date exercise price (in USD per share) \| $ / shares		$ 47.39
Stock Options \| Chief Financial Officer \| Tranche 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage		33.30%
Stock Options \| Executive Vice President
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted, shares	13,683
Award vesting period	3 years
Expiration period	10 years
Grant date exercise price (in USD per share) \| $ / shares	$ 50.06
Stock Options \| Executive Vice President \| Tranche 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage	33.30%
Stock Options \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period								3 years
Stock Options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period								5 years
Options
Award exercisability period, from date of grant (not greater than)								10 years
2005 Long-term Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant								5,000,000.0
Number of additional shares authorized under plan (in shares)							1,800,000.0
Maximum number of shares awarded, per employee, annual						1,000,000	2,500,000.0

Share-Based Compensation (Restricted Shares Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares			12 Months Ended
	Aug. 02, 2016	May 09, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Shares
Outstanding, beginning of period (in shares)			467,800	362,300	437,500
Granted (in shares)	1,896	49,064	68,400	266,100	106,900
Vested and issued (in shares)			(94,700)	(155,600)	(154,400)
Forfeited (in shares)			(91,400)	(5,000)	(27,700)
Outstanding, end of period (in shares)			350,100	467,800	362,300
Vested, end of period (in shares)			63,400	69,800	76,600
Weighted-Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)			$ 35.22	$ 22.74	$ 16.76
Granted, weighted-average grant-date fair value (in USD per share)			55.44	42.41	33.33
Vested, weighted-average grant-date fair value (in USD per share)			28.51	18.31	13.37
Forfeited, weighted-average grant-date fair value (in USD per share)			41.71	39.61	21.45
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)			39.29	35.22	22.74
Vested, end of period, weighted-average grant-date fair value (in USD per share)			$ 20.12	$ 14.76	$ 11.62

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	37.80%	40.20%	47.30%
Expected dividends	$ 0	$ 0	$ 0
Expected term in years	6 years	6 years	6 years
Risk-free rate	1.70%	1.70%	2.20%

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Shares
Outstanding, beginning of period (in shares)	727,700	871,200	994,900
Granted (in shares)	264,300	208,200	317,900
Exercised (in shares)	(126,800)	(348,000)	(386,300)
Forfeited or expired (in shares)	(92,900)	(3,700)	(55,300)
Outstanding, end of period (in shares)	772,300	727,700	871,200
Exercisable, end of period (in shares)	367,400
Weighted-Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 30.70	$ 23.40	$ 15.24
Options, grant date fair value (in USD per share)	55.86	42.13	33.54
Exercised, weighted-average exercise price (in USD per share)	31.75	19.22	10.24
Forfeited or expired, weighted-average exercise price (in USD per share)	42.66	35.72	26.77
Outstanding, end of period, weighted-average exercise price (in USD per share)	37.70	$ 30.70	$ 23.40
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 25.40
Options
Outstanding, end of period, weighted-average remaining contractual term	7 years 3 months 18 days
Exercisable, end of period, weighted-average remaining contractual term	6 years
Outstanding, end of period, aggregate intrinsic value	$ 14,118
Exercisable, end of period, aggregate intrinsic value	$ 11,083

Accumulated Other Comprehensive Loss (Components of AOCI) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from AOCI	$ 0	$ 0	$ 0
Components of Accumulated Other Comprehensive Loss	822,549	744,336	627,624	$ 563,360
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	(26,100)	(23,525)
Unrecognized net loss on pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	(252)	0
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	$ (26,352)	$ (23,525)	$ (23,412)	$ 739

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Long-term deferred tax assets	$ 1,000
Short-term deferred tax assets		$ 10,108
Valuation allowance	(3,437)	0
Unrecognized tax benefits	$ 3,651	$ 4,084	$ 3,420	$ 1,236
Effective income tax rate, change in enacted tax rate	(3.30%)	(2.60%)	(2.70%)
Earnings U.S income taxes not provided by	$ 42,500
Uncertain tax liability	$ 4,800

Income Taxes (Income Before Continuing Operations) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Income from Continuing Operations before Income Taxes:
United States									$ 93,582	$ 142,253	$ 122,588
Foreign									17,268	14,932	4,870
Income before income taxes	$ 18,802	$ 50,733	$ 50,228	$ (8,913)	$ 24,603	$ 43,181	$ 49,231	$ 40,170	$ 110,850	$ 157,185	$ 127,458

Income Taxes (Components of Provision for Income Taxes) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Current
Federal									$ 40,183	$ 6,080	$ 13,066
State									2,808	1,171	760
Foreign									4,242	3,905	3,228
Deferred
Federal									(5,421)	44,787	31,012
State									(163)	1,678	1,162
Foreign									(194)	(343)	(30)
Total provision for income taxes	$ 7,712	$ 19,092	$ 18,033	$ (3,382)	$ 10,667	$ 15,186	$ 17,428	$ 13,997	$ 41,455	$ 57,278	$ 49,198

Income Taxes (Components of Deferred Tax Balances) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$ 5,280	$ 5,083
Inventory capitalization	1,881	1,838
Inventory reserves	1,880	1,367
Net operating loss carryforwards	609	12,350
State income taxes	17,727	10,293
Accrued liabilities	2,174	2,162
Accrued compensation	9,574	0
Stock compensation	5,790	4,411
Other	7,925	300
Total deferred tax assets	52,840	37,804
Deferred Tax Liabilities
Property, plant and equipment	(9,157)	(833)
Intangible assets	(754,322)	(496,485)
Total deferred tax liabilities	(763,479)	(497,318)
Net deferred tax liability before valuation allowance	(710,639)	(459,514)
Valuation allowance	(3,437)	0
Net deferred tax liability	$ (714,076)	$ (459,514)

Income Taxes (Reconciliation of Effective Tax Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income tax provision at statutory rate	$ 38,798	$ 55,015	$ 44,610
Income tax provision at statutory rate, percentage	35.00%	35.00%	35.00%
Foreign tax benefit	$ (2,322)	$ (2,894)	$ (2,019)
Foreign tax benefit provision, percentage	(2.10%)	(1.80%)	(1.60%)
State income taxes, net of federal income tax benefit	$ 1,820	$ 3,284	$ 2,865
State income taxes, net of federal income tax benefit, percentage	1.70%	2.00%	2.30%
Goodwill adjustment for sale of asset	$ 3,208	$ 0	$ 206
Goodwill adjustment for sale of asset, percentage	2.90%	0.00%	0.20%
Nondeductible transaction costs	$ 686	$ 1,071	$ 2,936
Nondeductible transaction costs, percentage	0.60%	0.70%	2.30%
Nondeductible compensation	$ 342	$ 758	$ 566
Nondeductible compensation, percentage	0.30%	0.50%	0.40%
Other	$ (1,076)	$ 44	$ 34
Other, percentage	(1.00%)	0.00%	0.00%
Total provision for income taxes	$ 41,456	$ 57,278	$ 49,198
Total provision for income taxes, percentage	37.40%	36.40%	38.60%

Income Taxes (Uncertain Tax Liability Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance – beginning of year	$ 4,084	$ 3,420	$ 1,236
Additions based on tax positions related to the current year	583	664	2,229
Reductions based on lapse of statute of limitations	(1,016)	0	(45)
Balance – end of year	$ 3,651	$ 4,084	$ 3,420

Employee Retirement Plans (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, minimum annual contributions per participating employee, percent	1.00%
Defined contribution plan, maximum annual contributions per employee, percent	60.00%
Defined contribution plan, employer matching contribution, percent of match	65.00%
Defined contribution plan, employer matching contribution, percent of employees pay	6.00%
Defined contribution plan, employers matching contribution, vesting period	3 years
Defined contribution plan, cost recognized	$ 100
Net periodic benefit cost (income) (less than $1.0 million)	6
Funded (unfunded) status at end of year	$ (6,000)
Percentage of plan assets	100.00%
Pension plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit obligation	$ 61,714	$ 61,187
Net periodic benefit cost (income) (less than $1.0 million)	1,000
Funded (unfunded) status at end of year	(13,942)
Employer contribution	$ 6,078
Expected return on plan assets	6.25%
Fleet Employees Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, minimum annual contributions per participating employee, percent	2.00%
Defined contribution plan, maximum annual contributions per employee, percent	50.00%
Defined contribution plan, employer matching contribution, percent of match	100.00%
Defined contribution plan, employer matching contribution, percent of employees pay	6.00%
Defined contribution plan, cost recognized	$ 200

Employee Retirement Plans (Periodic Service Costs) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2017 USD ($)
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Interest cost	$ 456
Funded status at end of year	(6,000)
Pension plan
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Projected benefit obligation at date of acquisition	61,187
Interest cost	456
Actuarial (gain) loss	791
Benefits paid	(720)
Funded status at end of year	(13,942)
Projected benefit obligations at end of year	61,714
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at date of acquisition	41,560
Actual return on plan assets	854
Employer contribution	6,078
Benefits paid	(720)
Fair value of plan assets at end of year	$ 47,772

Employee Retirement Plans (Amounts Recognized in the Balance Sheet) (Details) - Pension plan $ in Thousands	Mar. 31, 2017 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Current liability	$ 463
Long-term liability	13,479
Total	$ 13,942

Employee Retirement Plans (Expected Return on Plan Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Interest cost	$ 456
Expected return on assets	(462)
Net periodic benefit cost (income)	(6)
Pension plan
Defined Benefit Plan Disclosure [Line Items]
Interest cost	456
Net periodic benefit cost (income)	(1,000)
Defined benefit obligation	$ 61,714	$ 61,187

Employee Retirement Plans (Expected Benefit Payments) (Details) - Pension plan $ in Thousands	Mar. 31, 2017 USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2018 (expectation) to participant benefits	$ 463
2018	3,152
2019	3,254
2020	3,329
2021	3,416
2022	3,578
2023-2027	$ 18,888

Employee Retirement Plans (Category of Plan Assets) (Details)	12 Months Ended
	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Total	100.00%
Percentage of Plan Assets	100.00%
Domestic large cap equities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	36.00%
Percentage of Plan Assets	41.00%
Domestic small/mid cap equities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	9.00%
Percentage of Plan Assets	7.00%
International equities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	15.00%
Percentage of Plan Assets	16.00%
Balanced/asset allocation
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	4.00%
Percentage of Plan Assets	2.00%
Fixed income and cash
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	36.00%
Percentage of Plan Assets	34.00%

Employee Retirement Plans Employee Retirement Plans (Accumulated Other Comprehensive Income (Loss)) (Details) - Pension plan - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Unrecognized actuarial (loss)		$ 399
Unrecognized prior service credit		$ 0
Scenario, Forecast
Defined Benefit Plan Disclosure [Line Items]
Unrecognized actuarial (loss)	$ 0
Unrecognized prior service credit	$ 0

Employee Retirement Plans (Weighted Average Assumptions) (Details) - Pension plan		12 Months Ended
	Jan. 26, 2017	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Discount rate	4.32%	4.21%
Expected return on plan assets		6.25%
Rate of compensation increase		0.00%

Commitments and Contingencies (Future Minimum Rental Payments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Operating Leased Assets [Line Items]
2018	$ 3,308
2019	3,035
2020	2,686
2021	1,458
2022	482
Thereafter	13
Total future minimum payments due	10,982	$ 8,434
Less: Sublease rentals	(690)	(1,165)
Minimum lease payments, net of sublease rentals	10,292	7,269
Operating leases, rent expense	2,000	$ 1,800	$ 1,600
Office Facilities
Operating Leased Assets [Line Items]
2018	2,743
2019	2,787
2020	2,587
2021	1,451
2022	478
Thereafter	13
Total future minimum payments due	10,059
Equipment
Operating Leased Assets [Line Items]
2018	565
2019	248
2020	99
2021	7
2022	4
Thereafter	0
Total future minimum payments due	$ 923

Commitments and Contingencies (Long-term Supply Agreement) (Details) - Third-party Manufacturing $ in Thousands	12 Months Ended
	Mar. 31, 2017 USD ($)
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years
2018	$ 1,013
2019	982
2020	559
2021	0
2022	0
Thereafter	0
Total purchase commitment	$ 2,554

Concentrations of Risk (Narrative) (Details)	12 Months Ended
Concentrations of Risk (Narrative) (Details)	Mar. 31, 2017 manufacturer customer	Mar. 31, 2016 manufacturer customer	Mar. 31, 2015 customer
Concentration Risk [Line Items]
Number of third-party manufacturers \| manufacturer	113
Sales \| Product concentration risk \| Top 5 customers
Concentration Risk [Line Items]
Concentration risk, percentage	40.00%	41.90%	38.20%
Sales \| Customer concentration risk
Concentration Risk [Line Items]
Number of customers exceeding concentration risk benchmark \| customer		1	1
Sales \| Customer concentration risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	21.10%	20.20%	18.10%
Number of customers exceeding concentration risk benchmark \| customer	1
Sales \| Supplier concentration risk
Concentration Risk [Line Items]
Concentration risk, percentage	78.40%	79.90%
Number of third-party manufacturers with long-term contracts \| manufacturer	47	55
Accounts receivable \| Customer concentration risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	33.10%

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information, Profit (Loss):
Revenues									$ 881,113	$ 803,088	$ 710,070
Other revenues									947	3,159	4,553
Total revenues	$ 240,670	$ 216,763	$ 215,052	$ 209,575	$ 207,855	$ 200,195	$ 206,065	$ 192,132	882,060	806,247	714,623
Cost of sales	110,487	92,216	91,087	87,984	89,604	83,411	86,125	79,896	381,774	339,036	308,400
Gross profit	130,183	124,547	123,965	121,591	118,251	116,784	119,940	112,236	500,286	467,211	406,223
Advertising and promotion	41,450	30,682	28,592	27,635	26,552	29,935	27,893	26,422	128,359	110,802	99,651
Contribution margin									371,927	356,409	306,572
Other operating expenses									166,314	96,094	99,013
Operating income	53,054	69,287	71,058	12,214	65,269	62,643	69,898	62,505	205,613	260,315	207,559
Other expense									94,763	103,130	80,101
Income before income taxes	18,802	50,733	50,228	(8,913)	24,603	43,181	49,231	40,170	110,850	157,185	127,458
Provision for income taxes	7,712	19,092	18,033	(3,382)	10,667	15,186	17,428	13,997	41,455	57,278	49,198
Net income	11,090	31,641	32,195	(5,531)	$ 13,936	$ 27,995	$ 31,803	$ 26,173	69,395	99,907	78,260
Loss on divestitures and sales of property and equipment	$ 268	$ (3,405)	$ (496)	$ 55,453					51,820	0	0
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									720,791	657,857	566,256
Other revenues									33	14	637
Total revenues									720,824	657,871	566,893
Cost of sales									282,750	250,018	216,781
Gross profit									438,074	407,853	350,112
Advertising and promotion									112,465	97,393	86,897
Contribution margin									325,609	310,460	263,215
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									73,287	57,670	57,729
Other revenues									17	43	64
Total revenues									73,304	57,713	57,793
Cost of sales									30,789	21,676	22,820
Gross profit									42,515	36,037	34,973
Advertising and promotion									13,434	11,114	10,922
Contribution margin									29,081	24,923	24,051
Household Cleaning
Segment Reporting Information, Profit (Loss):
Revenues									87,035	87,561	86,085
Other revenues									897	3,102	3,852
Total revenues									87,932	90,663	89,937
Cost of sales									68,235	67,342	68,799
Gross profit									19,697	23,321	21,138
Advertising and promotion									2,460	2,295	1,832
Contribution margin									17,237	21,026	19,306
Operating Segments
Segment Reporting Information, Profit (Loss):
Revenues									885,313	805,749	713,457
Operating Segments \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									724,991	660,518	569,643
Operating Segments \| International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									73,287	57,670	57,729
Operating Segments \| Household Cleaning
Segment Reporting Information, Profit (Loss):
Revenues									87,035	87,561	86,085
Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Revenues									(4,200)	(2,661)	(3,387)
Intersegment Eliminations \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									(4,200)	(2,661)	(3,387)
Intersegment Eliminations \| International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									0	0	0
Intersegment Eliminations \| Household Cleaning
Segment Reporting Information, Profit (Loss):
Revenues									0	$ 0	$ 0
Disposal group, disposed of by sale, not discontinued operations \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Loss on divestitures and sales of property and equipment									$ 51,800

Business Segments (Revenue by Product) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Revenue from External Customer [Line Items]
Total revenues	$ 240,670	$ 216,763	$ 215,052	$ 209,575	$ 207,855	$ 200,195	$ 206,065	$ 192,132	$ 882,060	$ 806,247	$ 714,623
Analgesics
Revenue from External Customer [Line Items]
Total revenues									122,175	119,465	114,551
Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									108,785	116,570	121,766
Women's Health
Revenue from External Customer [Line Items]
Total revenues									150,882	135,166	73,767
Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									101,312	94,587	96,968
Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									109,693	107,498	97,925
Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									87,353	85,074	67,095
Oral Care
Revenue from External Customer [Line Items]
Total revenues									108,099	51,125	46,399
Other OTC
Revenue from External Customer [Line Items]
Total revenues									5,829	6,099	6,215
Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									87,932	90,663	89,937
North American OTC Healthcare
Revenue from External Customer [Line Items]
Total revenues									720,824	657,871	566,893
North American OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									120,253	117,337	111,954
North American OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									90,795	100,148	103,686
North American OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									147,071	132,184	71,506
North American OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									76,500	74,568	77,596
North American OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									97,618	95,515	85,236
North American OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									85,194	82,941	64,806
North American OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									97,586	49,099	45,916
North American OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									5,807	6,079	6,193
International OTC Healthcare
Revenue from External Customer [Line Items]
Total revenues									73,304	57,713	57,793
International OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									1,922	2,128	2,597
International OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									17,990	16,422	18,080
International OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									3,811	2,982	2,261
International OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									24,812	20,019	19,372
International OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									12,075	11,983	12,689
International OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									2,159	2,133	2,289
International OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									10,513	2,026	483
International OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									22	20	22
Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									87,932	90,663	89,937
Household Cleaning \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									$ 87,932	$ 90,663	$ 89,937

Business Segments (Narrative) (Details) - Geographic Concentration Risk	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Sales \| UNITED STATES
Concentration Risk [Line Items]
Concentration risk, percentage	87.30%	87.40%	85.20%
Sales \| CANADA
Concentration Risk [Line Items]
Concentration risk, percentage	4.80%	5.20%	5.90%
Sales \| AUSTRALIA
Concentration Risk [Line Items]
Concentration risk, percentage	5.20%	5.60%	6.90%
Goodwill and Intangible Assets \| UNITED STATES
Concentration Risk [Line Items]
Concentration risk, percentage	96.50%	95.90%
Goodwill and Intangible Assets \| AUSTRALIA
Concentration Risk [Line Items]
Concentration risk, percentage	3.50%	4.10%

Business Segments (Assets by Segment) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 615,252	$ 360,191	$ 290,651	$ 190,911
Indefinite-lived intangible assets	2,589,155	2,020,046
Finite-lived intangible assets	314,458	302,677
Intangible assets, net (excluding goodwill)	2,903,613	2,322,723	2,134,700
Intangible assets, net (including goodwill)	3,518,865	2,682,914
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	576,453	330,615	263,411	160,157
Indefinite-lived intangible assets	2,404,336	1,823,873
Finite-lived intangible assets	287,056	277,762
Intangible assets, net (excluding goodwill)	2,691,392	2,101,635	1,912,633
Intangible assets, net (including goodwill)	3,267,845	2,432,250
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	32,554	22,776	20,440	23,365
Indefinite-lived intangible assets	83,558	85,901
Finite-lived intangible assets	6,468	2,237
Intangible assets, net (excluding goodwill)	90,026	88,138	87,372
Intangible assets, net (including goodwill)	122,580	110,914
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	6,245	6,800	6,800	$ 7,389
Indefinite-lived intangible assets	101,261	110,272
Finite-lived intangible assets	20,934	22,678
Intangible assets, net (excluding goodwill)	122,195	132,950	$ 134,695
Intangible assets, net (including goodwill)	$ 128,440	$ 139,750

Unaudited Quarterly Financial Information (Schedule of Quarterly Financial Information) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Total revenues	$ 240,670	$ 216,763	$ 215,052	$ 209,575	$ 207,855	$ 200,195	$ 206,065	$ 192,132	$ 882,060	$ 806,247	$ 714,623
Cost of sales	110,487	92,216	91,087	87,984	89,604	83,411	86,125	79,896	381,774	339,036	308,400
Gross profit	130,183	124,547	123,965	121,591	118,251	116,784	119,940	112,236	500,286	467,211	406,223
Operating Expenses
Advertising and promotion	41,450	30,682	28,592	27,635	26,552	29,935	27,893	26,422	128,359	110,802	99,651
General and administrative	28,760	22,131	18,795	19,457	20,232	18,135	16,462	17,589	89,143	72,418	81,273
Depreciation and amortization	6,651	5,852	6,016	6,832	6,198	6,071	5,687	5,720	25,351	23,676	17,740
Loss on divestitures	268	(3,405)	(496)	55,453					51,820	0	0
Total operating expenses	77,129	55,260	52,907	109,377	52,982	54,141	50,042	49,731	294,673	206,896	198,664
Operating income	53,054	69,287	71,058	12,214	65,269	62,643	69,898	62,505	205,613	260,315	207,559
Net interest expense	32,832	18,554	20,830	21,127	23,147	19,462	20,667	21,884
Loss on extinguishment of debt	1,420	0	0	0	17,519	0	0	451	1,420	17,970	0
Income before income taxes	18,802	50,733	50,228	(8,913)	24,603	43,181	49,231	40,170	110,850	157,185	127,458
(Benefit) provision for income taxes	7,712	19,092	18,033	(3,382)	10,667	15,186	17,428	13,997	41,455	57,278	49,198
Net income	$ 11,090	$ 31,641	$ 32,195	$ (5,531)	$ 13,936	$ 27,995	$ 31,803	$ 26,173	$ 69,395	$ 99,907	$ 78,260
(Loss) earnings per share:
Basic (in USD per share)	$ 0.21	$ 0.60	$ 0.61	$ (0.10)	$ 0.26	$ 0.53	$ 0.60	$ 0.50	$ 1.31	$ 1.89	$ 1.50
Diluted (in USD per share)	$ 0.21	$ 0.59	$ 0.60	$ (0.10)	$ 0.26	$ 0.53	$ 0.60	$ 0.49	$ 1.30	$ 1.88	$ 1.49
Weighted average shares outstanding:
Basic (in shares)	53,009	52,999	52,993	52,881	52,833	52,824	52,803	52,548	52,976	52,754	52,170
Diluted (in shares)	53,419	53,359	53,345	52,881	53,252	53,203	53,151	52,958	53,362	53,143	52,670
Comprehensive income, net of tax:
Currency translation adjustments	$ 9,282	$ (8,736)	$ 2,703	$ (5,824)	$ 6,449	$ 4,922	$ (11,079)	$ (405)	$ (2,575)	$ (113)	$ (24,151)
Unrecognized net loss on pension plans	(252)								(252)	0	0
Total other comprehensive loss	9,030	(8,736)	2,703	(5,824)	6,449	4,922	(11,079)	(405)	(2,827)	(113)	(24,151)
Comprehensive income	$ 20,120	$ 22,905	$ 34,898	$ (11,355)	$ 20,385	$ 32,917	$ 20,724	$ 25,768	$ 66,568	$ 99,794	$ 54,109

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Revenues
Net sales									$ 881,113	$ 803,088	$ 710,070
Other revenues									947	3,159	4,553
Total revenues	$ 240,670	$ 216,763	$ 215,052	$ 209,575	$ 207,855	$ 200,195	$ 206,065	$ 192,132	882,060	806,247	714,623
Cost of Sales
Cost of sales	110,487	92,216	91,087	87,984	89,604	83,411	86,125	79,896	381,774	339,036	308,400
Gross profit	130,183	124,547	123,965	121,591	118,251	116,784	119,940	112,236	500,286	467,211	406,223
Operating Expenses
Advertising and promotion	41,450	30,682	28,592	27,635	26,552	29,935	27,893	26,422	128,359	110,802	99,651
General and administrative	28,760	22,131	18,795	19,457	20,232	18,135	16,462	17,589	89,143	72,418	81,273
Depreciation and amortization	6,651	5,852	6,016	6,832	6,198	6,071	5,687	5,720	25,351	23,676	17,740
Loss on divestitures	268	(3,405)	(496)	55,453					51,820	0	0
Total operating expenses	77,129	55,260	52,907	109,377	52,982	54,141	50,042	49,731	294,673	206,896	198,664
Operating income	53,054	69,287	71,058	12,214	65,269	62,643	69,898	62,505	205,613	260,315	207,559
Other (income) expense
Interest income									(203)	(162)	(92)
Interest expense									93,546	85,322	81,326
Gain on sale of asset									0	0	(1,133)
Loss on extinguishment of debt	1,420	0	0	0	17,519	0	0	451	1,420	17,970	0
Equity in (income) loss of subsidiaries									0	0	0
Total other (income) expense									94,763	103,130	80,101
Income before income taxes	18,802	50,733	50,228	(8,913)	24,603	43,181	49,231	40,170	110,850	157,185	127,458
Provision for income taxes	7,712	19,092	18,033	(3,382)	10,667	15,186	17,428	13,997	41,455	57,278	49,198
Net income (loss)	11,090	31,641	32,195	(5,531)	13,936	27,995	31,803	26,173	69,395	99,907	78,260
Comprehensive income, net of tax:
Currency translation adjustments	9,282	(8,736)	2,703	(5,824)	6,449	4,922	(11,079)	(405)	(2,575)	(113)	(24,151)
Unrecognized net loss on pension plans	(252)								(252)	0	0
Total other comprehensive loss	9,030	(8,736)	2,703	(5,824)	6,449	4,922	(11,079)	(405)	(2,827)	(113)	(24,151)
Comprehensive income	$ 20,120	$ 22,905	$ 34,898	$ (11,355)	$ 20,385	$ 32,917	$ 20,724	$ 25,768	66,568	99,794	54,109
Prestige Brands Holdings, Inc.
Revenues
Net sales									0	0	0
Other revenues									0	0	0
Total revenues									0	0	0
Cost of Sales
Cost of sales									0	0	0
Gross profit									0	0	0
Operating Expenses
Advertising and promotion									0	0	0
General and administrative									6,612	5,737	4,571
Depreciation and amortization									3,170	4,050	3,381
Loss on divestitures									0
Total operating expenses									9,782	9,787	7,952
Operating income									(9,782)	(9,787)	(7,952)
Other (income) expense
Interest income									(47,881)	(48,342)	(48,543)
Interest expense									33,734	34,553	34,198
Gain on sale of asset											0
Loss on extinguishment of debt									0	0
Equity in (income) loss of subsidiaries									(67,467)	(98,803)	(76,383)
Total other (income) expense									(81,614)	(112,592)	(90,728)
Income before income taxes									71,832	102,805	82,776
Provision for income taxes									2,437	2,898	4,516
Net income (loss)									69,395	99,907	78,260
Comprehensive income, net of tax:
Currency translation adjustments									(2,575)	(113)	(24,151)
Unrecognized net loss on pension plans									(252)
Total other comprehensive loss									(2,827)	(113)	(24,151)
Comprehensive income									66,568	99,794	54,109
Prestige Brands, Inc., the issuer
Revenues
Net sales									112,557	111,747	106,439
Other revenues									295	347	385
Total revenues									112,852	112,094	106,824
Cost of Sales
Cost of sales									49,101	45,763	39,637
Gross profit									63,751	66,331	67,187
Operating Expenses
Advertising and promotion									13,581	9,465	8,828
General and administrative									9,033	9,098	9,090
Depreciation and amortization									634	594	592
Loss on divestitures									0
Total operating expenses									23,248	19,157	18,510
Operating income									40,503	47,174	48,677
Other (income) expense
Interest income									(85,064)	(85,882)	(73,755)
Interest expense									93,538	84,822	81,326
Gain on sale of asset											0
Loss on extinguishment of debt									1,420	17,970
Equity in (income) loss of subsidiaries									(49,302)	(70,953)	(51,573)
Total other (income) expense									(39,408)	(54,043)	(44,002)
Income before income taxes									79,911	101,217	92,679
Provision for income taxes									11,448	11,016	14,798
Net income (loss)									68,463	90,201	77,881
Comprehensive income, net of tax:
Currency translation adjustments									(2,575)	(113)	(24,151)
Unrecognized net loss on pension plans									(252)
Total other comprehensive loss									(2,827)	(113)	(24,151)
Comprehensive income									65,636	90,088	53,730
Combined Subsidiary Guarantors
Revenues
Net sales									708,335	643,330	555,388
Other revenues									1,033	3,116	4,452
Total revenues									709,368	646,446	559,840
Cost of Sales
Cost of sales									311,813	280,169	254,670
Gross profit									397,555	366,277	305,170
Operating Expenses
Advertising and promotion									101,573	90,353	79,944
General and administrative									65,528	51,198	55,209
Depreciation and amortization									21,013	18,617	12,752
Loss on divestitures									51,820
Total operating expenses									239,934	160,168	147,905
Operating income									157,621	206,109	157,265
Other (income) expense
Interest income									(5,644)	(5,087)	(5,373)
Interest expense									100,233	100,540	88,464
Gain on sale of asset											(1,133)
Loss on extinguishment of debt									0	0
Equity in (income) loss of subsidiaries									(9,481)	(8,564)	(2,013)
Total other (income) expense									85,108	86,889	79,945
Income before income taxes									72,513	119,220	77,320
Provision for income taxes									23,776	40,279	27,111
Net income (loss)									48,737	78,941	50,209
Comprehensive income, net of tax:
Currency translation adjustments									(2,575)	(113)	(24,151)
Unrecognized net loss on pension plans									(252)
Total other comprehensive loss									(2,827)	(113)	(24,151)
Comprehensive income									45,910	78,828	26,058
Combined Non-Guarantor Subsidiaries
Revenues
Net sales									64,422	50,672	51,630
Other revenues									1,655	1,776	1,497
Total revenues									66,077	52,448	53,127
Cost of Sales
Cost of sales									26,666	18,459	19,127
Gross profit									39,411	33,989	34,000
Operating Expenses
Advertising and promotion									13,205	10,984	10,879
General and administrative									7,970	6,385	12,403
Depreciation and amortization									534	415	1,015
Loss on divestitures									0
Total operating expenses									21,709	17,784	24,297
Operating income									17,702	16,205	9,703
Other (income) expense
Interest income									(1,217)	(531)	(456)
Interest expense									5,644	5,087	5,373
Gain on sale of asset											0
Loss on extinguishment of debt									0	0
Equity in (income) loss of subsidiaries									0	0	0
Total other (income) expense									4,427	4,556	4,917
Income before income taxes									13,275	11,649	4,786
Provision for income taxes									3,794	3,085	2,773
Net income (loss)									9,481	8,564	2,013
Comprehensive income, net of tax:
Currency translation adjustments									(2,575)	(113)	(24,151)
Unrecognized net loss on pension plans									0
Total other comprehensive loss									(2,575)	(113)	(24,151)
Comprehensive income									6,906	8,451	(22,138)
Eliminations
Revenues
Net sales									(4,201)	(2,661)	(3,387)
Other revenues									(2,036)	(2,080)	(1,781)
Total revenues									(6,237)	(4,741)	(5,168)
Cost of Sales
Cost of sales									(5,806)	(5,355)	(5,034)
Gross profit									(431)	614	(134)
Operating Expenses
Advertising and promotion									0	0	0
General and administrative									0	0	0
Depreciation and amortization									0	0	0
Loss on divestitures									0
Total operating expenses									0	0	0
Operating income									(431)	614	(134)
Other (income) expense
Interest income									139,603	139,680	128,035
Interest expense									(139,603)	(139,680)	(128,035)
Gain on sale of asset											0
Loss on extinguishment of debt									0	0
Equity in (income) loss of subsidiaries									126,250	178,320	129,969
Total other (income) expense									126,250	178,320	129,969
Income before income taxes									(126,681)	(177,706)	(130,103)
Provision for income taxes									0	0	0
Net income (loss)									(126,681)	(177,706)	(130,103)
Comprehensive income, net of tax:
Currency translation adjustments									7,725	339	72,453
Unrecognized net loss on pension plans									504
Total other comprehensive loss									8,229	339	72,453
Comprehensive income									$ (118,452)	$ (177,367)	$ (57,650)

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Current assets
Cash and cash equivalents	$ 41,855	$ 27,230	$ 21,318	$ 28,331
Accounts receivable, net	136,742	95,247
Inventories	115,609	91,263
Deferred income tax assets		10,108
Prepaid expenses and other current assets	40,228	25,165
Total current assets	334,434	249,013
Property, plant and equipment, net	50,595	15,540
Goodwill	615,252	360,191	290,651	190,911
Intangible assets, net	2,903,613	2,322,723	2,134,700
Other long-term assets	7,454	1,324
Intercompany receivables	0	0
Investment in subsidiary	0	0
Total Assets	3,911,348	2,948,791
Current liabilities
Accounts payable	70,218	38,296
Accrued interest payable	8,130	8,664
Other accrued liabilities	83,661	59,724
Total current liabilities	162,009	106,684
Long-term debt
Principal amount	2,222,000	1,652,500
Less unamortized debt costs	(28,268)	(27,191)
Long-term debt, net	2,193,732	1,625,309
Deferred income tax liabilities		469,622
Deferred income tax liabilities	715,086
Other long-term liabilities	17,972	2,840
Intercompany payables	0	0
Total Liabilities	3,088,799	2,204,455
Stockholders’ Equity
Common stock	533	530
Additional paid-in capital	458,255	445,182
Treasury stock, at cost	(6,594)	(5,163)
Accumulated other comprehensive income (loss), net of tax	(26,352)	(23,525)
Retained earnings (accumulated deficit)	396,707	327,312
Total Stockholders’ Equity	822,549	744,336	627,624	563,360
Total Liabilities and Stockholders’ Equity	3,911,348	2,948,791
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	6,168	4,440	11,387	24,644
Accounts receivable, net	0	0
Inventories	0	0
Deferred income tax assets		316
Prepaid expenses and other current assets	15,072	15,311
Total current assets	21,240	20,067
Property, plant and equipment, net	7,300	9,166
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	2,500	0
Intercompany receivables	1,510,308	1,457,011
Investment in subsidiary	1,708,095	1,641,477
Total Assets	3,249,443	3,127,721
Current liabilities
Accounts payable	2,150	2,914
Accrued interest payable	0	0
Other accrued liabilities	12,905	12,285
Total current liabilities	15,055	15,199
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities		0
Deferred income tax liabilities	0
Other long-term liabilities	0	0
Intercompany payables	2,411,839	2,368,186
Total Liabilities	2,426,894	2,383,385
Stockholders’ Equity
Common stock	533	530
Additional paid-in capital	458,255	445,182
Treasury stock, at cost	(6,594)	(5,163)
Accumulated other comprehensive income (loss), net of tax	(26,352)	(23,525)
Retained earnings (accumulated deficit)	396,707	327,312
Total Stockholders’ Equity	822,549	744,336
Total Liabilities and Stockholders’ Equity	3,249,443	3,127,721
Prestige Brands, Inc., the issuer
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	15,787	12,025
Inventories	16,484	9,411
Deferred income tax assets		681
Prepaid expenses and other current assets	245	257
Total current assets	32,516	22,374
Property, plant and equipment, net	439	210
Goodwill	66,007	66,007
Intangible assets, net	191,253	191,789
Other long-term assets	2,774	1,324
Intercompany receivables	2,477,928	2,703,192
Investment in subsidiary	2,397,916	1,527,718
Total Assets	5,168,833	4,512,614
Current liabilities
Accounts payable	14,576	7,643
Accrued interest payable	8,130	8,664
Other accrued liabilities	2,432	1,714
Total current liabilities	25,138	18,021
Long-term debt
Principal amount	2,222,000	1,652,500
Less unamortized debt costs	(28,268)	(27,191)
Long-term debt, net	2,193,732	1,625,309
Deferred income tax liabilities		60,317
Deferred income tax liabilities	55,945
Other long-term liabilities	0	0
Intercompany payables	1,260,499	1,241,084
Total Liabilities	3,535,314	2,944,731
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	1,280,947	1,280,947
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	(26,352)	(23,525)
Retained earnings (accumulated deficit)	378,924	310,461
Total Stockholders’ Equity	1,633,519	1,567,883
Total Liabilities and Stockholders’ Equity	5,168,833	4,512,614
Combined Subsidiary Guarantors
Current assets
Cash and cash equivalents	4,984	2,899	0	0
Accounts receivable, net	105,403	74,446
Inventories	89,255	72,296
Deferred income tax assets		8,293
Prepaid expenses and other current assets	23,444	8,379
Total current assets	223,086	166,313
Property, plant and equipment, net	42,260	5,528
Goodwill	516,691	271,409
Intangible assets, net	2,622,226	2,042,640
Other long-term assets	1,170	0
Intercompany receivables	1,832,286	1,083,488
Investment in subsidiary	276,933	81,545
Total Assets	5,514,652	3,650,923
Current liabilities
Accounts payable	49,025	24,437
Accrued interest payable	0	0
Other accrued liabilities	59,711	38,734
Total current liabilities	108,736	63,171
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities		408,893
Deferred income tax liabilities	659,132
Other long-term liabilities	17,920	2,682
Intercompany payables	2,253,319	1,570,265
Total Liabilities	3,039,107	2,045,011
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	2,183,644	1,359,921
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	(26,352)	(23,525)
Retained earnings (accumulated deficit)	318,253	269,516
Total Stockholders’ Equity	2,475,545	1,605,912
Total Liabilities and Stockholders’ Equity	5,514,652	3,650,923
Combined Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	30,703	19,891	9,931	3,687
Accounts receivable, net	15,552	8,776
Inventories	10,833	10,088
Deferred income tax assets		818
Prepaid expenses and other current assets	1,467	1,218
Total current assets	58,555	40,791
Property, plant and equipment, net	596	636
Goodwill	32,554	22,775
Intangible assets, net	90,134	88,294
Other long-term assets	1,010	0
Intercompany receivables	193,609	10,738
Investment in subsidiary	0	0
Total Assets	376,458	163,234
Current liabilities
Accounts payable	4,467	3,302
Accrued interest payable	0	0
Other accrued liabilities	8,613	6,991
Total current liabilities	13,080	10,293
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities		412
Deferred income tax liabilities	9
Other long-term liabilities	52	158
Intercompany payables	88,474	74,894
Total Liabilities	101,615	85,757
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	269,234	78,774
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	(26,100)	(23,525)
Retained earnings (accumulated deficit)	31,709	22,228
Total Stockholders’ Equity	274,843	77,477
Total Liabilities and Stockholders’ Equity	376,458	163,234
Eliminations
Current assets
Cash and cash equivalents	0	0	$ 0	$ 0
Accounts receivable, net	0	0
Inventories	(963)	(532)
Deferred income tax assets		0
Prepaid expenses and other current assets	0	0
Total current assets	(963)	(532)
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	(6,014,131)	(5,254,429)
Investment in subsidiary	(4,382,944)	(3,250,740)
Total Assets	(10,398,038)	(8,505,701)
Current liabilities
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities		0
Deferred income tax liabilities	0
Other long-term liabilities	0	0
Intercompany payables	(6,014,131)	(5,254,429)
Total Liabilities	(6,014,131)	(5,254,429)
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	(3,733,825)	(2,719,642)
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	78,804	70,575
Retained earnings (accumulated deficit)	(728,886)	(602,205)
Total Stockholders’ Equity	(4,383,907)	(3,251,272)
Total Liabilities and Stockholders’ Equity	$ (10,398,038)	$ (8,505,701)

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Operating Activities
Net income (loss)	$ 11,090	$ 31,641	$ 32,195	$ (5,531)	$ 13,936	$ 27,995	$ 31,803	$ 26,173	$ 69,395	$ 99,907	$ 78,260
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization									25,792	23,676	17,740
Loss on divestitures and sales of property and equipment	268	$ (3,405)	$ (496)	55,453					51,820	0	0
Gain on sale of asset									0	0	(1,133)
Deferred income taxes									(5,778)	46,152	28,922
Long term income taxes payable									581	(332)	2,294
Amortization of debt origination costs									8,633	8,994	8,821
Stock-based compensation costs									8,148	9,954	6,918
Loss on extinguishment of debt									1,420	17,970	0
Lease termination costs									524	0	785
Premium payment on 2012 Senior Notes									0	(10,158)	0
Loss (gain) on sale or disposal of property and equipment									573	(35)	321
Equity in (income) loss of subsidiaries									0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									(18,938)	1,824	1,608
Inventories									(10,262)	(3,005)	15,360
Prepaid expenses and other assets									(1,996)	(7,921)	4,664
Accounts payable									21,447	(11,348)	(17,637)
Accrued liabilities									2,497	(1,328)	9,332
Noncurrent assets and liabilities									(6,084)	0	0
Net cash provided by operating activities									147,772	174,350	156,255
Investing Activities
Purchases of property and equipment									(2,977)	(3,568)	(6,101)
Proceeds from divestitures									110,717	0	18,500
Proceeds from the sale of property and equipment									85	344	0
Proceeds from sale of asset									0	0	10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement									0	7,237	0
Proceeds from DenTek working capital arbitration settlement									1,419	0	0
Acquisition of DenTek, less cash acquired									0	(226,984)	0
Acquisition of Insight Pharmaceuticals, less cash acquired									0	0	(749,666)
Acquisition of the Hydralyte brand									0	0	(77,991)
Acquisition of C.B. Fleet, less cash acquired									(803,839)	0	0
Intercompany activity, net									0	0	0
Net cash used in investing activities									(694,595)	(222,971)	(805,258)
Financing Activities
Proceeds from issuance of Term Loan									1,427,000	0	720,000
Term Loan repayments resulting from refinancing									(687,000)	0	0
Proceeds from issuance of 2016 Senior Notes									0	350,000	0
Repayment of 2012 Senior Notes									0	(250,000)	0
Borrowings under Bridge term loans									0	80,000	0
Repayments under Bridge term loans									0	(80,000)	0
Term Loan repayments									(175,500)	(60,000)	(130,000)
Borrowings under revolving credit agreement									110,000	115,000	124,600
Repayments under revolving credit agreement									(105,000)	(96,100)	(58,500)
Payments of debt origination costs									(11,140)	(11,828)	(16,072)
Proceeds from exercise of stock options									4,028	6,689	3,954
Proceeds from restricted stock exercises									0	544	57
Excess tax benefits from share-based awards									900	1,960	1,330
Fair value of shares surrendered as payment of tax withholding									(1,431)	(2,229)	(2,104)
Intercompany activity, net									0	0	0
Net cash provided by financing activities									561,857	54,036	643,265
Effects of exchange rate changes on cash and cash equivalents									(409)	497	(1,275)
Increase (decrease) in cash and cash equivalents									14,625	5,912	(7,013)
Cash and cash equivalents - beginning of year				27,230				21,318	27,230	21,318	28,331
Cash and cash equivalents - end of year	41,855				27,230				41,855	27,230	21,318
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)									69,395	99,907	78,260
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization									3,170	4,050	3,381
Loss on divestitures and sales of property and equipment									0
Gain on sale of asset											0
Deferred income taxes									316	136	(192)
Long term income taxes payable									0	0	0
Amortization of debt origination costs									0	0	0
Stock-based compensation costs									8,148	9,794	6,918
Loss on extinguishment of debt									0	0
Lease termination costs									0		0
Premium payment on 2012 Senior Notes										0
Loss (gain) on sale or disposal of property and equipment									0	0	0
Equity in (income) loss of subsidiaries									(67,467)	(98,803)	(76,383)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									0	0	473
Inventories									0	0	0
Prepaid expenses and other assets									(2,261)	(9,580)	2,273
Accounts payable									(790)	929	(2,457)
Accrued liabilities									620	1,907	2,650
Net cash provided by operating activities									11,131	8,340	14,923
Investing Activities
Purchases of property and equipment									(1,153)	(2,460)	(5,029)
Proceeds from divestitures									0		0
Proceeds from the sale of property and equipment									0	0
Proceeds from sale of asset											0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement										0
Proceeds from DenTek working capital arbitration settlement									0
Acquisition of DenTek, less cash acquired										0
Acquisition of Insight Pharmaceuticals, less cash acquired											0
Acquisition of the Hydralyte brand											0
Intercompany activity, net									0	0	0
Net cash used in investing activities									(1,153)	(2,460)	(5,029)
Financing Activities
Proceeds from issuance of Term Loan									0		0
Term Loan repayments resulting from refinancing									0
Proceeds from issuance of 2016 Senior Notes										0
Repayment of 2012 Senior Notes										0
Borrowings under Bridge term loans										0
Repayments under Bridge term loans										0
Term Loan repayments									0	0	0
Borrowings under revolving credit agreement									0	0	0
Repayments under revolving credit agreement									0	0	0
Payments of debt origination costs									0	0	0
Proceeds from exercise of stock options									4,028	6,689	3,954
Proceeds from restricted stock exercises										544	57
Excess tax benefits from share-based awards									900	1,960	1,330
Fair value of shares surrendered as payment of tax withholding									(1,431)	(2,229)	(2,104)
Intercompany activity, net									(11,747)	(19,791)	(26,388)
Net cash provided by financing activities									(8,250)	(12,827)	(23,151)
Effects of exchange rate changes on cash and cash equivalents									0	0	0
Increase (decrease) in cash and cash equivalents									1,728	(6,947)	(13,257)
Cash and cash equivalents - beginning of year				4,440				11,387	4,440	11,387	24,644
Cash and cash equivalents - end of year	6,168				4,440				6,168	4,440	11,387
Prestige Brands, Inc., the issuer
Operating Activities
Net income (loss)									68,463	90,201	77,881
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization									634	594	592
Loss on divestitures and sales of property and equipment									0
Gain on sale of asset											0
Deferred income taxes									(3,691)	1,272	2,462
Long term income taxes payable									0	0	0
Amortization of debt origination costs									8,633	8,994	8,821
Stock-based compensation costs									0	0	0
Loss on extinguishment of debt									1,420	17,970
Lease termination costs									0		0
Premium payment on 2012 Senior Notes										(10,158)
Loss (gain) on sale or disposal of property and equipment									0	0	0
Equity in (income) loss of subsidiaries									(49,302)	(70,953)	(51,573)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									(3,762)	2,514	(294)
Inventories									(7,073)	(744)	5,690
Prepaid expenses and other assets									(1,428)	(116)	(28)
Accounts payable									6,933	814	(829)
Accrued liabilities									184	(2,749)	1,384
Net cash provided by operating activities									21,011	37,639	44,106
Investing Activities
Purchases of property and equipment									(327)	(93)	(119)
Proceeds from divestitures									0		0
Proceeds from the sale of property and equipment									0	0
Proceeds from sale of asset											0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement										0
Proceeds from DenTek working capital arbitration settlement									0
Acquisition of DenTek, less cash acquired										0
Acquisition of Insight Pharmaceuticals, less cash acquired											0
Acquisition of the Hydralyte brand											0
Intercompany activity, net									(823,723)	(228,343)	(809,157)
Net cash used in investing activities									(824,050)	(228,436)	(809,276)
Financing Activities
Proceeds from issuance of Term Loan									1,427,000		720,000
Term Loan repayments resulting from refinancing									(687,000)
Proceeds from issuance of 2016 Senior Notes										350,000
Repayment of 2012 Senior Notes										(250,000)
Borrowings under Bridge term loans										80,000
Repayments under Bridge term loans										(80,000)
Term Loan repayments									(175,500)	(60,000)	(130,000)
Borrowings under revolving credit agreement									110,000	115,000	124,600
Repayments under revolving credit agreement									(105,000)	(96,100)	(58,500)
Payments of debt origination costs									(11,140)	(11,828)	(16,072)
Proceeds from exercise of stock options									0	0	0
Proceeds from restricted stock exercises										0	0
Excess tax benefits from share-based awards									0	0	0
Fair value of shares surrendered as payment of tax withholding									0	0	0
Intercompany activity, net									244,679	143,725	125,142
Net cash provided by financing activities									803,039	190,797	765,170
Effects of exchange rate changes on cash and cash equivalents									0	0	0
Increase (decrease) in cash and cash equivalents									0	0	0
Cash and cash equivalents - beginning of year				0				0	0	0	0
Cash and cash equivalents - end of year	0				0				0	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)									48,737	78,941	50,209
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization									21,454	18,617	12,752
Loss on divestitures and sales of property and equipment									51,820
Gain on sale of asset											(1,133)
Deferred income taxes									(1,934)	45,070	26,795
Long term income taxes payable									581	(332)	2,294
Amortization of debt origination costs									0	0	0
Stock-based compensation costs									0	0	0
Loss on extinguishment of debt									0	0
Lease termination costs									524		785
Premium payment on 2012 Senior Notes										0
Loss (gain) on sale or disposal of property and equipment									573	1	0
Equity in (income) loss of subsidiaries									(9,481)	(8,564)	(2,013)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									(5,725)	(388)	5,146
Inventories									(2,856)	213	8,981
Prepaid expenses and other assets									1,235	1,977	2,631
Accounts payable									14,155	(11,284)	(16,734)
Accrued liabilities									1,798	(1,943)	3,560
Noncurrent assets and liabilities									(6,084)
Net cash provided by operating activities									114,797	122,308	93,273
Investing Activities
Purchases of property and equipment									(1,378)	(521)	(739)
Proceeds from divestitures									110,717		18,500
Proceeds from the sale of property and equipment									85	0
Proceeds from sale of asset											10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement										7,237
Proceeds from DenTek working capital arbitration settlement									1,419
Acquisition of DenTek, less cash acquired										(226,984)
Acquisition of Insight Pharmaceuticals, less cash acquired											(749,666)
Acquisition of the Hydralyte brand											0
Acquisition of C.B. Fleet, less cash acquired									(803,839)
Intercompany activity, net									823,723	228,343	731,166
Net cash used in investing activities									130,727	8,075	9,261
Financing Activities
Proceeds from issuance of Term Loan									0		0
Term Loan repayments resulting from refinancing									0
Proceeds from issuance of 2016 Senior Notes										0
Repayment of 2012 Senior Notes										0
Borrowings under Bridge term loans										0
Repayments under Bridge term loans										0
Term Loan repayments									0	0	0
Borrowings under revolving credit agreement									0	0	0
Repayments under revolving credit agreement									0	0	0
Payments of debt origination costs									0	0	0
Proceeds from exercise of stock options									0	0	0
Proceeds from restricted stock exercises										0	0
Excess tax benefits from share-based awards									0	0	0
Fair value of shares surrendered as payment of tax withholding									0	0	0
Intercompany activity, net									(243,439)	(127,484)	(102,534)
Net cash provided by financing activities									(243,439)	(127,484)	(102,534)
Effects of exchange rate changes on cash and cash equivalents									0	0	0
Increase (decrease) in cash and cash equivalents									2,085	2,899	0
Cash and cash equivalents - beginning of year				2,899				0	2,899	0	0
Cash and cash equivalents - end of year	4,984				2,899				4,984	2,899	0
Combined Non-Guarantor Subsidiaries
Operating Activities
Net income (loss)									9,481	8,564	2,013
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization									534	415	1,015
Loss on divestitures and sales of property and equipment									0
Gain on sale of asset											0
Deferred income taxes									(469)	(326)	(143)
Long term income taxes payable									0	0	0
Amortization of debt origination costs									0	0	0
Stock-based compensation costs										160	0
Loss on extinguishment of debt									0	0
Lease termination costs									0		0
Premium payment on 2012 Senior Notes										0
Loss (gain) on sale or disposal of property and equipment									0	(36)	321
Equity in (income) loss of subsidiaries									0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									(9,451)	(302)	(3,717)
Inventories									(764)	(1,860)	555
Prepaid expenses and other assets									458	(202)	(212)
Accounts payable									1,149	(1,807)	2,383
Accrued liabilities									(105)	1,457	1,738
Net cash provided by operating activities									833	6,063	3,953
Investing Activities
Purchases of property and equipment									(119)	(494)	(214)
Proceeds from divestitures									0		0
Proceeds from the sale of property and equipment										344
Proceeds from sale of asset											0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement										0
Proceeds from DenTek working capital arbitration settlement									0
Acquisition of DenTek, less cash acquired										0
Acquisition of Insight Pharmaceuticals, less cash acquired											0
Acquisition of the Hydralyte brand											(77,991)
Intercompany activity, net									0	0	77,991
Net cash used in investing activities									(119)	(150)	(214)
Financing Activities
Proceeds from issuance of Term Loan									0		0
Term Loan repayments resulting from refinancing									0
Proceeds from issuance of 2016 Senior Notes										0
Repayment of 2012 Senior Notes										0
Borrowings under Bridge term loans										0
Repayments under Bridge term loans										0
Term Loan repayments									0	0	0
Borrowings under revolving credit agreement									0	0	0
Repayments under revolving credit agreement									0	0	0
Payments of debt origination costs									0	0	0
Proceeds from exercise of stock options									0	0	0
Proceeds from restricted stock exercises										0	0
Excess tax benefits from share-based awards									0	0	0
Fair value of shares surrendered as payment of tax withholding									0	0	0
Intercompany activity, net									10,507	3,550	3,780
Net cash provided by financing activities									10,507	3,550	3,780
Effects of exchange rate changes on cash and cash equivalents									(409)	497	(1,275)
Increase (decrease) in cash and cash equivalents									10,812	9,960	6,244
Cash and cash equivalents - beginning of year				19,891				9,931	19,891	9,931	3,687
Cash and cash equivalents - end of year	30,703				19,891				30,703	19,891	9,931
Eliminations
Operating Activities
Net income (loss)									(126,681)	(177,706)	(130,103)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization									0	0	0
Loss on divestitures and sales of property and equipment									0
Gain on sale of asset											0
Deferred income taxes									0	0	0
Long term income taxes payable									0	0	0
Amortization of debt origination costs									0	0	0
Stock-based compensation costs									0	0	0
Loss on extinguishment of debt									0	0
Lease termination costs									0		0
Premium payment on 2012 Senior Notes										0
Loss (gain) on sale or disposal of property and equipment									0	0	0
Equity in (income) loss of subsidiaries									126,250	178,320	129,969
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									0	0	0
Inventories									431	(614)	134
Prepaid expenses and other assets									0	0	0
Accounts payable									0	0	0
Accrued liabilities									0	0	0
Net cash provided by operating activities									0	0	0
Investing Activities
Purchases of property and equipment									0	0	0
Proceeds from divestitures									0		0
Proceeds from the sale of property and equipment									0	0
Proceeds from sale of asset											0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement										0
Proceeds from DenTek working capital arbitration settlement									0
Acquisition of DenTek, less cash acquired										0
Acquisition of Insight Pharmaceuticals, less cash acquired											0
Acquisition of the Hydralyte brand											0
Intercompany activity, net									0	0	0
Net cash used in investing activities									0	0	0
Financing Activities
Proceeds from issuance of Term Loan									0		0
Term Loan repayments resulting from refinancing									0
Proceeds from issuance of 2016 Senior Notes										0
Repayment of 2012 Senior Notes										0
Borrowings under Bridge term loans										0
Repayments under Bridge term loans										0
Term Loan repayments									0	0	0
Borrowings under revolving credit agreement									0	0	0
Repayments under revolving credit agreement									0	0	0
Payments of debt origination costs									0	0	0
Proceeds from exercise of stock options									0	0	0
Proceeds from restricted stock exercises										0	0
Excess tax benefits from share-based awards									0	0	0
Fair value of shares surrendered as payment of tax withholding									0	0	0
Intercompany activity, net									0	0	0
Net cash provided by financing activities									0	0	0
Effects of exchange rate changes on cash and cash equivalents									0	0	0
Increase (decrease) in cash and cash equivalents									0	0	0
Cash and cash equivalents - beginning of year				$ 0				$ 0	0	0	0
Cash and cash equivalents - end of year	$ 0				$ 0				$ 0	$ 0	$ 0

Subsequent Events (Narrative) (Details) - $ / shares				12 Months Ended
Subsequent Events (Narrative) (Details) - $ / shares	May 08, 2017	Aug. 02, 2016	May 09, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Subsequent Event [Line Items]
Options granted, shares				264,300	208,200	317,900
Options granted, weighted-average exercise price (in USD per share)				$ 55.86	$ 42.13	$ 33.54
Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Common stock units granted in period, shares		1,896	49,064	68,400	266,100	106,900
Award vesting period			3 years
Stock Options
Subsequent Event [Line Items]
Options granted, shares			224,843
Award vesting rights, percentage			33.30%
Award vesting period			3 years
Expiration period			10 years
Subsequent event
Subsequent Event [Line Items]
Options granted, shares	180,211
Subsequent event \| Performance Shares
Subsequent Event [Line Items]
Common stock units granted in period, shares	35,593
Subsequent event \| Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Common stock units granted in period, shares	54,269
Award vesting period	3 years
Subsequent event \| Stock Options
Subsequent Event [Line Items]
Award vesting period	3 years
Expiration period	10 years
Options granted, weighted-average exercise price (in USD per share)	$ 56.11
Tranche 1 \| Subsequent event \| Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Award vesting rights, percentage	33.30%
Tranche 1 \| Subsequent event \| Stock Options
Subsequent Event [Line Items]
Award vesting rights, percentage	33.30%
Tranche 2 \| Subsequent event \| Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Award vesting rights, percentage	33.30%
Tranche 2 \| Subsequent event \| Stock Options
Subsequent Event [Line Items]
Award vesting rights, percentage	33.30%
Tranche 3 \| Subsequent event \| Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Award vesting rights, percentage	33.30%
Tranche 3 \| Subsequent event \| Stock Options
Subsequent Event [Line Items]
Award vesting rights, percentage	33.30%

Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Reserves for sales returns and allowance
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	$ 8,823	$ 6,716	$ 7,395
Amounts charged to expense	41,173	41,217	34,598
Deductions	(41,417)	(40,085)	(35,277)
Other	850	975	0
Valuation allowances and reserves, balance at end of year	9,429	8,823	6,716
Reserves for trade promotions
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	12,641	9,932	6,101
Amounts charged to expense	69,475	62,331	60,499
Deductions	(69,713)	(62,409)	(56,668)
Other	2,790	2,787	0
Valuation allowances and reserves, balance at end of year	15,193	12,641	9,932
Reserves for consumer coupon redemptions
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	4,323	1,672	1,742
Amounts charged to expense	7,616	6,235	5,089
Deductions	(7,745)	(5,637)	(5,159)
Other	420	2,053	0
Valuation allowances and reserves, balance at end of year	4,614	4,323	1,672
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	815	1,277	1,035
Amounts charged to expense	177	(276)	340
Deductions	360	(186)	(98)
Other	0	0	0
Valuation allowances and reserves, balance at end of year	1,352	815	$ 1,277
Deferred tax valuation allowance
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	0
Amounts charged to expense	0
Deductions	0
Other	3,437
Valuation allowances and reserves, balance at end of year	$ 3,437	$ 0

Business and Basis of Presentation (Intangible Assets) (Details)	12 Months Ended
	Mar. 31, 2017
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years